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Abstract 
 Multidrug resistance (MDR) mediated by a drug efflux mechanism is one of the 
major drug resistance problems not only in bacteria but also in other microorganisms.  
NorA MDR efflux protein is a well characterized and major efflux pump in the 
pathogenic Gram-positive bacterium, Staphylococcus aureus.   It contributes to the 
resistance to berberine and ciprofloxacin antibiotics by extrusion of these drugs from the 
cells of S. aureus.  In order to overcome this type of drug resistance by dual action 
agents incorporating efflux pump inhibitor properties and antibacterial activity, a variety 
of new, aryl group-substituted 2-aryl-5-nitro-1H-indole efflux pump inhibitors were 
synthesized. In the synthesis of these 2-aryl-5-nitro-1H-indoles, a new procedure for the 
N-acylation of indoles was developed based on DCC/DMAP coupling with carboxylic 
acids. This method was particularly effective with 5-nitro-1H-indole.  The activity of 
these indole derivatives as inhibitors of the NorA MDR pump in S. aureus was 
assessed.  It was found that some of the 2-aryl-5-nitro-1H-indole derivatives potentiated 
the activity of the antibacterial agents berberine and ciprofloxacin against the resistant 
strain, K2361, of S. aureus.  The new 2-aryl-5-nitro-1H-indole inhibitors were 
particularly effective in potentiating the antibacterial activity of berberine.  The 
compound [4-benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol (43) was the most potent 
NorA pump inhibitor found in this work.  
 A number of dual action antibacterial agents were designed and synthesized.  
These included dual action prodrugs, in which the MDR pump inhibitor and berberine 
were attached in the same molecule with enzymatically cleavable linkages (ester or 
amide groups), and dual action drugs with a non-cleavable linkage (methylene group).  
In the synthesis of the dual action agents, a direct new approach to 13-substituted 
berberine derivatives was found.  This approach involved alkylation of 8-
 xi
allyldihydroberberine followed by the elimination of propene.  The antimicrobial 
activity of these indole-berberine compounds was assessed against a variety of 
pathogenic microorganisms.  One of the dual action drugs, 9,10-dimethoxy-13-[2-(5-
nitro-1H-indol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium 
bromide (64), was a potent antimicrobial agent at a clinically viable concentration 
against various bacteria in vitro, including Staphylococcus aureus K2361, Enterococcus 
faecalis V583, and Salmonella enterica Serovar Typhimurium SL1344R2. This 
compound also had good activity against the protozoan, Plasmodium falciparum K1 (in 
vitro).   
 In the case of the dual action prodrugs, the amide prodrugs were more active than 
the ester prodrugs against the Gram-positive bacterium S. aureus and vice versa against 
the Gram-negative bacterium S. enterica Serovar Typhimurium.  However, minimum 
inhibitory concentrations for all the dual action drugs and dual action prodrugs were 
near or at clinically useful concentrations (ca. 1µg/mL or less) as antibacterial agents 
against S. enterica Serovar Typhimurium SL1344R2, and they showed 400- to 1600-
fold higher activity than the parent antibacterial agent berberine.  The design principle 
of having in the one molecule an MDR inhibitor moiety and an antibacterial moiety was 
established as a viable one, which potentially could be extended to other types of 
antimicrobial agents. 
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Abstract 
 Multidrug resistance (MDR) mediated by a drug efflux mechanism is one of the 
major drug resistance problems not only in bacteria but also in other microorganisms.  
NorA MDR efflux protein is a well characterized and major efflux pump in the 
pathogenic Gram-positive bacterium, Staphylococcus aureus.   It contributes to the 
resistance to berberine and ciprofloxacin antibiotics by extrusion of these drugs from the 
cells of S. aureus.  In order to overcome this type of drug resistance by dual action 
agents incorporating efflux pump inhibitor properties and antibacterial activity, a variety 
of new, aryl group-substituted 2-aryl-5-nitro-1H-indole efflux pump inhibitors were 
synthesized. In the synthesis of these 2-aryl-5-nitro-1H-indoles, a new procedure for the 
N-acylation of indoles was developed based on DCC/DMAP coupling with carboxylic 
acids. This method was particularly effective with 5-nitro-1H-indole.  The activity of 
these indole derivatives as inhibitors of the NorA MDR pump in S. aureus was 
assessed.  It was found that some of the 2-aryl-5-nitro-1H-indole derivatives potentiated 
the activity of the antibacterial agents berberine and ciprofloxacin against the resistant 
strain, K2361, of S. aureus.  The new 2-aryl-5-nitro-1H-indole inhibitors were 
particularly effective in potentiating the antibacterial activity of berberine.  The 
compound [4-benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol (43) was the most potent 
NorA pump inhibitor found in this work.  
 A number of dual action antibacterial agents were designed and synthesized.  
These included dual action prodrugs, in which the MDR pump inhibitor and berberine 
were attached in the same molecule with enzymatically cleavable linkages (ester or 
amide groups), and dual action drugs with a non-cleavable linkage (methylene group).  
In the synthesis of the dual action agents, a direct new approach to 13-substituted 
berberine derivatives was found.  This approach involved alkylation of 8-
 xi
allyldihydroberberine followed by the elimination of propene.  The antimicrobial 
activity of these indole-berberine compounds was assessed against a variety of 
pathogenic microorganisms.  One of the dual action drugs, 9,10-dimethoxy-13-[2-(5-
nitro-1H-indol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium 
bromide (64), was a potent antimicrobial agent at a clinically viable concentration 
against various bacteria in vitro, including Staphylococcus aureus K2361, Enterococcus 
faecalis V583, and Salmonella enterica Serovar Typhimurium SL1344R2. This 
compound also had good activity against the protozoan, Plasmodium falciparum K1 (in 
vitro).   
 In the case of the dual action prodrugs, the amide prodrugs were more active than 
the ester prodrugs against the Gram-positive bacterium S. aureus and vice versa against 
the Gram-negative bacterium S. enterica Serovar Typhimurium.  However, minimum 
inhibitory concentrations for all the dual action drugs and dual action prodrugs were 
near or at clinically useful concentrations (ca. 1µg/mL or less) as antibacterial agents 
against S. enterica Serovar Typhimurium SL1344R2, and they showed 400- to 1600-
fold higher activity than the parent antibacterial agent berberine.  The design principle 
of having in the one molecule an MDR inhibitor moiety and an antibacterial moiety was 
established as a viable one, which potentially could be extended to other types of 
antimicrobial agents. 
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1 Chapter1: Introduction    
1.1 Isoquinoline alkaloids as natural antimicrobial agents 
Antimicrobials can be both natural products and synthetic chemicals, which are 
designed to inhibit or destroy pathogenic microorganisms, such as bacteria, fungi, 
protozoa, and viruses.  Amongst the natural products, alkaloids play an important role as 
medicinal agents and as poisons, and they have been found in such varied sources as 
plants, animals, insects, marine invertebrates and microorganisms. A general definition 
of an alkaloid has been given by Pelletier1 as “An alkaloid is a cyclic compound 
containing nitrogen in a negative oxidation state which is of limited distribution in 
living organisms.”  Alkaloids can be classified into several categories based on the 
chemical structure of their nucleus. Isoquinoline alkaloids are thus based on the 
isoquinoline nucleus.  A few isoquinoline alkaloids, such as berberine and sanguinarine, 
are currently used clinically as antimicrobial agents,2 but many others show 
antimicrobial activity.  Berberine and sanguinarine occur in several genera of families 
including the Berberidaceae, Papaveraceae, and Rutaceae, and possess a variety of 
pharmacological properties including antimicrobial, antileukemic, antiulcerous, gastric 
antisecretory, and enzyme inhibitory activities.2,3   
O
O N
OCH3
OCH3
N
O
O
O
O CH3
Berberine (1)                                                    Sanguinarine  
Berberine is a member of the protoberberine class of isoquinoline alkaloids, but 
sanguinarine is a member of the benzophenanthridine class of these alkaloids. The 
mechanism of antimicrobial activity of berberine and sanguinarine is related to their 
effect on DNA intercalation and inhibition reverse transcription and DNA synthesis in 
 2
microorganism cells.4 The therapeutic uses of berberine are in the treatment of infected 
eyes and eye irritations (MurineTM) while sanguinarine is used as an antiplaque in 
toothpaste and mouthwash.5 Sanguinarine has been classified by the FDA as being 
unsafe for use in food and drugs.6    
 
1.1.1 Antimicrobial activity and structure-activity relationships 
(SARs) of berberine and related alkaloids 
 Berberine was first isolated from the plant Xanthoxylon cava in 1926. Berberine 
extracts from plants have been used in the treatment of cholera and other bacterial 
diarrhoeas in Native American, Chinese, and Japanese traditional folk medicine for 
centuries.  It has been reported that berberine and related alkaloids exhibit antibacterial 
activity against Gram-positive bacteria (e.g. Staphylococcus aureus, Staphylococcus 
epidermidis, Enterococcus faecalis, Bacillus subtilis) and Gram-negative bacteria (e.g. 
Escherichia coli, Klebsiella pneumoniae), antifungal activity against Candida albicans 
and Aspergdlus fumigatus, antiplasmodal activity against Plasmodium falciparum, and 
several other pharmacological activities.  The extensive antimicrobial screening data 
(Amin et al.7) of berberine sulfate are shown in Table 1-1.  Moreover, it has recently 
been reported that berberine possesses anti-tumour activity.8   It is likely that berberine 
and its analogues show these activities because of the presence of the iminium ion 
moiety in the aromatic structure which could react with nucleophilic amino acid 
residues in enzymes and receptors of microorganisms.  There have been some previous 
studies on the relationships between the structure and biological activity of these 
compounds in order to determine the structural regions important for antimicrobial 
activity.  These studies may be summarized as follows: 
Table 1-1 A ntibacterial activity o f berberinium sulfate7
Organism Minimum growth inhibitory concentration
(ag/mL (xM*
Bacillus pumilus 25 57.7
Bacillus cerus 50 115.5
Bacillus sublilis 25 57.7
Corynebacterium diphtheriae 6.2 14.3
Escherichia coli 50 -  greater than 100 115.5 -  greater than 230.9
Klebsiella pneumoniae 25 57.7
Pseudomonas pyocyanea >100 >230.9
Pseudomonas fluorescens >100 >230.9
Salmonella paratyphi >100 >230.9
Salmonella schottmuelleri >100 >230.9
Salmonella typhimurium >100 >230.9
Salmonella typhi >100 >230.9
Shigella boydii 12.5 28.9
Staphylococcus aureus 6.2 - 50.0 14.3 - 115.5
Staphylococcus albus 50 115.5
Streptococcus pyogenes 12.5 28.9
Vibrio cholerae Inaba 569B 25 57.7
Vibrio cholerae E l Tor Ogawa 50 115.5
Xanthomonas citri 3.1 7.2
Xanthomonas campestris 6.2 14.3
Xanthomonas malvacearum 12.5 28.9
Erwinia carotovora 100 230.9
Pseudomonas mangiferae >100 >230.9
Pseudomonas solanacearum >100 >230.9
Candida utilis 12.5 28.9
Candida albicans 12.5 28.9
Candida tropicalis 3.1 7.2
Sporotrichum schenkii 6.2 14.3
*The m inim um inhibitory concentrations were converted from |xg/mL into (iM, using a 
calculated m olecular w eight o f  berberinium sulfate o f 433 daltons.
Influence of the oxygen substituents in ring A
According to Iwasa et al,9 the antimalarial activity of protoberberine alkaloids was 
influenced by the type of oxygen substituent on ring A (Figure 1-la). Compounds 
having a methylenedioxy group on ring A (where Ri + R2 = CH2) showed a higher 
activity against P. falciparum  than compounds having a methoxy group at the same
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positions, (R1 = R2 = OCH3).  In addition, replacement of a methoxy group at C-2 or C-
3 by a hydroxy group resulted in an increase in activity.   
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Figure 1-1 General structures and numbering of protoberberine alkaloid derivatives for SARs 
 
Influence of substituents on ring C 
 There have been several investigations by Iwasa et al9-12 on the effect of 
substituents at C-8, C-13, and of the quaternary ammonium ion of this ring on 
antibacterial and antimalarial activities.  For example, the introduction of an alkyl group 
at C-8 (R3 = CH3, C2H5, n-C3H7, and n-C4H9) (Figure 1-1a) increased the antibacterial 
activity against S. aureus and B. subtilis as the alkyl side chain length increased.  
Adding a bromine atom at C-12 on ring D of these compounds also increased 
antibacterial activity (Figure 1-1a).  Substitution of various alkyl groups at C-13 (R4, 
Figure 1-1a) was evaluated and optimized.  The alkyl side chain length was increased 
from methyl to n-hexyl group, with the 13-hexylberberine derivatives found to exhibit 
the highest antibacterial activity.  The R4 substituent at C-13 also was changed to OH, 
OMe, OEt, OCOOEt, and OCON(Me)2. Their antimalarial activities were lower than 
berberine itself against P. falciparum.  Reduction of protoberberinium salts (Figure 1-
1a) to tetrahydroberberine derivatives (Figure 1-1b) significantly reduced the 
antibacterial activity against S. aureus and B. subtilis.  Making the N-metho salts (R7 = 
Me in Figure 1-1b), and also adding a methyl group at C-13 caused an increase in 
activity.  Moreover, changing of the B/C junction of the N-metho salt derivatives in the 
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tetrahydroberberine series from trans to cis caused a decrease in the activity.  The SARs 
for antibacterial and antimalarial activities were not compared by Iwasa.   
 
 Influence of type and position of oxygen on ring D 
 The type of oxygen group at C-9 strongly affected the antimicrobial activity in the 
berberine series. It has been reported13 that berberine and berberrubine, the latter 
differing in structure from berberine only at C-9, where R5 = H (Figure 1-1a), both 
mediate DNA cleavage but in the DNA cleavage assay berberrubine was more active 
than berberine.   Alkylation of the hydroxy group of berberrubine at C-9 with an alkyl 
halide, where the alkyl groups were hexyl, heptyl, octyl, nonyl, decyl, and undecyl 
groups, gave alkyl ether products with higher antibacterial activities against Gram-
positive bacteria than those for berberrubine.  The activities increased as the alkyl chain 
length increased up to dodecyl, but alkyl chains longer than the dodecyl had decreased 
activity.  In the same way, acylation of the hydroxy group of berberrubine at C-9 was 
also investigated.  The acyl groups were varied from octanoyl, decanoyl, lauroyl, 
myristoyl, to palmitoyl groups.  The antibacterial activities increased as the length of the 
chain increased, but then decreased with longer chains than the lauroyl group.14,15  
 
1.1.2 Cytotoxicity of berberine and related alkaloids 
 Berberine is known to possess cytotoxic activity.  The IC50 values are 7.32 µM 
against KB cells (human carcinoma of the nasopharynx),16 0.03 µM against Hela 
(human uterus carcinoma), less than 0.03 µM against SVKO3 (human ovary carcinoma), 
Fadu (human pharynx carcinoma), Hep-2 (human larynx carcinoma) and moderate 
toxicity against primary cultures from mouse embryos and human fibroblasts.  The 
cytotoxic activity comparison of berberine with related alkaloids was evaluated using 
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human cancer cell lines.  Berberine showed higher cytotoxicity than lincangenine, 8-
hydroxydihydroberberine and 8-hydroxylincangenine, and thaicanine which has a trans-
quinolizidine conformation.17  
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 In addition, Iwasa et al18 investigated the cytotoxicity of several protoberberine 
alkaloids against human cancer cell lines (lung, colon, CNS, stomach, ovarian, breast, 
renal, melanoma), and they showed that the cytotoxic activity paralleled the 
antimicrobial activity.  Compounds bearing a methylenedioxy group at C-2 and C-3 
were more cytotoxic than those with a methoxy group at the same positions.  
Compounds having alkyl side chains at C-13 also showed cytotoxicity, with an increase 
in cytotoxicity occurring with an increasing chain length. 
 
1.1.3 Structural features for antimicrobial  and cytotoxic activities 
 In summary, it has been established that the following features are important for 
antimicrobial and cytotoxic activities in the berberine series: 
1.  a quaternary nitrogen atom 
2.  aromaticity of ring C 
3.  the type of O-alkyl substituent on rings A and D 
4.  the size of  the substituent at C-13. 
  
1.2 Antibacterial drug resistance problem
A number of antibiotics were developed in the 20th century to combat bacterial 
infections. Penicillin, one of the earliest antibiotics, is produced by the fungal species 
Penicillium sp. and was found to have the ability to kill S. aureus, a bacterium 
responsible for causing skin infections. Other antibiotics found in the same period, and 
shown in Table 1-2, include the sulfonamides and streptomycin which were used to 
combat a wide range of bacterial infections. 19
Table 1-2 Evolution of resistance to antibiotics20
Antibiotic Year deployed Resistance observed
Sulfonamides 1930s 1940s
Penicillin 1943 1946
Streptom ycin 1943 1959
Chloram phenicol 1947 1959
Tetracyclin 1948 1953
Erythromycin 1952 1988
V ancomycin 1956 1988
M ethicillin 1960 1961
A mpicillin 1961 1973
Cephalosporins 1960s late 1960s
The discovery of successful antibiotics encouraged scientists to research and
develop new antibiotics. However, pathogenic microbes also have tried to develop
intrinsic self-protection to combat these antibiotics resulting in the emergence of
bacterial resistance (Table 1-2). Antibiotic resistant bacteria have now become a major
worldwide health problem. During the past six to seven decades, over 100
antibiotics/antibacterial agents have been discovered and developed. The major classes
of antibacterial agents are (3-lactams (e.g. penicillin, methicillin, cephalosporins),
aminoglycosides, tetracyclines, sulfonamides, macrolides (e.g. erythromycin),
7
 8
quinolones and glycopeptides (e.g. vancomycin).  These antibiotic classes are grouped 
according to their targets at the surface of the bacterial cell or inside the cell.21 One of 
the most significant antibiotic resistance problems observed in clinical practice is the 
increase in the number of the isolates of methicillin-resistant S. aureus (MRSA) strains.  
MRSA is the most common antibiotic-resistant organism in hospitals, and ranks as the 
most frequently isolated pathogen associated with blood stream infections in North 
America between 1997-2001.22 Several variations of multidrug resistance (MDR) have 
been found in MRSA isolates, with resistances to macrolide-lincosamide-streptogramin 
B (MLSB) antibiotics, fluoroquinolones and other antibiotics.  Vancomycin was the last 
line of defence against serious infections caused by MRSA, but the emergence of 
vancomycin resistance of S. aureus was reported in Japan in 1996,23 and subsequently 
in many other countries.   Similarly, Enterococcal strains are also commonly isolated 
pathogens in blood steam infections in North America.22 Many Enterococcus faecium 
isolates are now vancomycin-resistant and E. faecalis isolates also showed resistance to 
aminoglycosides and β-lactams.  Unfortunately, the dual drug quinupristin-dalfopristin 
(SynercidTM, a new drug that has activity against MDR S. aureus and has been 
introduced into hospital use) does not control E. faecalis.24,25 Clearly, new drugs are 
urgently needed to overcome the serious multidrug resistance problem in pathogenic 
bacteria. 
 
1.3 Mechanisms of antimicrobial resistance 
 Antibacterial agents can kill bacteria or stop their growth by attacking three main 
targets in bacterial systems: bacterial cell wall biosynthesis, bacterial protein synthesis, 
and bacterial DNA replication and repair.26 In response, bacteria have developed a 
number of resistance mechanisms to protect themselves from antibacterial agents.  
These bacterial survival strategies fall into three major types, as outlined in the 
following sub-sections.
1.3.1 Resistance by antibacterial alteration
Resistance to a wide range of antibacterial agents can be achieved by modification 
of the antibacterial agents. This mechanism results in destruction of the antibacterials 
by deactivating the drugs to inactive forms. For example, deactivation of penicillin and 
cephalosporin antibiotics can be caused by (3-lactamase enzymes, which are produced 
by resistant bacteria (Figure 1-2). The strained four-membered p-lactam ring, the active 
structural moiety in the penicillin antibiotics, can be opened by p-lactamase to give
• • • • • 97penicilloic acid, which is inactive as an antibiotic.
Figure 1-2 Antibiotic destruction by enzymes produced by resistant bacteria (Figure from reference 
26)
1.3.2 Resistance by bacterial target modification
This mechanism involves modification of the drug target to such an extent that it 
is insensitive to the antibiotic, whilst still keeping its essential cellular function. An 
example of this occurs in vancomycin-resistant Enterococci (VRE). The mode of action 
of vancomycin involves the disrupting of bacterial cell wall synthesis.
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Peptidoglycan is an important protein in bacterial cell wall synthesis. Cross- 
linking o f  peptidoglycans occurs at the D-Ala-D-Ala terminus o f peptidoglycan and this 
is important for cell wall strength. Vancomycin acts by binding to the D-Ala-D-Ala 
terminus o f  the peptidoglycan and preventing this essential cross-linking by the 
transpeptidase enzyme. The vanHA genes o f E. faecium  encode a new pathway o f  cell 
biosynthesis which involves a change in the D-Ala terminus to an ester linkage with D- 
lactate (Figure 1-3) that results in a poor binding o f vancomycin to the modified 
peptidoglycan terminus o f  jV-acyl-D-Ala-D-lactate and allows the VRE to survive .28,29
^ V r V
W-acyl-OAIa-D-Aia A/-acyM> Ala-D- Lac
Figure 1-3 Binding of vancomycin to D-Ala-D-Ala as peptidoglycan models (Figure from reference 
26)
1.3.3 Resistance by reducing antibacterial permeability
This resistance mechanism reduces the intracellular accumulation o f antibacterial 
agents in bacterial cells through transmembrane proteins. The action o f membrane- 
based efflux pumps has been shown to play an important role in the recent development 
of multidrug resistance to antibiotics .30,31 Basically, the development o f  efflux-mediated 
resistance occurs through the up-regulation o f  genes encoding transporters that 
efficiently extrude drugs from the bacterial cell and result in a low ineffective
1 0
concentration o f  the drugs in the cell. For example, tetracycline and erythromycin 
antibiotics are pumped out from bacterial cells (e.g. E. coli) via efflux pump protein 
(Figure 1-4). The pump exports these drugs from the bacterial cell faster than the drug 
diffuses into the cell, so the intracellular drug concentration is not high enough to 
destroy the cell.
Figure 1-4 Drugs are pumped out of bacterial cells via efflux pump proteins (Figure from reference
1.4 Bacterial efflux pump classification
To date, five families o f bacterial drug efflux pumps have been identified based 
on the energy source used for extruding substrates and on sequence similarity (Table 1- 
3). Bacteria can possess efflux proteins from one or more families. The Major 
Facilitator Superfamily (MFS), Resistance-Nodulation Division Family (RND), Small 
Multidrug Resistance Family (SMR), and Multidrug and Toxic Compound Extrusion 
Family (MATE) use a proton motive force (PMF), pH gradient and electrochemical 
formation to efflux antibacterial agents in exchange for protons. The ATP-Binding 
Cassette Superfamily (ABC) o f transporter proteins derive their energy from ATP 
hydrolysis.30
MFS transporters contain about 400 amino acids and have been classified into two 
subfamilies, which have 12 and 14 transmembrane helices (Figure 1-5). The pumps
Antibiotic
• Eiythromycins
• Tetracyclines
Resistance mechanism
Bacteria manufacture protein pumps that pump 
the antibiotic out so that it does not accumulate 
to a high enough internal concentration to block 
protein synthesis
26)
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with 14-helix transporters are QacA, EmrB from E.coli, TetK from S. aureus, TetL from 
Bacillus stearothermophilus, and TcmA from Streptomyces glaucescens. Others having 
12-helix transporters are Bit and Bmr from Bacillus subtilis, EmeD from E. coli, and 
NorA from S. aureus. The substrates of this family are a variety of organic cations, 
including quaternary ammonium compounds such as benzalkonium chlorides, which are 
pumped out by QacA, plus uncharged drugs such as chloramphenicol which is extruded 
by NorA and Bmr.32
Table 1-3 Antibacterial Resistance Efflux Families, Biochemical Characteristics, Efflux Substrates 
and Bacteria Hosts33
Family Biochemical Characteristics Chemical Substrates Bacterial Hosts (genera)
M ajor Facilitator
Superfamily
(MFS)
12 or 14-membrane 
spanning segments
antibiotics, quaternary 
amm onium compounds 
basic dyes, 
phosphonium ions
Mycobacterium
Lactobacillus
Staphylococcus
Bacillus
Escherichia
Streptococcus
Vibrio
Resistance Nodule 
Cell Division 
(RND)
M ulti-com ponent 
segments: mem brane 
protein
basic dyes, detergents 
antibiotics, fatty acids
Escherichia
Pseudomonas
Neisseria
Haemophilus
Small M ultidrug 
Resistance Family 
(SMR)
Approxim ately 100-120 
amino acids in primary 
structure, 4 helices
antibiotics, quaternary 
amm onium com pounds 
antiseptics, tertraphenyl 
phosphonium, ethidium
Bacillus
Escherichia
Mycobacterium
Staphylococcus
Multidrug and Toxic 
Compound Extrusion 
Family (ABC)
12-putative mem brane 
spanning segments
dyes, fluoroquinolones 
am inoglycosides
Haemophilus
Vibrio
Bacillus
SMR transporters are the smallest known translocases with about 110 amino 
acids, and only 4 transmembrane domains; an example is the EmrE transporter from E. 
coli. The substrates are similar to the MFS, namely hydrophobic cations, but the range
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is narrower than that o f  the MFS transorters .34 Many multidrug transporters o f the MFS 
and SMR families have acidic residues at a similar position in helix 1, suggesting that 
they are using a similar mechanism to bind to similar substrates .35
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Figure 1-5 Diagram of the membrane topology of proton-driven drug pumps in Gram-negative 
bacteria35
RND transporters contain about 1000 amino acids, which make them much bigger 
than the MFS transporters, with a similar 12-helical structure except for 
extracytoplasmic domains between helices 1 and 2 and between helices 7 and 8  (Figure 
1-5). A mutation o f  the pumps in this family leads to susceptibility to a wide range o f 
substrates, which carry positive, negative or no charge, suggesting that the pumps can 
capture their substrates, which are only partially inserted into the membrane lipid 
bilayer.36 Recently, the crystal structures o f  outer membrane TolC37 and inner 
(cytoplasmic) membrane AcrB38 transporter proteins in E. coli have been solved while
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that o f  AcrA protein is still unknown (Figure 1-6). The structures o f TolC and AcrB 
proteins were predicted to line up to from one continuous channel, which is connected 
together with the AcrA protein. This system exports a wide range o f  substrates from 
both cytoplasm and periplasm to the outside o f  the bacterial cells. This double 
protection system confers resistance to antibiotics and makes E. coli dangerous 
pathogenic bacterium.
Cytoplasm
Figure 1-6 Proposed model of the AcrB-AcrA-TolC drug export complex in E. coli3*
MATE transporters were the most recently identified family, with 12 
transmembrane helices containing a total o f  450 amino acids. The NorM  transporter 
from Vibrio parahaemolyticus has been characterized as a multidrug Na+- antiporter, 
which confers resistance to cationic compounds, dyes, fluoroquinolones, and 
aminoglycosides.39 No proposed mechanism has been reported.
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Figure 1-7 Diagram of the membrane topology of drug transporters belonging to the ABC
superfamily
ABC transporters represent a minority o f  efflux pumps. They derive their 
transport energy from ATP hydrolysis and have two similar halves, each containing two 
parts o f twelve transmembrane domains arranged into six a-helices, and a nucleotide- 
binding domain (NBD) (Figure 1-7). The wide range o f  substrates o f this family 
includes dyes, ionophoric peptides, lipids and steroids. Recently, the MacB transporter 
from E. coli has been identified as being involved in the extrusion o f  macrolide 
antibiotics.35 The proposed general mechanism o f the pumps in this family can be 
described by the process involved in the LmrA pump from Lactococcus lactis, which is 
a multidrug transporter with structural and functional identity with the P-glycoprotein 
(P'Pg) pump in humans (Figure 1-8). The interconversion o f  two conformational forms 
of the protein is induced by ATP, which have a high-affmity transport-competency in 
°ne intracellular site, and a low-affmity drug-release site in an extracellular region.
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Figure 1-8 Simple model of P-gp transport 
“The NBDs are represented in yellow and the membrane-spanning domains in green.  Step 1: binding of 
ATP to the NBD of one half of the transporter triggers drug binding to a high-affinity intracellular drug-
binding site.  Step 2-3: ATP is hydrolysed, occluding the drug-binding site.  Step 3-4: release of the 
generated Pi leads to the exposure of the drug at an extracellular-facing, low-affinity drug-binding site on 
the same domain.  At this point the drug can be released.  As a result of the remaining ADP and co-
operative interaction between the two NBDs, ATP is likely to bind to the non-liganded NBD.  Step 4-5: 
further conformational changes are likely to result in the exposure of a high-affinity drug-binding site on 
the intracellular side of the membrane domain that is associated with the liganded NBD.  Step 5-6: drug 
binding at this site results in ATP hydrolysis and the drug-binding site becomes occluded.  Step 7-1: 
release of Pi exposes a low-affinity drug-binding site at the extracellular side and the drug is released.  
Release of the drug and ADP allows the return of the transporter to the original conformation, and the 
cycle can begin again.”35  
 
1.5 Bacterial MDR pump inhibitors 
 There are a few proposed mechanisms of inhibitor action against MDR 
transporters: these include direct binding of the inhibitor to the binding sites of the 
pump protein causing no drug transport,40 destruction of the pumps’ energy by 
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inhibiting binding of ATP and modifying protein structure by an inhibitor interaction 
with the cell membrane.29,41  
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Figure 1-9 Inhibitors of MDR pumps 
 A number of potential inhibitors of bacterial efflux pumps have been discovered, 
such as MC-207,110, a broad-range inhibitor and the first inhibitor active against 
multiple RND transporters in Gram-negative bacteria, which was produced by 
Microcide Pharmaceuticals.42 It is an aminonaphthalene derivative of a phenylalanine-
arginine dipeptide (Figure 1-9), and it was found to possess superior activity to inhibit 
RND multidrug pumps of P. aeruginosa, Enterobacteriacea, Haemophilus influenza 
and Stenotrophomonas maltophilia, which potentiates the effects of fluoroquinolone 
antibiotics.42-44 Several semisynthetic tetracycline analogues have been synthesised, of 
which the most potent analogue with ability to inhibit the TetB protein, is 13-
cyclopentylthio-5-hydroxytetracycline (13-CPTC, Figure 1-9).  This compound has 
been shown to inhibit tetracycline efflux in E. coli.45  INF 392, the most potent synthetic 
NorA pump inhibitor of a series of INF analogues (Figure 1-9), has been shown to 
potentiate the bacteriocidal activity of ciprofloxacin or ethidium bromide in S. aureus; 
INF392 also reduced the number of spontaneous mutants in S. aureus to ciprofloxacin 
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by 50-fold or more.33,46 5´-Methoxyhydnocarpin-D (5´-MHC-D, which had originally 
been given the name 5´-methoxyhydnocarpin, 5´-MHC),47-49 a natural potent inhibitor 
of the NorA pump, was found in a leaf extract of Barberry (Berberis fremontii) and was 
found to potentiate the activity of typical substrates of the NorA pump, such as: 
berberine, ethidium bromide, and triphenylphosphonium ion.47 Some inhibitors of the 
NorA pump will be discussed further in Chapter 3 as part of this thesis. 
 
1.6 Definitions of dual action prodrugs and dual action drugs 
 Dual action prodrugs, also known as mutual prodrugs, are pharmacological 
derivatives of two different but generally synergistic drug molecules, combined together 
with a covalent linkage, which requires spontaneous or enzymatic transformation within 
the body to release the two active compounds.50,51 Over the past two decades, the 
prodrug concept has been optimized in an attempt to solve some problems found in a 
large number of existing drugs, and has also become an integral part of the new drug 
design process.  The application of a prodrug approach has been successful in the 
enhancement of the parent drug activity, for example, with dual action antibiotic hybrids 
of cephalosporins and quinolones that attack bacteria with two completely different 
modes of action.  Cephalosporins are active against Streptococci and belong to the β-
lactam class of antibiotics, and quinolones are active against β-lactam-resistant strains.   
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Figure 1-10 Release of quinolone on hydrolysis of a cephalosporin-quinolone ester prodrug 
 
 For a quinolone to be microbiologically active then its 3-carboxyl group must be 
free.  The 3-carboxyl group of the quinolone is combined to a cephalosporin nucleus at 
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position 3 via an ester link (Figure 1-10).  Quinolone activity is generated by one of 
three mechanisms.  Firstly, when the prodrug is in the presence of an active β-
lactamase, which catalyzes the hydrolysis of the amide bond in the β-lactam ring, 
resulting in ring opening and subsequent release of the quinolone carboxylic acid; 
secondly, when the prodrug undergoes spontaneous hydrolysis; and thirdly, when the 
penicillin-binding proteins (PBPs) in the cytoplasmic membrane of bacteria are acylated 
by the cephalosporin causing inhibition of cell-wall synthesis and cell death via the 
standard mode of action of β-lactam antibiotics.  Therefore, the dual action prodrug 
cephalosporin-quinolone esters act as cephasporins and also as prodrugs for 
quinolones.52-54  
 Dual action drugs (or hybrid drugs) are pharmacological derivatives of two 
different drug molecules attached to each other and do not require biotransformations to 
release the two active compounds.50 The dual action prodrug and dual action drug 
approaches of parent compounds A and B can be illustrated as shown in Figure 1-11.     
 
A BCleavable   Linker
A BNon-cleavable     Linker
Enzymatic or Non-enzymatic
         Biotranformation
A Target 1 + B Target 2
Target 1 A B
Dual action prodrug
Dual action drug
A and B are different pharmacological drugs
A B Target 2
+
No biotransformation
 
Figure 1-11 Diagram illustrating dual action prodrug and drug approaches 
  
 The main aim of the work in this thesis was to attempt to overcome the 
antibacterial resistance problem in certain bacteria using compounds based on both the 
dual action prodrug and dual action drug concepts. Both design concepts were to 
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incorporate two molecular components having different biochemical targets, and were 
to be delivered to the target sites in the bacterial cell in effective concentrations.  Some 
of the advantages and disadvantages of dual action drugs and dual action prodrugs are 
summarized in Table 1-4, and a comparison made with the administration of two 
separate drugs (dual drug approach).  This last approach has been used successfully in 
antibacterial therapy, for example with Augmentin (amoxicillin (antibacterial) and 
potassium clavulanate (β-lactamase inhibitor)).55 A key potential advantage of the dual 
action drugs or prodrugs was the synchronous (or near synchronous) delivery in high 
concentration of active components to different bacterial target sites. 
 
Table 1-4 Comparison of dual action drugs and dual action prodrugs with two separate drugs (dual 
drugs). 
Type  Advantages  Disadvantages  
Dual Drugs  • Known components administered  • Formulation; administration  
   
• Different pharmacokinetics of  
   each drug  
   
• Drug may not synchronously  
   accumulate at bacterial sites  
    • More side effects 
Dual Action  
Drugs  
• Synchronous delivery to different bacterial 
   target sites and in high concentrations  
• Each activity may be reduced 
  (e.g. steric reasons) 
  • Slower development of resistance • Molecular weight high 
 • Improved formulation  
 • Improved chemical stability  
 • Decreased toxicity  
Dual Action  
Prodrugs  
• Synchronous or near synchronous delivery  
  of active agents  
• Synthetic difficulties 
 
  • Slower development of resistance?   • Molecular weight high 
 • Improved formulation  
 • Improved chemical stability  
 • Decreased toxicity  
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1.6.1 Design principles of dual action antimicrobials  
 One of the three resistance mechanisms of bacteria to antibiotics, as mentioned 
above, is mediated through reducing antibacterial permeability.  Recently, there has 
been a report by Stermitz et al.47 on the synergistic antibacterial activity in components 
of a medicinal plant, Berberis fremontii, involving the alkaloid berberine (1) and the 
flavonolignan 5´-MHC-D (Figure 1-9).   Berberine possesses a planar aromatic cationic 
center that is thought to provide the antimicrobial activity and also to serve as a 
recognition site by efflux pump proteins in the microbial cells; berberine is pumped out 
from the cells thus reducing its potency.  5´-MHC-D flavonolignan is not a typical 
MDR substrate or antibacterial agent, but it can potentiate the activity of berberine by 
blocking the MDR (NorA) pump in S. aureus as shown in Figure 1-12. 
 
Figure 1-12 "A model of the synergistic action of berberine and an MDR inhibitor that are both 
produced by B. fremontii.  Berberine accumulates in the cell driven by the membrane potential.  
The NorA pump extrudes berberine.  The MDR inhibitor 5'-MHC, which has been renamed to 5'-
MHC-D and confirmed its structure by HMBC NMR spectroscopic data,49 blocks the NorA pump, 
potentiating the antibiotic action of berberine."47  
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 This knowledge could be adapted to attack resistant strains of pathogenic bacteria 
by using an MDR pump inhibitor in combination with an antimicrobial agent which is 
normally effluxed by this pump.  Thus, the design of dual action prodrugs and dual 
action drugs to combat antibacterial resistance by reducing this antibacterial 
permeability mechanism could be achieved potentially via a combination of 
antibacterial agent and MDR pump inhibitor in the same molecule.  The linkage 
between the two moieties could be designed to cleave under bacterial enzymatic action 
(e.g. ester or amide hydrolysis) for dual action prodrugs, or to be a non-cleavable under 
enzymatic action for dual action drugs.  The prodrugs should deliver synchronously (or 
near synchronously) the antibacterial agent and the MDR pump inhibitor in high 
concentration at or near the appropriate bacterial sites, and a dual mode of action would 
be exerted.  Additionally, this approach could help to eliminate the undesirable 
properties associated with administering the two parent molecules separately (dual 
drugs) as summarized in Table 1-4.  Similar considerations could apply to the 
development of novel antimalarial agents.   
O
O
O
O
OCH3
OH
N
H
O2N R
5,7-Deoxyhydnocarpin-D                        2-Aryl-5-nitro-1H-indole derivatives
OH
 
 There are a variety of antimicrobial agents and many types of MDR pump 
inhibitors.  In this project the antimicrobial agent of interest was the alkaloid berberine, 
which has a range of antimicrobial activity, and the MDR pump inhibitor was focussed 
on the flavonolignan 5,7-deoxyhydnocarpin-D,56 the most potent synthetic NorA pump 
inhibitor, and on the simpler 2-aryl-5-nitro-1H-indole NorA pump inhibitor derivatives. 
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Berberine Linker Pump Inhibitor
Non-cleavable linker
       (C-C bond)
      Cleavable linker
(ester or amide bond)
Antibacterial Berberine derivative
+
Pump inbibitor
Dual action drug
(Dual action prodrug)  
Figure 1-13 Diagram illustrating the dual action prodrug and dual action drug designs 
 
 As shown in Figure 1-13, the dual action prodrugs and dual action drugs of efflux 
pump inhibitor-berberine prodrugs are formed to enhance a drug’s utility.  Once inside 
the bacterial cell the dual action efflux pump inhibitor-berberine prodrugs with 
cleavable linkages should revert to the antibacterial berberine derivative and efflux 
pump inhibitor at the same time by an enzymatic or non-enzymatic process, and then 
show their activities when they reach the target sites in high concentration.  The dual 
action efflux pump inhibitor-berberine hybrids with a non-cleavable linkage are similar 
to the ones with cleavable linkage, but would not require a post-barrier transformation 
process to release the two parent moieties. 
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1.7 Aims of project 
 The aims of this project were: 
1.  To design new antimicrobial agents of berberine-based derivatives based on the 
dual action prodrug and dual action drug concepts.  
LinkerPotent Pump Inhibitor 13
N
OMe
OMe
Model of dual action agents
O
O
X-
 
2.  To develop a synthetic route to the dual action agents. 
3.  To synthesize variants on the dual action agents with different enzyme-sensitive 
linking groups (substituted ester; amide), and enzyme-insensitive linking groups. 
4.  To assess the antibacterial potency (and spectrum of activity) and antimalarial 
activity of the new derivatives produced, and to define structure-activity 
relationships. 
5.  To identify leads for further drug development.  
6.  To measure MDR inhibition of the new efflux pump inhibitors in the NorA efflux 
pump.   
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2 Chapter2: Synthesis of berberine derivatives  
On the basis of the SARs of berberine analogues discussed in Chapter 1, substitution 
at C-13 of berberine can increase the antibacterial activity.  Thus, a combination of an 
efflux pump inhibitor via the 13-position of berberine, based upon the dual action 
prodrug and dual action drug concepts, formed the basis for the synthetic targets in this 
study.  The inhibitor was expected to act synergistically by preventing the expulsion of 
the berberine-based pump substrate.  
 A number of 13-substitued berberine derivatives were thus prepared from 
berberine chloride in 3 steps via dihydroberberine (Scheme 2-1) or in 2 steps via 8-
acetonyldihydroberberine derivatives (Scheme 2-2).9,57,58  
O
O N
OCH3
OCH3
Berberine (1)
O
O N
OCH3
OCH3
O
O N
OCH3
OCH3
O
O N
OCH3
OCH3
RR
Reduction
Enamine alkylation
Oxidation
dihydroberberine (2)
13-substituted dihydroberberine13-substituted berberine  
Scheme 2-1 Preparation of 13-substituted berberine derivatives from berberine via 
dihydroberberine (Note: for simplicity the counterion for the salts is omitted in this Scheme and, on 
occasion, also in subsequent Schemes) 
 
 In the first synthetic approach, berberine (1) was reduced with sodium 
borohydride59 and potassium carbonate in methanol57 to afford dihydroberberine (2), 
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followed by enamine alkylation with electrophiles (R-X), and subsequent oxidation with 
N-chlorosuccinimide (NCS) or N-bromosuccinimide (NBS) to give the 13-substitued 
berberine salt derivatives.  The target compounds were also prepared in 2 steps (Scheme 
2-2) by treatment of 1 with acetone and aqueous sodium hydroxide solution to afford 8-
acetonyldihydroberberine and subsequent enamine alkylation with electrophiles (R-X) 
followed by elimination of acetone to afford the salt derivatives.  One problem 
associated with the 8-acetonyldihydroberberine route is that the berberine salt (1) can be 
regenerated quite readily by elimination.60  
 
O
O N
OCH3
OCH3
Berberine (1)
O
O N
OCH3
OCH3
O
O N
OCH3
OCH3
R
Mannich reaction
1. Enamine alkylation
2. Elimination
CH2COCH3
13-substituted berberine
8-acetonyldihydroberberine
 
Scheme 2-2 Preparation of 13-substituted berberines in 2 steps via 8-actonyldihydroberberine 
 
2.1 Retrosynthesis of efflux pump inhibitor-berberine dual action 
agents 
The preparation of efflux pump inhibitor-berberine dual action agents with a 
cleavable linker can be achieved via the DCC coupling of berberine acid derivative with 
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a range of pump inhibitors.  The alcohol derivative of the pump inhibitors can be 
attached to a berberine acid derivative via an ester linkage.  Similarly, the amine 
derivatives of pump blockers can be attached to a berberine acid derivative to form an 
amide linkage (Model study 1).  Alternatively, the dual action agents may be achieved 
via enamine alkylation of dihydroberberine derivatives with an inhibitor containing an 
alkyl halide group to give products both with cleavable and non-cleavable linkages 
(Model study 2).  The general retrosynthetic analysis with respect to the two model 
studies is shown in Scheme 2-3. 
LinkerPump Inhibitor
(b) Linker Attached
     (Model study 2)
(a) Making Linker
     (Model study 1)
Linker = CH2OCOCH2,
                CH2NHCOCH2, CH2
13
N
O
O
OMe
OMe
N
O
O
OMe
OMe
COOH
Pump InhibitorPump Inhibitor CH2Y Z
+ +
N
O
O
OMe
OMe
Y = OH, NH Z = CH2OCOCH2X, CH2NHCOCH2X,
       CH2X
X = Halogen
 
Scheme 2-3 General retrosynthetic analysis of efflux pump inhibitor-berberine dual action agents 
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2.2 Synthetic strategies 
2.2.1 Model Study 1 
 In this model study, in summary, the tetrahydroberberine acid derivative 4 was 
prepared (Scheme 2-4), and then coupled with benzyl alcohol as an MDR inhibitor 
model.  Subsequent oxidation then gave the berberine salt (7). 
 Preparation of the model target compound 7 began from commercially available 
berberine chloride (1), which was reduced with sodium borohydride to give 
dihydroberberine (2).  Enamine alkylation of 2 with ethyl bromoactetate produced the 
13-substituted iminium salt (2a) as an unstable product, which was reduced immediately 
with sodium borohydride in methanol to afford the 13-substituted tetrahydroberberine 
(3).  Hydrolysis of 3 with an aqueous solution of lithium hydroxide in methanol gave 
the tetrahydroberberine acid (4).  DCC coupling of 4 with benzyl alcohol then afforded 
the benzyl ester (5), followed by oxidation with NBS to yield the model target 
compound (7).  A detailed discussion of these steps is given in the following sub-
sections. 
 29
O
O N
OCH3
OCH3
+
Cl - O
O N
OCH3
OCH3
O
O N
 +
OCH3
OCH3
1
EtOOCH2C
O
O N
OCH3
OCH3
EtOOCH2C
Reduction
Reduction
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O N
OCH3
OCH3
PhH2COOCH2C
Enamine 
alkylation
PhCH2OH
Scheme 2-4 Synthetic strategy for preparation of efflux pump inhibitor-berberine prodrug via DCC 
coupling. 
 
2.2.1.1 Reduction of berberine chloride 
  Berberine chloride (1) has been reported to be reduced to its enamine (2) in high 
yield using NaBH4 in an aprotic solvent  (e.g. pyridine) or in a protic solvent (e.g. 
MeOH) in the presence of K2CO3, the yield of 2 were 73%59 and 98%57, respectively.  
In the present work, compound 2 was prepared by both methods.  Reaction of 1 with 
NaBH4 in pyridine (Scheme 2-5) was found in the present study to afford a higher yield 
(96%) of 2 than from NaBH4 and MeOH in the presence of K2CO3 (53%, Scheme 2-6).  
A possible mechanism for the latter reagent conditions is via a hydride transfer to C-8, 
and then abstraction of the proton at C-13 by carbonate (Scheme 2-6).  This method was 
easier to handle than the NaBH4/pyridine method which required anhydrous conditions, 
and the unpleasant solvent, pyridine. 
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Scheme 2-5 Preparation of dihydroberberine (2) using NaBH4 in pyridine 
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Scheme 2-6 Preparation of dihydroberberine (2) using NaBH4 in MeOH and K2CO3 
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Scheme 2-7 Possible by-product berberine hydroxide generated in the presence of strong base 
 In the NaBH4/MeOH reaction, a possible by-product could be formed from 
MeOH in the presence of strong base, which can generate a methoxide ion.  The 
methoxide ion could attack at the C-8 atom of 1 to form an 8-methoxy enamine.  
Subsequently, the enamine formed might be protonated by water in the reaction and 
followed by washing successively the crude product with water (a stronger acid than 
methanol), leading to elimination of methanol and formation ultimately of the hydroxide 
(rather than methoxide) of 1 (Scheme 2-7).61   
2.2.1.2 Enamine alkylation and reduction
The alkylation of enamine 2 with ethyl bromoacetate produced the non-purified 
iminium salt intermediate a in high yield (Scheme 2-8).
Scheme 2-8 Preparation of 13-ethylethanoate tetrahydroberberine (3)
Under various anhydrous reaction conditions, the highest yield of a obtained was 
96% using neat ethyl bromoacetate and a reaction temperature of 100°C. Initially, the 
reaction was tried using a solvent, e.g. toluene, to dissolve the starting enamine 2  first, 
then an excess of dry ethyl bromoactate was added to the solution, and the reaction was 
then carried out at 80°C. The yields obtained were in the range of 60-70%, with many 
low polarity by-products being observed on TLC. Fortunately, the by-products were 
easily removed by trituration with toluene. As a result of the instability of the 
intermediate a, it was reduced immediately by NaBH4 in EtOH at room temperature to 
yield the ester 3 in 8 8 % yield. The structure of 3 was confirmed by the *H NMR 
spectrum, which showed the loss of the signal attributed to H-13, but a signal assigned 
to H-13a as a broad singlet at 8  3.72 was observed instead. In addition, the data showed 
a set of signals assigned to the methylene protons at 5 2.30 (1H), 2.44 (1H), and 3.98 
(2H), which were attributed to the CH2CO and OCH2 groups respectively, together with 
a triplet signal ascribed to the methyl substituent of the ethyl ester at 5 1.15. MS (Cl)
31
 32
showed the molecular ion peak at m/z 426.  All the spectroscopic data was consistent 
with the addition of an ethyl ethanoate substituent to the dihydroberberine at C-13. 
 
2.2.1.3 Ester hydrolysis 
 The hydrolysis of ester 3 was attempted in both acidic and basic conditions.  In 
the case of acidic hydrolysis, 2M HCl and 1M H2SO4 did not hydrolyze ester 3 at room 
temperature.  Monitoring of the reaction by TLC before work-up of the reaction showed 
the disappearance of the starting ester 3 and the presence of a more polar component 
than ester 3.  After neutralization with NaHCO3, and extraction with EtOAc, the product 
spot on TLC (silica gel) reverted back to the same Rf  as the starting ester 3.  It is likely 
that 3 was protonated on the nitrogen atom by the acid without hydrolysis occurring, 
and then the free base of 3 was produced after neutralization.  In contrast to the acidic 
hydrolysis, the hydrolysis of 3 under basic conditions proceeded smoothly.  Thus, 
reaction of 3 with 2% LiOH in MeOH at 60oC62 gave the carboxylic acid 4 in 95% yield 
(Scheme 2-9) after acidification.  The 1H NMR and 13C NMR spectra confirmed the 
structure of acid 4 with the absence of ethyl group signals, and the presence of a 
carboxylic acid carbonyl signal at δ 173.6 in the 13C NMR, together with the MS (EI) 
spectrum which showed a molecular ion peak at m/z 397 consistent with this product.  
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     MeOH
O
O N
OCH3
OCH3
HOOCH2C
95%
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Scheme 2-9 Preparation of acid derivative 4 
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2.2.1.4 Esterification 
 The esterification of carboxylic acid 3 with benzyl alcohol was accomplished in 
the presence of DCC and DMAP under anhydrous conditions.  Attempts to esterify the 
acid 4 with benzyl alcohol using EDCI with DMAP or DCC with HOBt in anhydrous 
DMF were not successful.  The benzyl ester 5 was obtained in 32% yield (Scheme 2-10) 
with DCC and DMAP in DMF.   
O
O N
OCH3
OCH3
HOOCH2C
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PhCH2OH, DMF
DCC, DMAP,
         32%
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OCH3
OCH3
PhH2COOCH2C
 
Scheme 2-10 Preparation of the benzyl ester berberine derivative 5 
 Initially the esterification was attempted using 1.5 eq of benzyl alcohol, 1.0 eq of 
acid 4 in DMF in the presence of DCC and DMAP and heating at 40oC for 5 days.  The 
reaction was monitored by TLC (silica gel) until no starting acid 4 could be detected, 
and then the reaction mixture was concentrated by distillation at 110oC to remove the 
DMF.  Removal of the excess benzyl alcohol required increasing the distillation 
temperature to 150oC, which gave many unwanted by-products.  However, using 
exactly 1 equivalent of benzyl alcohol overcame this difficulty.  In the 1H NMR 
spectrum of 5, signals assigned to five aromatic protons at δ 7.19-7.35 were apparent, 
together with signals at δ 2.37 and 2.52 that were assigned to the CH2CO protons, and at 
δ 4.97 which was ascribed to the OCH2 protons. 
 
 34
2.2.1.5 Oxidation 
 The oxidation of tetrahydroberberines to their berberine salt derivatives was 
achieved using an oxidizing agent, such as I2 in EtOH and NBS in CHCl3.  Following a 
literature procedure,63 an initial trial oxidation reaction of ester 3 was performed using I2 
in EtOH.  The iodide salt 6a was produced in 97% yield (Scheme 2-11).   
 
O
O N
+
OCH3
OCH3
R
X-
(3) R = CH2COOCH2Et
(5) R = CH2COOCH2Ph
O
O N
OCH3
OCH3
R
(6a) X = I, R = CH2COOCH2Et, 97%
(7a) X = I, R = CH2COOCH2Ph, 16%
(7b) X = Br, R = CH2COOCH2Ph, 85%
I2, EtOH or
NBS, CHCl3
 
Scheme 2-11 Oxidation of tetrahydroberberines to their berberine salt derivatives  
 
 Under similar conditions to those used for the oxidation of 6a, the ester 5 was 
oxidized to produce 7 in low yield.  Unlike the oxidation of 3, the oxidation of 5 did not 
give any insoluble product material after the addition of Na2SO3 to destroy the excess I2.   
Thus, the reaction mixture was evaporated and chromatographed on silica gel, but due 
to the very strong interaction between the silica gel and product 7a, purification was 
quite difficult.  In a modified procedure, a large volume of EtOH was used in the 
oxidation reaction, and purification on alumina gave 7a in 16% yield.  Following a 
general literature procedure,57 the oxidation of ester 5 was also carried out with NBS in 
chloroform to afford the bromide salt 7b in high yield (85%).  This method was milder 
and quicker than that of iodine in EtOH.  Moreover, the purification of product 7b did 
not require recourse to chromatography.  The structure of 7b was confirmed by the 
presence of a singlet signal in the 1H NMR ascribed to H-8, which moved dramatically 
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downfield from δ 3.50 and 4.18 (2H, in 5) to 10.56 (1H, in 7).  Additionally, two proton 
signals assigned to H-8 and H-13a in the starting material 5 were absent in the 1H NMR 
spectrum of the product 7b.  The MS (ES) showed a positive ion peak at m/z 484, which 
corresponded to the molecular weight of compound 7. 
 
2.2.2 Model Study 2 
 The basic synthetic strategy was to prepare the enamine (9) first, followed by 
alkylation to the 13-substituted berberinium salts.  A brief discussion on the two-step 
preparation of the model target compounds 6b, 7b, 10-11 began from the commercially 
available berberine chloride (1).  Compound 1 was reacted with allyltributyltin to give 
8-allyldihydroberberine (9). Subsequent enamine alkylation of 9 with a range of 
alkylating agents produced the model targets (6b, 7b, 10-11) in moderate yield.  The 
detailed discussion is given in the following sub-sections. 
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Scheme 2-12 Synthetic strategy for preparation of model efflux pump inhibitor-berberine prodrugs 
via enamine alkylation. 
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2.2.2.1 Allylation 
 α-Allylation of isoquinoline alkaloids can be accomplished by reaction with 
allyltin reagents, resulting in high yields of product.  Commercially available 
allyltributyltin was used as the allylating agent in the preparation of the enamine 9.  
Based on an adapted literature procedure,64 the reaction was achieved by simply adding 
excess allyltributyltin to a suspension of berberine chloride (1) in DCM in a sealed tube 
and heating at 100oC for 8 hours.  The product 9 was then obtained in 92% yield. 
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Scheme 2-13 Preparation of 8-allyldihydroberberine 9 
 
 The structure of 9 was confirmed by the presence of a characteristic signal pattern 
attributed to the allyl substituent in the 1H NMR spectrum. It showed two groups of 
multiplet signals at δ 4.83-4.92 (2H) and 5.74-5.88 (1H), which were characteristic of 
methylene and methine protons attached to an sp2 carbon  (CH2=CH-).  A multiplet 
signal at δ 4.83-4.92 (2H) was assigned to the allylic methylene protons of the allyl 
substituent.  In addition, the signal ascribed to H-8 moved dramatically upfield from δ 
9.76 in the chloride salt of 1 to δ 4.83-4.92 in the enamine 9, with an accompanying 
change in multiplicity from a singlet in 1 to a multiplet in 9 due to the coupling between 
H-8 and the allylic sp3 methylene group.  The MS CI) showed a molecular ion signal at 
m/z 378, which matched the molecular weight of compound 9. 
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2.2.2.2 Enamine alkylation 
 13-Substituted berberine derivatives can be accessed by C-alkylation of 8-
acetonyldihydroberberine as mentioned above in Scheme 2-2.  The problem with the 8-
acetonyldihydroberberine route is that the berberine salt (1) itself can be regenerated via 
a retro-Mannich reaction, which is competitive with the enamine alkylation to generate 
13-substitued berberine derivatives.60 To avoid this problem, the new 8-
allyldihydroberberine 9 route was utilized.  Heating of enamine 9 with a variety of 
bromide derivatives (ethyl bromoacetate, benzyl bromoacetate, phenacyl bromide and 
benzyl bromide) at 100oC afforded the 13-substituted salts (6b, 7b, 10-11) in moderate 
yield (scheme 2-14).  It was found that using neat bromide alkylating agent derivatives 
gave better yields than with an added solvent except in the case of phenacyl bromide, 
for which a solution in acetonitrile was preferable. 
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(6b) R = CH2CO2CH2CH3, 59%
(7)   R = CH2CO2CH2Ph, 57%
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(11) R = CH2Ph, 62%
100oC
 
Scheme 2-14 Preparation of 13-substituted berberine salt derivatives 
 
 Mechanistically (Scheme 2-15), the formation of the salts may be rationalized in 
terms of initial enamine alkylation of 9 to give the intermidiate 9a, followed by a [3,3]-
sigmatropic rearrangement to 9b and a subsequent retro-ene reaction65 to afford the salts 
6b, 7b, 10-11 and propene.  The alternative step of direct elimination of propene from 
9a cannot be excluded however.  While the acetonyldihydroberberine route to 13-
substituted berberinium salts may also involve a [3,3]-sigmatropic rearrangement of a 
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tautomeric enol intermediate, this is considered less likely in view of the very low enol 
concentration expected; the driving force again would be the eventual formation of the 
aromatic ring in the berberine.  
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Scheme 2-15 Proposed mechanism of formation of 13-substituted berberine salt derivatives 
 
 The structures of the 13-substituted berberine salts were confirmed by NMR 
spectroscopic analysis and mass spectrometry.  The 1H NMR spectrum of 6b, 7b, 10 
and 11 revealed the loss of the allyl group with no signals present that could be ascribed 
to this substituent.  The presence of a signal assigned to the H-8 proton appeared in the 
region of δ 10.46-10.61 as a singlet, while a triplet in the range of δ 2.9-3.2 was ascribed 
to the C5 protons.  A broad signal at δ 4.6-5.0 was ascribed to the C-6 protons, which 
the methoxy group signals appeared at δ 3.8-4.2 and four aromatic methine proton 
signals were also apparent.  In addition, a signal ascribed to the methine carbon of C-8 
in the region of δ 145-148 was observed in the 13C NMR of the products.  Besides the 
characteristic signal pattern attributed to the berberinium salt nucleus, the expected ethyl 
ethanoate substituent signals of compound 6b were seen in the 1H NMR spectrum at δ 
1.37 (3H) as a triplet, 4.36 (2H) as a quartet and 4.27 (2H) as a singlet.  The MS (ES) 
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showed a positive ion signal at m/z 422 which was consistent with the molecular ion of 
6b.  Compound 10 was also confirmed by a singlet signal attributed to the methylene 
protons attached to the carbonyl function at δ 5.07, and a signal integrating for five 
aromatic protons in the aromatic region.  Moreover, the presence of a signal assigned to 
the CO in the 13C NMR spectrum was observed at δ 196.7 and MS (ES) showed a 
positive ion peak at m/z 454 [MH]+, which was consistent with the molecular ion of 10.  
The 1H and 13C NMR spectra of compound 11 were broadly similar to those of 10 
except for the absence of a carbonyl group signal in the 13C NMR spectrum in the 
former compound.   
 In summary, the “model study 2” provided a concise new route to access 13-
substituted berberine salts and it was chosen over “model study 1” for the later 
preparation of the berberine-pump inhibitor dual action agents.  In order to use this 
route, it was necessary to prepare a variety of alkyl halide derivatives of the pump 
inhibitors.  The efflux pump inhibitors and their synthesis are discussed in the following 
sub-sections. 
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3 Chapter3: Synthesis of Efflux pump inhibitors  
3.1 NorA efflux pump 
 NorA protein is a major multidrug transport protein in the human pathogenic 
bacterium S. aureus, an organism which possesses several multidrug efflux pump 
proteins.66 The NorA pump is a member of the Major Facilitator (MF) Superfamily 
having 12 transmembrane-spanning segments and is dependant on the transmembrane 
proton gradient to transport potentially harmful compounds out of the bacterial cell, and 
is driven by the proton motive force as a source of energy.  The NorA protein is located 
in the cytoplasmic membrane and is encoded by the naturally occurring chromosomal 
norA gene, conferring an intrinsic resistance to a variety of structurally unrelated 
antibiotics.67 The mechanism by which the NorA efflux protein recognizes multiple 
structurally dissimilar substrates is still unclear.   
 
3.2 Substrates of the NorA efflux pump 
 As noted above, the NorA efflux pump actively exports a wide variety of 
compounds that are all structurally very different from each other, making it a powerful 
first line of defence for S. aureus against toxic molecules.  Both naturally occurring and 
synthetic compounds can be pump substrates, including hydrophilic fluoroquinolones 
and monocationic organic compounds such as berberine, ethidium bromide, 
tetraphenylphosphonium, benzalkonium, chlorhexidine, pentamidine, norfloxacin and 
others (Figure 3-1).66,68 The precise mechanism of multidrug recognition of the NorA 
pump is unclear due to the difficulty of performing high-resolution X-ray structural 
analysis on integral membrane proteins.  Unfortunately none of the efflux pump 
proteins belonging to the MF superfamily have been crystallized with bound substrates, 
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which would provide a better understanding of how the efflux pump proteins can bind 
and transport a wide range of structurally dissimilar substrates.  Recently, the structures 
of the first few homologous transporters to MFS-type multidrug efflux transporters, 
lactose permease LacY and glycerol-3-phosphate transporter GlpT, which are not 
multidrug efflux transporters per se, have been solved.  These structures confirmed the 
proposal that their hydrophilic substrates were bound to the MF superfamily 
transporters within an intramembranous cavity.69-71  
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Figure 3-1 Chemical structures of some NorA substrates 
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3.3 Inhibitors of the NorA efflux pump 
 Recently, efflux pump inhibitors of the NorA efflux pump have been investigated 
in order to potentiate the activity of antibiotics which are substrates of the efflux pump.  
A variety of natural product and synthetic inhibitors of the NorA efflux pump have been 
reported.   
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Figure 3-2 Chemical structures of NorA inhibitors 
 
 Reserpine (Figure 3-2), an indole alkaloid obtained from root extracts of 
Rauwolfia serpentina, was the first compound identified68 as a potential inhibitor of 
NorA, which, when combined with a hydrophilic fluoroquinolone antibiotic, can 
potentiate the antibiotic potency. Reserpine enhanced the activity of ciprofloxacin (MIC 
= 8 µg/mL) against a fluoroquinolone-resistant strain of S. aureus SA-1199B, a strain 
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that overexpresses NorA, by eight-fold at a concentration of 20 µg/mL.72 Reserpine also 
prevented emergence of fluoroquinolone resistance in S. aureus73 and S. pneumoniae.74 
Since reserpine is neurotoxic to humans at the concentration required for NorA 
inhibition it cannot be used clinically as a NorA inhibitor.46 This lead to a search for 
other compounds with more selective activity.     
 A number of structurally different inhibitors of NorA, such as the synthetic INF 
analogues, have been reported by Influx Inc. (Chicago, IL) (Figure 3-2).  Screening of a 
chemical library containing 9600 compounds for NorA inhibitor activity resulted in 399 
compounds (4%) which were structurally unrelated, and which had inhibitory activity 
which was at least equipotent to that of reserpine.  The chemical inhibitor library was 
divided into several groups.   The first group consisted of indole derivatives, of which 
30 compounds were found to be active, and 7 of these were nitroindoles.  The second 
active group included compounds containing trichloromethylaminal functionality. 
However, it was considered likely that compounds with this group would be toxic to 
humans and therefore no further characterization of this group was conducted.  The 
third group contained biphenyl urea derivatives, with 11 compounds present in this 
library being found to be active.  The last group contained structurally dissimilar 
compounds including INF392, INF277, and INF 240 (Figure 3-2).  Five of the most 
potent INF analogue inhibitors were tested in combination with ciprofloxacin against 
Staphylococcus aureus strain SA-1199B and found to act synergistically and also 
reversed ciprofloxacin resistance four-fold (MIC of ciprofloxacin 2 versus 8 µg/mL) at 
a concentration of 0.2, 0.4, 0.8, 1.5 and 1.5 µg/mL for INF392, INF240, INF277, 
INF271, and INF55, respectively.46 The most potent inhibitor of all the INF analogues 
was INF392, which was more potent than reserpine by fifty-fold.  Also, INF392 reduced 
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the MIC values of ethidium bromide and ciprofloxacin by eight-fold against SA-1199B 
at a concentration of 0.4 µg/mL.75    
 A synthetic inhibitor of P-glycoprotein-mediated mammalian tumour multidrug 
resistance, GG918 (Figure 3-2), was discovered to be a NorA inhibitor and was 
equipotent to reserpine in potentiating the activity of norfloxacin and ciprofloxacin 
against some strains of S. aureus.  In combination with ciprofloxacin, GG918 reduced 
the MIC of ciprofloxacin against SA-1199B eight-fold at a concentration of 10 µg/mL, 
but did not show synergistic activity at the same concentration against the RN4220 
strain of S. aureus, which carries a gene encoding the MsrA macrolide efflux protein.  
Moreover, GG918 enhanced the activity of norfloxacin eight-fold against SA-1199B 
and by four-fold against RN4220 at a concentration of 10 µg/mL.72   There was no 
significant inhibitory activity of GG918 in combination with moxifloxacin against all 
tested strains.    
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Figure 3-3 Naturally occurring NorA inhibitors from Berberis species 
 
 Berberine-producing plants from Berberis species have been found to produce 
potent NorA inhibitors, including porphyrin pheophorbide a and the flavonolignan 5´-
MHC-D,47-49 that act synergistically with the antibacterial berberine against S. aureus.  
Berberine contains a planar aromatic cationic center which is recognized by efflux 
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proteins in bacterial cells, resulting in its extrusion from the bacterial cells.  
Pheophorbide a, and 5´-MHC-D, have no antibacterial activity alone but have been 
shown to boost the activity of an ineffective antibiotic such as berberine against a NorA-
producing strain of S. aureus.  These results may help explain why Berberis plants are 
relatively free of bacterial plant infections.  The MIC of pheophorbide a and 5´-MHC-D 
were 0.5 and 1.2 µg/mL, respectively, in the presence of 30 µg/mL of berberine a 
concentration (which is one-eighth of its MIC against wild-type S. aureus RN4222).48 
Many synthetic flavonolignans and simple flavones were synthesized in order to 
determine structure-activity relationships (SARs) for synergistic activity with berberine 
against S. aureus RN4222.  Many of those compounds showed a synergistic action with 
a sub-inhibitory concentration of berberine (30 µg/mL, 1/8 of the MIC) in the MIC 
range of 0.08-163 µg/mL.  The most potent flavonolignan-based NorA inhibitor was 
5,7-deoxyhydnocarpin-D and the most potent flavone-based inhibitor was 4´-n-
propoxyflavone (Figure 3-4) with MIC values of 0.08 and 0.4 µg/ml, respectively, in 
combination with a sub-inhibitory concentration of berberine in S. aureus.  The results 
revealed that the free hydroxy groups in ring A were not necessary for NorA inhibitory 
activity.56 The effect of stereochemistry on activity was not reported for the 5,7-
deoxyhydnocarpin-D flavonolignan.  
 
O
O
O
O
OH
OMe
OH
A C
B
D
5,7-deoxyhydnocarpin-D 4'-n-propoxyflavone
O
O
O(CH2)2CH3
 
Figure 3-4 The most potent synthetic flavonolignan (relative configuration shown) and flavone of 
NorA inhibitors 
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 Recently, some naturally occurring flavonol  and isoflavone NorA inhibitors 
(Figure 3-5) have been identified.  A weak antibacterial, α-linolenic acid (MIC, 62.5 
µg/mL against S. aureus wild-type 8325-4), was isolated from the leaf and stem extracts 
of Lupinus argenteus, along with the flavonoids chrysoplenetin and biochanin A which 
potentiated the antibacterial activity of that acid.   
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Figure 3-5 Natural flavonol and isoflavone NorA inhibitors, and the antibacterial, α-linolenic acid 
 
 Biochanin A was the most potent inhibitor in this plant, and it was shown to 
completely inhibit S. aureus and B. megaterium (11561, M. Cannon) growth at a 
concentration of 6.25 µg/mL in combination with a sub-inhibitory concentration of 
berberine (30 µg/mL) or a sub-inhibitory concentration of α-linolenic acid (30 µg/mL).  
Moreover, a SAR study of the flavone series found that the monomethoxy B-ring 
derivatives of isoflavones were more potent than disubstitued B-ring derivatives.56,76    
 Additionally, in either the flavonolignans or flavonols, it was found that 
compounds bearing a free hydroxy group at C-3 in ring C did not show efflux pump 
inhibitory activity.  In contrast, compounds bearing a methoxy group at the same 
position showed inhibitory activity in S. aureus.  For example, a combination of 
chrysoplenetin, a natural flavonol extracted from Artemisa annua, at a concentration of 
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6.25 µg/mL with a sub-inhibitory dose of berberine, completely inhibited the growth of 
S. aureus 8325-4.77  
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 More recently, a new antibacterial flavonoid and six known phenolic compounds 
(Figure 3-6) were isolated78 from the plant, Dalea versicolor, and they showed direct or 
synergistic activities against S. aureus and B. cereus.  Both the methoxychalcone 
derivative and stilbene derivative were equally the most potent inhibitors in this plant at 
a concentration of 3.3 µg/mL in combination with a sub-inhibitory concentration of 
berberine against S. aureus 8325-4, whereas dalversinol and the tetrahydroxyflavanone 
derivative (Figure 3-6) had direct activity with MICs of 31.3 and 7.8 µg/mL, 
respectively.  Typically, medicinal plants produce efflux pump inhibitors to potentiate 
their own weak antibiotics.  However, Dalea versicolor was the first plant reported in 
the literature that produced both strong antibacterials and efflux pump inhibitors. It is 
likely that dalversinol and the tetrahydroxyflavanone derivative, which have a flavanone 
nucleus, might not be NorA pump substrates.  
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Figure 3-7 Natural polyacylated neohesperidoside efflux inhibitors 
 
 Polyacylated neohesperidosides (Figure 3-7) isolated from Geranium caespitosum 
were found to potentiate the antibacterial activity of berberine, rhein (an anthraquinone), 
ciprofloxacin and norfloxacin against S. aureus 8325-4.  Neither the monoester nor 
diester derivatives showed potentiation activity with berberine, whereas the tetraester 
and pentaester derivatives did with MIC values of 3.12-6.25 µg/mL in the presence of a 
sub-inhibitory concentration of berberine.79 
 From all the literature data, the synthetic NorA inhibitor 5,7-deoxyhydnocarpin-
D,56 with an MIC value of 0.08 µg/mL, is the most potent inhibitor discovered so far.  In 
comparison to reserpine having efflux pump inhibitory activity at a concentration of 20 
µg/mL in combination with a sub-inhibitory dose of berberine,77 it was found that 5,7-
deoxyhydnocarpin-D was more active than reserpine by 250-fold against S. aureus 
8325-4.  Thus, in the present study this inhibitor was chosen initially for synthesis and 
ultimately for combination with berberine to make dual action prodrugs and dual action 
antibacterials. 
 
3.3.1 Synthesis of 5,7-deoxyhydnocarpin-D (12) 
 Following a literature procedure,56 commercially available coniferyl alcohol and 
3´,4´-dihydroxyflavone were oxidatively coupled using Ag2CO3.  Either Ag2CO3 or 
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horseradish peroxide (HRP) was used previously56 for the preparation of 12 and 14 
yielding a mixture of different regioisomers.  The silver reactions gave 12 as a major 
regioisomer, having ring D at C-13 with the beta position, whereas the HRP reactions 
gave 14 as the major regioisomer product having ring D at C-12 with the alpha position.   
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Scheme 3-1 Preparation of flavonolignan 12 
 
 The reaction with Ag2CO3 was performed in a solvent mixture of 2:1 
benzene/acetone at 60oC for 10h.  Purification of the crude product by column 
chromatography gave only one major fraction, which was shown to be a mixture of 
regio- and stereoisomers on the basis of the 1H NMR spectroscopic data.  Further 
purification of the fraction was performed by PLC with multiple development, resulting 
in 7 product bands with similar Rf values.  Three of these bands were processed to 
afford the regiopure compound 12 as a major product, and two minor products, 13(a or 
b) and 14 (Scheme 3-1), which were confirmed by NMR spectroscopic analysis.  Guz et 
al.49,56 were not able to separate a mixture of 12 and 14 using HPLC methods.  As 
acetylation of the mixture 12/14 facilitated an easier separation of the mixed products, 
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the NMR spectroscopic data of the peracetate derivative of 12 were reported by these 
authors.  
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Scheme 3-2 Free radical mechanism for the formation of 12 and 14 
 Mechanistically, the coupling of coniferyl alcohol and 3´,4´-dihydroxyflavone is 
likely to proceed via the corresponding phenoxy radicals and phenoxide anions, which 
then react via an intermolecular Michael-type addition of the phenoxide anion a or b on 
the oxidation product c, followed by intramolecular free radical coupling80 to give either 
12 or 14 (Scheme 3-2).  The formation of 12 and 14 depended on whether anions a or b 
were formed, with anion a being the precursor of product 12 and anion b being the 
precursor of product 14.81 
 The structure of 12 was confirmed by NMR spectroscopic analysis and mass 
spectrometry.  In the 1H NMR spectrum, the four ring A aromatic protons gave signals 
in the aromatic region (δ 7.06-8.20), which appeared as two doublet of doublets (dd) 
attributed to H-5 and H-8, and two doublet of doublet of doublets (ddd) were ascribed to 
H-6 and H-7.  Three aromatic proton signals ascribed to those of ring B were also in a 
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similar region to those of ring A and they appeared as a meta-coupled doublet assigned 
to H-2´, and an ortho-coupled doublet assigned to H-5´ and H-6´.  A singlet signal 
attributed to H-3 of ring C appeared at δ 6.72.  Three aromatic proton signals for ring D 
appeared as an ortho-coupled doublet assigned to H-5´´ and H-6´´ at δ 6.95 (2H), and as 
a singlet attributed to H-2´´, as well as methoxy and hydroxy signals at δ 3.92 and 5.83 
as a singlet and broad singlet, respectively.  The hydroxymethyl proton signals appeared 
at δ 3.58 and 3.85 as two doublet of doublets sets, and the presence of signals at δ 5.00 
(d, J = 8.4 Hz) and δ 4.08-4.14 (m), for the methine protons H12/H13; these could 
correspond to either isomer 12a or 12b (Figure 3-8). 
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Figure 3-8 Possible structures of 12 and 14 
 
 Connectivities in structure 12 were established from the HMBC experiment, and 
the upfield chemical shift value of H-13 (δ 5.00, d) (relative to the value for H-12 at δ 
5.03 (d) in 14) confirmed49 the regioisomer shown (12  12a; Figure 3-8).   
 The structure of the regioisomer 14 was confirmed by 1H NMR spectroscopic 
analysis, in which the 1H NMR spectrum was almost identical to that of 12 including a 
characteristic doublet signal at δ 5.03 (d, J = 8.4 Hz) for H-12ax-H-13ax coupling.  The 
chemical shift of the signal for H-12 (in 14) was slightly more downfield than that of H-
13 (in 12).  Thus, the isomer 14 was assigned as 12b (Figure 3-8). 
 The 1H NMR spectrum of 13 was similar to that of 12 and 14 except for the 
presence of signals attributed to H-12 and H-13 at δ 5.27 (d, J = 3.0 Hz) and δ 4.57-4.63 
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(m) corresponding to either structure 13a or 13b (Scheme 3-1).  Therefore, if 13 was a 
mixture of 12 and 14, two sets of doublet signals in the region of δ 4.9-5.0 with a vicinal 
coupling constant for diaxial protons H-12, H-13 (Jax,ax  ~ 8-13 Hz ) would be expected 
in the 1H NMR spectrum.  On the contrary, the 1H NMR spectrum of 13 revealed a 
single doublet signal at δ 5.27 (d, J = 3.0 Hz) indicating a vicinal coupling of axial and 
equatorial protons (Jax,eq ~ 2-6 Hz) or of diequatorial protons (Jeq,eq ~ 2-5 Hz).82 
Therefore 13, therefore, is tentatively assigned as one of the isomers as shown in 
Scheme 3-3. 
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Scheme 3-3 Possible regioisomers of 13 (relative configurations shown) 
 
 Unfortunately no spectroscopic data for compounds 12, 13, and 14 were reported 
in the literature.  The data for the peracetate derivative of 12 were reported however and 
thus acetylation of this compound was undertaken. 
 
3.3.1.1 Acetylation of the regioisomer 12 
 Acetylation of 12 was preformed using standard acetic anhydride/pyridine 
conditions. The structure of the diacetate product 15 was confirmed by NMR 
spectroscopic analysis and mass spectrometry. 
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Scheme 3-4 Preparation of the peracetate derivative of 12 
 
Table 3-1 A comparison of 1H NMR spectroscopic data for 14 with those reported56 for the 
peracetate of 5,7-deoxyhydnocarpin-D 
1H 15 (δ ppm, CDCl3) Report Data56 (δ ppm, CDCl3) 
OAc 2.06 (s) 2.09 (s) 
OAc 2.31 (s) 2.35 (s) 
OCH3 3.85 (s) 3.89 (s) 
H-11 4.02 (dd, 12.3, 4.2) 4.04 (dd, 12.4, 4.4) 
H-12 4.26-4.36 (m) 4.36 (m) 
H-11 4.38 (dd, 12.2, 3.2) 4.42 (dd, 12.4, 3.2) 
H-13 4.98 (d, 7.8) 5.01 (d, 8.0) 
H-3 6.73 (s) 6.76 (s) 
H-6'' 6.97 (dd, 7.8, 1.5) 7.02 (m) 
H-2'' 6.99 (s) 7.00 (d, 2.0) 
H-5'' 7.09 (d, 8.4) 7.12 (d, 8.0) 
H-8 7.09 (d, 8.4) 7.12 (d, 8.0) 
H-7 7.39 (br.t, 8.1) 7.42 (ddd, 8.2, 6.8, 0.8) 
H-5' 7.48-7.54 (m) 7.54 (dd, 8.4, 1.6) 
H-6' 7.48-7.54 (m) 7.63 (dd, 8.0, 2.0) 
H-2' 7.58 (d, 2.1) 7.61 (d, 2.0) 
H-6 7.63-7.70 (m) 7.70 (ddd, 8.6, 7.0, 1.6) 
H-5 8.20 (dd, 7.8, 1.5) 8.23 (dd, 8.4, 1.6) 
 
 NMR spectroscopic data for 15 was almost the same as that for the peracetate of 
5,7-deoxyhydnocarpin-D reported in the literature (Table 3-1).56    Unfortunately, the 
key correlation of H-13 to C-3´ was not seen in the HMBC spectrum as expected.  Thus, 
the identity of 15 with the peracetate of 5,7-deoxyhydnocarpin-D would not be 
confirmed.  Due to the difficulties experienced, further work on compound 12 and its 
coupling to a berberine acid derivative, was not pursued. 
 
3.3.2 Synthesis o f  2 -ary l-5 -n itro -l//-in d o les
Synthetically more accessible efflux pump inhibitors were then investigated. INF 
5 5 , one of the most active synthetic NorA efflux pump inhibitors amongst the indole 
analogues, was the inhibitor of choice (Figure 3-2). At a concentration of 1.5 |J.g/mL, 
INF55 potentiated the activity of ciprofloxacin four-fold against S. aureus SA1199-B. 
Thus, the next target pump inhibitors were designed to modify INF55 (5-nitro-2-phenyl- 
l//-indole) in order to provide a linking functionality in the new target molecule, which 
could be attached to the antibacterial berberine based on the dual action prodrug and 
dual action drug concepts.
2-(2-methoxyphenyl)-5-nitro-l//-indole 2-(4-methoxyphenyl)-5-nitro-l//-indole 
Figure 3-9 Related INF55 derivatives were predicted to possess NorA inhibitory activity83
Some related 2-aryl-5-nitro-l//-indole derivatives (Figure 3-9) have been
predicted83 by CoMFA (3D-QSAR) analysis to have pump blocking activity. In
particular, 2-(2-methoxyphenyl)-5-nitro-l//-indole was predicted to show comparable
activity to INF55, with ort/jo-substitution on the 2-phenyl ring, while 2-(4-
methoxyphenyl)-5-nitro-l//-indole, with ^ara-substitution on the 2-phenyl ring was
predicted to be less active than INF55. Therefore, the linking functionality for the 2-
aryl-5-nitro-l//-indole derivatives in the present study was designed to be preferentially
at the orr/zo-position on the 2-phenyl ring. Subsequently, simple lipophilic groups such
as OCH3 and OCH2Ph, which could also act as H-bond acceptors, were added as
substituents in the me/a-position on the 2 -aryl ring in order to investigate structure-
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activity relationships.  However, preparation of the linking functionality for these 
designed compounds at the para-position on the 2-phenyl ring was not ruled out and an 
attempt to access these via the Fischer indole synthesis was also undertaken (Section 
3.3.3).   
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Scheme 3-5 Designed INF55 derivatives to access the dual action prodrugs and dual action drugs 
 Following the model study 1 (Section 2.2.1), an alcohol derivative of INF55 
(Scheme 3-5) was eventually chosen as the first functionalised pump inhibitor target in 
order to access ultimately the dual action prodrug with a cleavable ester linkage.  
Subsequently, the alcohol derivative was converted to an amine for making the dual 
action prodrug with a potentially cleavable amide linkage.  Alternatively, the alcohol 
could be converted to a variety of halide derivatives, such as; bromoacetate, 
bromoacetamide, and bromide derivatives, in order to access the dual action ester and 
amide prodrugs, and dual action drugs via the methodology established in model study 
2 (Section 2.2.2).  
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3.3.3 Attempted synthesis of 2-aryl-5-nitro-1H-indoles via Fischer 
indolization 
 Prior to the synthesis of the ortho-substituted 2-aryl group analogues of INF55, 
some preliminary work was undertaken aimed at para-substituted analogues. Synthesis 
of the alcohol derivative 16g of 5-nitro-2-phenyl-1H-indole (Scheme 3-6) was the first 
synthetic target in this early phase of the work.  It was expected this derivative could be 
accessed by the well established Fischer indole route for synthesizing substituted 
indoles via arylhydrazones.  It was proposed that using commercially available 4-
nitrophenylhydrazine and 4-acetylbenzonitrile as reagents with an acid catalyst, the 
indole 16e could be prepared.  Subsequent hydrolysis of the benzonitrile 16e would 
afford the benzoic acid 16f, and then selective reduction of the acid would give the 
desired benzyl alcohol 16g.  
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Scheme 3-6 Synthetic strategy to 4-(5-nitro-1H-indol-2-yl)benzyl alcohol (16g) 
 
 The general mechanism84for the Fisher indolisation reaction is shown in Scheme 
3-7.  Proton-tautomerization of hydrazone 16, which is simply prepared by the treatment 
of 4-nitrophenylhydrazine and 4-acetylbenzonitrile with an acid catalyst, generates the 
enehydrazine 16a.  A subsequent [3,3]-sigmatropic rearrangement, the key step of the 
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mechanism, gives 16b and then elimination of ammonia affords the desired indole 16e.  
An acid catalyst is necessary to accelerate the formation of the enehydrazine 16a from 
the proton-tautomerization of hydrazone 16.  A variety of acid catalysts can be 
employed, for example metal halides (zinc chloride is the most frequently used), 
mineral acids (hydrochloric, sulfuric, and polyphosphoric acids), and organic acids 
(actetic acid).85-88 Moreover, microwave irradiation has been used to facilitate this 
reaction.89   
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Scheme 3-7 Mechanism for the Fischer indole synthesis of 16e 
 
 The Fischer indole synthesis of 16e from 4-nitrophenylhydrazine and 4-
acetylbenzonitrile was attempted a number of times with various types of acid catalysts 
such as p-toluenesulfonic acid, glacial acetic acid, hydrochloric acid, phosphoric acid, 
polyphosphoric acid and BF3-etherate.  All reactions gave the same product, the 
hydrazone 16, which was confirmed by 1H NMR and MS spectroscopic data.  The 1H 
NMR spectrum of 16 in CDCl3 showed four doublet signals which integrated for eight 
aromatic protons with ortho-coupling at δ 7.40 (2H) and 8.15 (2H) which were 
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attributed to H-2, H-6 and H-3, H-5 on the aromatic ring bearing the para-nitro 
substituent, and at δ 7.86 (2H) and 8.00 (2H) ascribed to H-2´, H-6´ and H-3´, H-5´ on 
the aromatic ring bearing the para-cyano substituent.  A singlet signal at δ 3.35 (3H) 
was assigned to the methyl group adjacent to the imine functionality together with a 
singlet signal at δ 10.43 attributed to the hydrazone NH proton.  The MS (EI) spectrum 
showed a signal at m/z 280, which represented the molecular ion of compound 16.  Both 
the 1H NMR and MS spectroscopic data were consistent with the hydrazone 16 and not 
consistent with the indole 16e for which a characteristic signal (δ 6.5–7.0) for the H-3 
proton of the indole would be expected.  The problem associated with this method was 
the inability to access the key [3,3]-sigmatropic rearrangement (16a to 16b) (Scheme 3-
8) possibly due to the presence of electron-withdrawing substituents (-NO2 and –CN 
groups) on both aromatic rings, which may hinder the protonation step and 
rearrangement. 
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Scheme 3-8 Effect of electron-withdrawing groups on the [3,3]-sigmatropic rearrangement of 16a 
 More severe conditions were then investigated involving microwave irradiation at 
high energy levels with short heating periods.  The reactions were carried out under acid 
conditions using either formic acid or neat ZnCl2.90  Unfortunately, none of the desired 
product 16b was observed, and only hydrazone 16 was detected in formic acid reaction.  
With neat ZnCl2 the conditions were too severe and no products were isolated.   
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 Therefore, alternative methods for the synthesis of 5-nitro-2-phenyl-1H-indole 
derivatives bearing alcohol functionality were considered and the Fischer indole 
synthesis strategy was abandoned.   
 Several routes have been described for the synthesis of 5-nitro-2-phenyl-1H-
indole (Scheme 3-9), including a palladium-assisted reaction of 4-nitro-2-bromoaniline 
and α-piperidinostyrene,91 the Fischer indole synthesis of acetophenone with 
phenylhydrazine and subsequent nitration,92 and reaction of 4-nitroaniline and dimethyl-
(2-oxo-2-phenyl-ethyl)-sulfonium bromide followed by cyclisation.93 However, there 
are limitations with respect to functional group tolerances and selective introduction of 
functionalities at desired positions in these approaches.  With the commercial 
availability of 5-nitro-1H-indole in mind, particular attention in the alternative 
approaches focussed on preformed indoles and introduction of an ortho-substituted aryl 
group at the indolic C2 position. 
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Scheme 3-9 Preparation of  5-nitro-2-phenyl-1H-indole (INF55) 
 
3.3.4 Synthetic strategy for 2-ary l-5 -n itro -l//-in d oIe  derivatives via 
palladium  cyclization
A regioselective synthesis of 2-arylindoles from indole was reported by 
Itahara.94,95 His work involved the synthesis of 2-(o-indolyl)benzoic acids via ring 
closure of 1-aroylindoles using palladium acetate followed by hydrolysis (Scheme 3-
indole *  V /
l -a ro y lin d o le s
~R O
6 -o \o -6 I I - is o in d o lo |2 ,l- a |in d o lc s  o -(2 -in d o ly l)b en zo ic  ac id s
R = H, 47%
= CH3, 42%
= Cl, 43%
R = H, 75%
= CH3, 74% 
= Cl, 70%
Scheme 3-10 Preparation of o-(2-indolyl)benzoic acids via intramolecular ring closure of 1-
aroylindoles94,95
Itahara’s approach was of interest as it was a regioselective and concise three-step 
method with potential for the introduction of a range of substituents. It was expected 
that the 2 -(o-indolyl)benzoic acids produced could be easily reduced to the desired 
primary alcohols, and the latter then converted to other substituted derivatives. Thus, 
the general method of Itahara was adapted in the current work using commercially 
available 5-nitro-l//-indole (17) as a starting material for the synthesis of 2-(o- 
indolyl)benzyl alcohols as shown in Scheme 3-11.
60
 61
N-acylation
N
O2N
N
H
O2N
O R
Ring closure
N
O2N
O
R
N
H
O2N
HOH2C
R
Hydrolysis
Reduction
N
H
O2N
BrH2C
R
Bromination
Amination O-alkylation
N
H
O2N
BrH2COCOH2C
R
N
H
O2N
HOOC
R
N
H
O2N
H2NH2C
R
N
H
O2N
BrH2COCHNH2C
R
N-alkylation
Proposed substituents ; 
R = OCH3, OCH2Ph
17
18; R = H 33; R = H
38; R = H41; R = H53; R = H
45; R = H
51; R = H
49; R = H  
Scheme 3-11 Synthetic strategy for 5-nitro-2-phenyl-1H-indole derivatives 
 The basic synthetic strategy was to initially prepare N-benzoyl-5-nitroindole (18) 
by N-acylation of the commercially available 5-nitro-1H-indole (17), followed by an 
intramolecular oxidative ring-closure by palladium cyclisation, then ring-opening by 
amide hydrolysis and subsequent specific reduction of the benzoic acid 38 to afford the 
benzyl alcohol 41 which could then be converted into various alkylating agents 49, 51 
and 53.  The bromoacetate 51 was prepared from 41 in one-step by O-alkylation and the 
benzyl bromide 53 was also prepared from 41 in one-step by bromination, whereas the 
bromoacetamide 49 was prepared from the benzylamine 45 obtained in turn from 
amination of 41.  Similarly, the other methoxy and benzyloxy derivatives of alcohol 41 
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were to be prepared and then the various alkylating agents also would be synthesized 
following the same synthetic strategy.   
 
3.3.4.1 N-acylation of indoles 
 The N-acylation of indoles is a well established reaction that is used to protect the 
indolic nitrogen with an acyl group96,97 which can then be easily removed by base 
hydrolysis98, and also to provide precursors for intramolecular cyclization.99 The most 
common N-acylation method requires the generation of an indole anion (by addition of 
a base, e.g. BuLi,100 NaH,101,102 KOH,102 and K2CO3103) followed by nucleophilic attack 
on an acyl halide.  N-acetylation of indoles can be achieved in high yields using acetic 
anhydride in combination with TEA and a catalytic amount of DMAP.104 Also direct N-
acylation of indole with carboxylic acids catalyzed by boric acid affords N-acylated 
indoles in moderate yield.105 
 In the present work, a variety of N-acylated indoles (Scheme 3-12) were prepared 
via the acid chloride method with strong bases, NaH (method A) or n-BuLi (method B), 
at low temperature, together with the direct coupling method with carboxylic acids and 
boric acid (method C).  Additionally, a new method using carboxylic acids with DCC   
N
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R
 R = H, OCH3, NO2, F (18-32)
24 R = H, R1 = Ph
25 R = H, R1 = Ph-p-OCH3
26 R = H, R1 =Ph-o-OCH3
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32 R = NO2, R1 =Ph-o-OCH3
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Scheme 3-12 Methods for N-acylation of indoles 
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and DMAP as carboxylate activators at room temperature (method D) was explored.  It 
was found the NaH and n-BuLi methods under low temperature conditions worked well 
with commercially available benzoyl chlorides only, leading to the desired N-acylated 
indole products in high yields except for 22 with the 4-benzyloxybenzoyl chloride, 
which was very sensitive to moisture.  To avoid the use of acid chlorides, direct 
coupling of carboxylic acids to the indoles using boric acid in mesitylene at reflux was 
trialled, but only low yields of N-acylated products were obtained.  Thus, investigation 
of a simpler and milder new method for the direct acylation of indoles with carboxylic 
acids using DCC as the coupling agent was developed in this project.  High yields were 
obtained when an electron-withdrawing group was present at C-5, however this method 
was less effective with a C-5 electron donating group (Table 3-2).      
 A variety of N-acylated products of indoles bearing electron-donating and 
electron-withdrawing groups were synthesized by methods A-D (Scheme 3-12) in order 
to compare yields and to find the optimal approaches.  The results from Table 3-1 
revealed the most efficient methods for the N-acylation of indole and its derivatives 
bearing an electron-donating group at C-5 were methods A and B using the highly 
flammable NaH and n-BuLi, respectively, and the appropriate acid chlorides.  Method B 
(using n-BuLi) required a shorter reaction time and less reaction steps than method A.  
In the case of indoles with electron-withdrawing groups at C-5, the simple and efficient 
method for N-acylation was method D using carboxylic acids and DCC/DMAP at room 
temperature, which involved milder conditions and avoided the extra step of acid 
chloride preparation when they were not available commercially. 
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Table 3-2 Percentage yields of N-acylated products of indoles 
Product Yield (%) Product Yield (%)
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D                    32
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 D                    15
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 D                     91
 B                     44
 
 D                     95
 D                     80
 B                     30
 D                     95
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 C                      4
 D                     89
 D                      87
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Method Method
 
3.3.4.1.1 Discussion of the N-acylation of indole 
 The preparation of N-benzoyl indole 24 was carried out via methods A and D and 
yields were compared with the yield reported for method C.105 Method A required 
reaction of indole with NaH for 2 h to ensure complete formation of the indole sodium 
salt.  Subsequent alkylation of the deprotonated indole with benzoyl chloride at –60oC 
to 70oC then afforded the desired product 24, which had almost the same Rf value as the 
starting indole, resulting in a difficult purification by chromatography since some 
starting material remained.  Recrystallization of 24 from warm ethanol afforded 24 in 
88% yield.  In comparison, method D involved a direct acylation of indole with benzoic 
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acid using the dehydrating agent DCC in the presence of DMAP to afford 24 in low 
yield (32%) together with unreacted indole.  In this case the low yield is probably a 
result of incomplete deprotonation of the indolic NH (pKa ~ 17) by the DMAP, since 
the indolide anion is presumably involved in the key penultimate nucleophilic attack on 
the acid-DCC intermediate (Scheme 3-13).  In general terms, the carboxylic acid forms 
an adduct with DCC which then acts as a good leaving group, on subsequent 
nucleophilic attack by the indolide anion (generated by DMAP deprotonation) to afford 
the desired amide and dicyclohexylurea.  An additional preparation of 24 via direct 
acylation of indole with benzoic acid in the presence of boric acid has been reported 
previously by Terashima and afforded 24 in 45% yield.105 The role of boric acid in this 
reaction is unclear.    
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Scheme 3-13 Mechanism of the DCC coupling of indole and carboxylic acid in the presence of 
DMAP 
 The preparation of 25 was also achieved by method D using indole and 4-
methoxybenzoic acid with DCC/DMAP.  The reaction was carried out overnight at 
room temperature to afford 25 in 46% yield.  The amide 25 had also been made 
previously by Welstead in 75% yield96 by method A using NaH and 4-methoxybenzoyl 
chloride.  Thus in this case method A was again better than method D.   
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 The preparation of 26 was accomplished by method D using indole with 2-
methoxybenzoic acid and DCC/DMAP.  The reaction was carried out for 3 days giving 
26 in 34% yield.  The structure of 26 was confirmed by NMR spectroscopy and mass 
spectrometry.  The 1H NMR spectrum revealed the absence of a broad singlet signal 
near δ 8.00 which could be assigned to the indolic NH.  The presence of a 3-proton 
singlet at δ 3.79 was attributed to the aromatic methoxy group.  A broad doublet signal 
at δ 8.44 was assigned to H-7.  The broad signal for H-7 appeared to be associated with 
partial conformational restriction in the acylated region of the molecule.  Signals 
attributed to H-3´, 4´, 5´ and 6´ in the o-methoxybenzoyl moiety appeared as multiplets 
in the region of δ 7.00-7.60.  Additionally, in the 13C NMR spectrum a signal at δ 167.2 
was assigned to the carbonyl carbon, while the HRMS (EI) spectrum supported the 
supported the molecular formula of 26. 
 
3.3.4.1.2 Discussion of the N-acylation of 5-methoxyindole 
 The preparation of 27 (Table 3-2) was achieved by method D using 5-
methoxyindole with benzoic acid and DCC/DMAP.  The reaction mixture was stirred at 
room temperature overnight to afford 27 in 32% yield, whereas the preparation of 27 
has been reported in 72% yield by method A using 5-methoxyindole with benzoyl 
chloride and a strong base (NaH).96 With an electron-donating group at C-5 in the 
indole, product formation in method D proceeded generally in low yield, and was not 
successful in the attempted synthesis of acylated product from 5-methoxyindole and 2-
methoxybenzoic acid.  Since the methoxy substituent is an electron-donating group, it 
would increase electron density adjacent to the indole nitrogen in the para position 
reducing the acidity of the 5-methoxyindole and hence retarding indolide anion 
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formation via reaction with DMAP.  The structure of 27 was confirmed by 1H NMR 
spectroscopic data and mass spectrometry.  The 1H NMR spectrum showed the presence 
of a singlet signal ascribed to the methoxy group at δ 3.88 and the absence of a broad 
singlet signal which could be attributed to an indolic proton.  Two sets of multiplets 
between δ 7.48-7.75, integrating for a total of 5 protons, were attributed to the aromatic 
protons of the benzoyl moiety.  Additional confirmation of the structure was provided 
by the HRMS (EI) spectrum, which showed a molecular ion signal at m/z 251.0950, 
consistent with the molecular formula of 27.  In a similar result to that of 27, application 
of method D to the reaction of 5-methoxyindole and 4-methoxybenzoic acid afforded 
the N-acyl product 28 in only 9% yield. 
 
3.3.4.1.3 Discussion of the N-acylation of 5-nitroindole 
 In contrast to the results with 5-methoxyindole, the preparation of 18 (Table 3-2) 
was successful using both method A and D from 5-nitroindole and benzoic acid, 
resulting in high yields (89-91%) without chromatographic purification, whereas this 
compound previously has been prepared in only moderate yield by Cho et al. in a study 
of selective cyclooxygenase-2 inhibitors.103 Cho’s method involved reaction of 5-
nitroindole and benzoyl chloride with potassium carbonate in DMF to afford 18 in 43% 
yield.  In the current study, the structure of 18 was confirmed by NMR spectroscopic 
analysis and mass spectrometry.  The 1H NMR spectrum showed a multiplet signal (δ 
7.54-7.80) integrating for five protons which was attributed to the aromatic protons of 
the benzoyl moiety.  Additional confirmation of the structure was provided by the 
HRMS (EI) spectrum with a signal at m/z 266.0688, which was consistent with the 
molecular ion of compound 18.  
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 In the attempt to explore the effects of DMAP, DCC and carboxylic acid 
concentrations on the reaction outcome, 5-nitroindole and 4-methoxybenzoic acid were 
reacted using varying amounts of DMAP, DCC and the carboxylic acid.  All reactions 
gave product 19 in high yields (91-97%) as shown in Table 3-3.  Taking into account 
reaction time, the preferred conditions were those for entry 1. 
 
Table 3-3 A variety of reagent amounts for the synthesis of 19 via method D 
Entry 5-nitroindole acid DCC DMAP reaction time yield 
 (eq) (eq) (eq) (eq) (h) (%) 
1 1 2 2 1 4 95 
2 1 1.3 1.3 0.1 72 97 
3 1 2 2 0.1 6 91 
 
Moreover, the preparation of 19 was carried out from 5-nitroindole and 4-
methoxybenzoyl chloride via n-BuLi (method B) to afforded 19 in moderate yield 
(44%).  Confirmation of the structure of 19 was provided by NMR spectroscopic 
analysis and mass spectrometry.  The 1H NMR spectrum revealed a singlet at δ 3.92 
which integrated for three protons and was attributed to the methoxy protons.  The 
appearance of two equivalent signals integrating for two protons each at δ 7.05 and 7.77 
were attributed to the aromatic protons in the para-substituted benzoyl moiety.  
Furthermore, a signal ascribed to the carbonyl carbon was seen in the 13C NMR 
spectrum at δ 167.9, and in the HRMS (EI) a molecular ion peak was observed at m/z 
296.0796 which corresponded to the molecular weight of 19. 
 Following the optimal conditions established for the synthesis of 19 via method 
D, compound 32 was prepared from 5-nitroindole and 2-methoxybenzoic acid to afford 
32 in 80% yield after recrystallization.  The structure of 32 was confirmed by NMR 
spectroscopic analysis and mass spectrometry.  
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Scheme 3-14 Preparation of 4-benzyloxybenzoyl chloride 
 
 The first attempted preparation of the amide 22 was carried out by method B 
using 5-nitroindole and the moisture-sensitive 4-benzyloxybenzoyl chloride.  The 
preparation of 4-benzyloxybenzoyl chloride (Scheme 3-14) was based on a literature 
procedure106 using 4-hydroxybenzoic acid and benzyl bromide in K2CO3 to generate 20 
in 81% yield.  Subsequent hydrolysis of the ester 20 using KOH afforded the acid 21 in 
91% yield, followed by reaction with oxalyl chloride under anhydrous conditions to 
afford the corresponding acid chloride.  The acid chloride was found to be unstable due 
to moisture sensitivity and could not be chromatographed, and thus the yield of the 
subsequent acylated indolic product 22 was low (30%).  Following the procedure used 
to prepare 19 by method D, 22 was prepared from 5-nitroindole and the acid 21.  The 
reaction was carried out at 40oC in order to accelerate the reaction.  However, the result 
was different from what was expected.  The reaction was monitored by TLC for 5 days, 
and a consistent ratio of 1 to 1 of starting indole and product 22 was observed after day 
2 of the reaction.  The reaction was stopped after 5 days and the mixture 
chromatographed to afford 22 in 52% yield.  It is likely that the N-acylated product 22 
was partially hydrolyzed under the prolonged basic conditions regenerating some of the 
5-nitroindole.  The structure of 22 was confirmed by NMR spectroscopy and mass 
spectrometry.  The 1H NMR spectra of 22 were similar to 19 with the same signal 
pattern above 6 ppm except for additional aromatic multiplet signals (δ 7.36-7.48) 
integrating for five protons attributed to the five aromatic protons of the benzyl 
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substituent.  The 13C NMR spectrum also showed an additional five aromatic signals in 
the range of δ 127.5-135.8 when compared to the spectrum for 19.  Moreover, the 1H 
NMR spectrum showed a distinct signal at δ 5.19 integrating for two protons, which 
was ascribed to the methylene protons of the benzyloxy substituent and a methylene 
carbon signal was also seen in the 13C NMR at δ 70.3.  The molecular formula of 22 
was established by HRMS (EI). 
 Following the procedure described by Terashima105 (method C), the reaction of 5-
nitroindole and phenylacetic acid and boric acid in mesitylene at 185oC was investigated 
for the preparation of 23 (Table 3-2).  However, the N-acylated product 23 was only 
obtained in very low yield (4%).  Similarly, with method A using 5-nitroindole and 
phenyl acetyl chloride with NaH in DMF at –60 to 70oC overnight, amide 23 was again 
obtained in only low yield (19%).  The structure of 23 was confirmed by NMR 
spectroscopic analysis and mass spectrometry.  The 1H NMR spectrum showed a signal 
integrating for two protons at δ 4.29 which was attributed to the methylene protons of 
the phenyl acetyl moiety.  An aromatic signal integrating for five protons was seen at δ 
7.29-7.42 as a multiplet and was ascribed to the five aromatic protons of the phenyl 
acetyl moiety.  Additionally, the 13C NMR spectrum showed a signal attributed to the 
carbonyl carbon at δ 164.9 while the HRMS (CI) data was consistent with the molecular 
formula of 23. 
 
3.3.4.1.4 Discussion of the N-acylation of 5-fluoroindole 
 The preparation of a series of N-acylated products (29-31) (Table 3-2) of 5-
fluoroindole with various carboxylic acids (benzoic acid, 4-methoxybenzoic acid and 2-
methoxybenzoic acid) was carried out by method D.  Compounds 29-31were obtained 
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in high yield (85-89%) after chromatography.  The structures of 29-31 were confirmed 
by NMR spectroscopic analysis and mass spectrometry.  The 1H NMR spectra of those 
compounds revealed the absence of a signal attributable to an indolic NH proton.  The 
1H NMR spectrum of 29 showed the presence of aromatic signals (δ 7.40-7.65 as 
multiplets) integrating for five protons consistent with the presence of the benzoyl 
moiety.  Further confirmation was provided in the 13C NMR spectrum through a signal 
attributed to the carbonyl carbon at δ 168.5 as well as by the HRMS (EI) spectrum 
which gave a molecular ion peak at m/z 239.0738, consistent with the molecular 
formula of 29. 
 The 1H NMR spectrum of 30 was very similar to that of 29 except for the loss of 
one aromatic signal around δ 6.90-7.80 and the presence of a singlet signal (δ 3.91) 
integrating for three protons assigned to the methoxy protons.  The HRMS (EI) 
spectrum afforded a molecular ion peak at m/z 269.0854, consistent with the molecular 
formula of 29. 
 All spectroscopic data for 31 were closely comparable to those of 30, with a small 
difference in splitting pattern of the signals attributed to the aromatic protons of the 
benzoyl moiety in a range of δ 6.90-7.80, and the signal assigned to H-7 at δ 8.44 
appeared as a broadened multiplet in 31.  The HRMS (EI) spectrum showed a signal at 
m/z 269.0854, representing the molecular ion of 31. 
 
3.3.4.2 Cyclization of the N-acylated indoles 
 The cyclisation of the N-acylated indoles 18, 19 and 22 was accomplished via a 
palladium(II)-promoted oxidative intramolecular reaction.  Accordingly, following a 
method for the intramolecular reaction of 1-aroylindoles by palladium acetate which has 
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been reported previously by Itahara94 and shown in Scheme 3-10,  the N-acylated indole 
18 (Scheme 3-15) was reacted with one equivalent of palladium(II) acetate in glacial 
acetic acid.  The reaction was carried out at 110oC to afford the expected ring-closed 
product 33. 
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Scheme 3-15 Intramolecular ring-closure of the N-acylated indoles 
 
The reaction mixture, which still contained some of the starting indole 18, was 
separated by flash chromatography.  The separation was very difficult however due to 
the very similar chromatographic properties of 33 and 18 and the tendency of 33 to elute 
very slowly from the column.  Thus, the separation by flash chromatography was 
changed to vacuum liquid chromatography (VLC) which used reduced pressure and this 
then gave a more rapid separation.  Additionally, 33 had unusual solubility properties, in 
that it was only partially soluble in various solvents such as DCM, DCM/MeOH, 
PS/EtOAc and DMSO.  After chromatography, 33 was obtained in 50% yield.  The 1H 
NMR spectrum of 33 revealed the loss of the doublet signal at δ 7.50 which could be 
ascribed to H-2 in the starting material, together with the loss of an aromatic proton 
signal.  The characteristic signal attributed to H-11 appeared at δ 6.79 as a singlet, 
which strongly supported the structure of 18. 
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 Mechanistically,107,108 the oxidative cyclization of the N-acylated product 18 
probably involves initial indole C-2 palladation to form an σ−indolylpalladium(II) 
complex 18a, which would be promoted by protonation of the acetate ligand of 
Pd(OAc)2 by acetic acid (Scheme 3-16).  Subsequently, complex 18a could undergo an 
intramolecular insertion into the benzoyl ring to give 18b, followed by β-hydride 
elimination of 18b to afford the ring-closed product 33.  
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Scheme 3-16 Mechanism for the palladium(II)-promoted oxidative cyclization 
 
 As this reaction consumed one equivalent of Pd(OAc)2, which is expensive and 
could not be recovered, the cyclization was then attempted using a catalytic amount of 
Pd(OAc)2.  Following a literature procedure109,110 using cupric acetate to reoxidize Pd(0) 
to Pd(II), a solution of acetic acid solution containing 18, 0.1 equivalents of Pd(OAc)2 
and 2.6 equivalents of Cu(OAc)2.H2O was heated under an air atmosphere at 95oC for 5 
days to give 33 in 29% yield, with over 50% of the starting material 18 still remaining.  
The attempted reoxidation of the Pd metal back to Pd(II) by Cu(OAc)2 was thus 
unsuccessful and hence one equivalent of Pd(II) was still required for the preparation of 
derivatives of 18.   
 In further work, the N-acylated product 19 was reacted with 1.0 equivalent of 
Pd(OAc)2 in glacial acetic acid to afford the ring-closed product 34 in high yield (74%, 
Scheme 3-15).  It is likely that the electron releasing para-substitutent of 18a (R = 
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OCH3) would facilitate the insertion step for ring closure (Scheme 3-16).  Confirmation 
of the structure of 34 was again provided by NMR spectroscopic analysis and mass 
spectrometry.  The 1H NMR showed a characteristic signal for ring-closed product at δ 
6.77 as a singlet attributed to H-11 and which had no correlation with any nearby proton 
in the gCOSY spectrum.  The absence of the signal which could be ascribed to H-2 
around δ 7.55 was also noted.  Further support for the structure was provided by the 
HRMS (EI) with a signal at m/z 294.0648, indicating the molecular formula of 
compound 34. 
 Another derivative of 22 (R = OCH2Ph, Scheme 3-15) was prepared by reaction 
of the N-acylated product 22 and Pd(OAc)2 in glacial acetic acid to afford the ring-
closed product 35 in 20% yield and the unexpected products 36 and 37 in 20 and 35% 
yields, respectively (Scheme 3-15).  Debenzylation can be readily accomplished under 
acidic conditions at reflux.111 Therefore, the cleavage of the benzyloxy subsituent in 22 
and 35 could both occur together with the cyclization of 22.  The mixture was purified 
by VLC and 35 was easily removed from the chromatographically inseparable mixture 
of 36 and 37.  Fortunately, the components of 36 and 37 had different solubility 
properties, as 37 was completely soluble in 2% MeOH in DCM but 36 was not.  Thus, a 
suspension of the mixture of 36 and 37 in 2% MeOH in DCM was filtered to give the 
ring-closed product 36 as a solid and 37 was retained in the filtrate.  The phenol 36 
could be converted to 35 in good yield by benzylation of the phenoxide anion with 
benzyl bromide (Scheme 3-17). 
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Scheme 3-17 Benzylation of compound 35 with benzyl bromide 
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 In the 1H NMR of 35 a diagnostic singlet at δ 6.79 was assigned to H-11.  
Unfortunately, the 13C NMR spectrum in CDCl3 as solvent revealed only 
methine/methylene carbon signals and the quaternary carbon signals were not seen.  
Due to the partial solubility of compound 35 in CDCl3, the concentration of 35 was too 
dilute for the quaternary carbon signals to be detected.  The 13C NMR spectrum was 
reattempted in DMSO-d6, and in a solvent mix of CDCl3/CD3OD, in which the 
solubility of 35 was much higher.  The 13C NMR experiments were carried out at 25oC 
overnight, however the same problem arose as with the CDCl3 spectrum with no 
quaternary carbon signals being seen and some of 35 precipitated in the NMR tube.  The 
mass spectral data indicated cyclisation to 35 had occurred.   
 The structure of 36 was also confirmed by NMR spectroscopic analysis.  The 1H 
NMR revealed a characteristic singlet signal assigned to H-11 at δ 7.07.  The absence of 
a signal which could be ascribed to the methylene protons of the benzyloxy substituent 
around δ 5.20 was also noted.   
 The structure of 37 was confirmed similarly by 1H NMR spectroscopic analysis.  
The 1H NMR showed the loss of signals which could be assigned to the methylene 
protons and the five aromatic protons of benzyloxy substituent.  A doublet signal at δ 
6.72 was attributed to H-3 and the gCOSY spectrum showed it was coupled to a doublet 
signal at δ 7.53, which was thus assigned to H-2.  The HRMS (EI) spectrum showed a 
molecular ion peak at m/z 282.0638, indicating the molecular formula of 37 to be 
C15H10N2O4. 
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3.3.4.3 Amide hydrolysis of the cyclized products 
 N, N-Disubstituted amides can be hydrolysed under acidic or alkaline conditions.  
Based on the method of Itahara,95 alkaline hydrolysis of the cyclized products 33-35 
was achieved at 82oC using t-BuOK in t-BuOH containing a small amount of H2O.  The 
amide hydrolysis was unsuccessful under normal conditions with either HCl/MeOH in 
the presence of H2O or NaOH/MeOH in the presence of H2O.  
 
N
O2N
O
33; R = H
34; R = OCH3
35; R = OCH2Ph
N
H
O2N COOH
R
R
38; R = H, 95%
39; R = OCH3, 94%
40; R = OCH2Ph, 96%
t-BuOK, t-BuOH/H2O
82oC
 
Scheme 3-18 Amide hydrolysis of the cyclized products 33-35 
 
 On TLC analysis of the first attempted hydrolysis of 33, with t-BuOK in t-BuOH 
(82oC, N2) for 12h only one clean product spot could be detected and none of the 
starting material 33.  The reaction was then stopped and the literature work-up 
procedure was followed.  The reaction mixture was evaporated and diluted with a large 
amount of water.  The mixture was then carefully neutralized with dilute HCl and 
extracted with diethyl ether.  The ether extracts were dried with sodium sulfate and 
evaporated to give a brown semicrystalline residue which was triturated with 
ether/hexane to give the desired product 38 but, surprisingly, in very low yield (11%).  
It was suspected the work-up procedure might be the problem and thus it was 
reconsidered.  The hydrolysis of 33 was reattempted with t-BuOK in t-BuOH containing 
a small amount of H2O at 82oC, and after 12h, the reaction mixture was concentrated 
and then added to a large amount of ice water.  The reaction mixture was then acidified 
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to pH1 using dilute HCl to give a yellow suspension.  The suspension was saturated 
with solid NaCl and then vigorously stirred until the yellow suspension changed to a 
yellow solution.  The reaction solution was then extracted with diethyl ether to afford 
the desired acid 38 in high yield (95%).  Presumably the effect of the NaCl was 
important in reducing acid solubility in the aqueous phase and thus assisting extraction 
of the product into the diethyl ether.  Structural confirmation of 38 was provided by 
NMR spectroscopic analysis and mass spectrometry.  The 1H NMR spectrum showed a 
similar signal pattern to the 1H NMR spectrum of the starting cyclized product 33.  
However, the 13C NMR spectrum displayed a downfield signal attributed to the 
carbonyl carbon of a carboxylic acid at δ 171.7, while the HRMS (EI) spectrum 
supported the molecular formula of 38.  
 Following the modified work-up procedure, the other two acid derivatives 39 and 
40 were prepared from 34 and 35 in the same manner, and were obtained in 94% and 
96% yields, respectively.  The structure confirmation of 39 and 40 was provided by 
NMR spectroscopic analysis and mass spectrometry.  The 1H NMR spectrum of 39 
showed a similar spectrum to the starting material 34 but with additional signal which 
could be attributed to the indolic proton at δ 12.07 and this was confirmed by gHMBC 
analysis.  The 13C NMR spectrum revealed a signal ascribed to the carbonyl carbon of 
the acid at δ 167.9 and the HRMS (EI) spectrum had a molecular ion peak at m/z 
312.0749, supportive of the molecular formula of 39.  The 1H NMR spectra of 40 
showed similar signals to those of 39, together with extra signals which could be 
assigned to the benzylic ether group. 
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3.3.4.4  Reduction of acids to alcohols 
 Carboxylic acids are easily reduced to primary alcohol by LiAlH4 which is a 
powerful but non-selective reagent.  Alternative reagents were thus considered and 
selective reduction of benzoic acid derivatives 38-40 in the presence of the nitro 
substituent to the corresponding alcohols was accomplished with borane in 
tetrahydrofuran without disturbing the reducible nitro substituent.  Moreover, the 
reaction was remarkably facile and proceeded in high yield.  A possible mechanism 
involves the formation of an acyloxyborane in the first step (Scheme 3-19).  
Subsequently, this moiety can undergo further reaction with borane and eventually 
hydrolysis to the corresponding alcohol and boric acid.112,113 
 
RCOOH  +  BH3
THF
RCOOBH2 RCH2OB
H2O RCH2OH  +  B(OH)3  
Scheme 3-19 Possible mechanism for reduction of carboxylic acids with borane in tetrahydrofuran 
 
N
H
O2N CH2OH
N
H
O2N COOH
R R
BH3-THF
rt, N2, 2h
38; R = H
39; R = OCH3
40; R = OCH2Ph
41; R = H, 99%
42; R = OCH3, 95%
43; R = OCH2Ph, 85%  
Scheme 3-20 Selective reduction of the benzoic acid derivatives in the presence of a nitro 
substituent 
 
 The benzoic acid 38 was reacted112 with excess borane-tetrahydrofuran complex 
to afford the corresponding alcohol 41 in high yield (99%) (Scheme 3-20).  The 
aromatic nitro group is inert toward borane.  In the 1H NMR spectrum of 41 the 
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presence of the new hydroxymethyl group was confirmed by a signal integrating for two 
protons at δ 4.77.  A signal for this methylene carbon was also apparent at δ 65.1 in the 
13C NMR spectrum, and this assignment was confirmed by a DEPT experiment..   
 The other benzyl alcohol derivatives 42 and 43 were prepared similarly from their 
benzoic acid derivatives 39 and 40 in 95% and 85% yield, respectively (Scheme 3-20).  
The 1H NMR analysis of 42 confirmed the formation of the benzyl alcohol derivative 
with the presence of a signal ascribed to the methylene protons at δ 4.70.  The presence 
of a signal attributed to a methylene carbon at δ 64.6 and the absence of a carbonyl 
group signal was noted in the 13C NMR spectrum.  Correspondingly, the structure of 43 
was confirmed by the disappearance of the signal assigned to the carbonyl carbon at δ 
167.9 in the starting material 40 and the appearance of a signal attributed to the 
methylene carbon at δ 70.2 in the 13C NMR spectrum.  Further confirmation of the 
structure of the benzyl alcohol derivative 43 was provided by the presence of a two 
proton singlet signal attributed to a methylene proton at δ 5.08 in the 1H NMR 
spectrum; an M+ signal at m/z 374.1256 in the HRMS (EI) spectrum was consistent with 
the molecular formula C22H18N2O4.   
 
3.3.4.5 Attempted conversion of alcohols to amines 
 Typical methods to convert primary alcohols to primary amines involve a three-
step procedure via the transformation of the alcohol to the corresponding halide or 
sulfonate, which then undergoes nucleophilic substitution by the azide anion to afford 
an alkyl azide and subsequent reduction of the azide to the desired primary amine.114-116 
Alternatively the conversion of an alcohol to such an amine can be achieved in a facile 
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one-pot process by a combination of reactions.  An alcohol may be converted to the 
corresponding azide/amine by using NaN3 and PPh3 in 20% CCl4 in DMF.117 
 
R-OH
NaN3
CCl4-DMF (1:4)
PPh3 (1eq)
PPh3 (>2eq)
R-N3
R-NH2
R-N=PPh3
H2O
via azide
PPh3 R-N=N-N=PPh3
-N2
(iminophosphorane)
(phosphazide)
 
Scheme 3-21 A facile one pot methodology for the conversion of alcohols to azides or amines 
 
 Treatment of alcohols with NaN3 and two equivalents of PPh3 in CCl4-DMF (1:4) 
at 90oC afforded their corresponding amines117 (Staudinger reaction) in excellent yield 
(85-95%).   Using one equivalent of PPh3 in the same manner117 afforded the 
corresponding azides.  Azide formation occurs with the first equivalent of PPh3, and the 
azide can then react with the second equivalent of PPh3 producing the 
iminophosphorane intermediate (via the phosphazide), which can then be converted to 
the amine by hydrolysis with water (Scheme 3-21).  Thus treatment of alcohol 41 with 
NaN3 and PPh3 (2 equivalents) in 25% CCl4 in DMF at 90oC, followed by the addition 
of excess water to hydrolyze the expected iminophosphorane intermediate 44a, afforded 
the undesired azide 44 without any of the desired amine 45 (or intermediate 44a).  The 
azide 44 was obtained in 74% yield. 
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Scheme 3-22 Attempted preparation of the benzylamines 45 and 48 
 
 The reaction was reattempted in the same manner as previously except that the 
reaction time was extended to ensure that the azide 44 had sufficient time to react with 
the second equivalent of PPh3.  Water was then added to the reaction with warming at 
50oC overnight as suggested in the literature,117,118 however neither intermediate 44a nor 
amine 45 were observed.  After chromatography, only the azide 44 was obtained in 74% 
yield.  The 1H NMR spectrum of 44 showed a distinct 2-proton singlet at δ 4.40 which 
was attributed to the methylene protons, the signal position being upfield relative to the 
corresponding signal in the starting alcohol 41.  The 13C NMR spectrum also displayed 
a signal ascribed to the methylene carbon at δ 54.0, which was consistent with a CH2 
which is shielded by a neighbouring azide group. Additionally, the HRMS (EI) 
spectrum revealed a molecular ion signal at m/z 294.0987, consistent with the molecular 
formula C15H12N5O2. 
 The azide derivative 47 was also prepared in the same manner as for 44, from 
treatment of the alcohol 42 with NaN3 and 2 equivalents of PPh3 at 90oC.  It is possible 
that with both 44 and 47, the temperature was not sufficiently high for the phosphazide 
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intermediate formation and hence formation of 44a and 47a.  Alternative azide 
reduction methods were then investigated. 
 
3.3.4.6 Reduction of azides to amines 
 Azides can be reduced easily to primary amines by a number of reducing agents, 
including NaBH4, which usually gives poor yields but is selective.  However, the 
reducing power of NaBH4 is augmented by using either THF or t-BuOH as a solvent 
with dropwise addition of MeOH.  Following a general literature procedure,119 the azide 
44 was reduced with NaBH4 in THF-MeOH at reflux with stirring for 2 days.  TLC 
analysis of the reaction mixture indicated some of the starting material 44 still remained 
together with the formation of two new products, one at a lower Rf than the azide 44 and 
another as a streak from the baseline.  After separation of the former product, NMR 
analysis and mass spectrometry suggested that it was the cyclized product 46.  The 1H 
NMR spectrum revealed the loss of the signal previously ascribed to the indolic NH 
proton and the appearance of a downfield singlet integrating for two protons at δ 5.12, 
which was attributed to the methylene protons.  The HRMS (EI) spectrum, which 
showed a molecular ion signal at m/z 250.0732, was also consistent with the molecular 
formula of the cyclized product 46.  It is possible that 46 forms from the amine 45 via 
its borane complex, followed by nucleophilic attack on a methylene carbon by an 
indolide anion which may be generated in the basic conditions (Scheme 3-23).  The 
other product, which was observed as a streak from the baseline on TLC, was predicted 
to be the desired amine 45, which would bind strongly to the acidic silica gel.  The 
amine 45 was separated by column chromatography with an eluting solvent mix of 
DCM in MeOH plus triethylamine.   
o 2n . ■H,N,
0 ,N - 0,N.
NaBH4, THF
with dropwise addition 
o f MeOH 
reflux, 2days 46; 14%
Scheme 3-23 Reduction of the azide 44 to amine 45 with NaBH4 in THF with dropwise addition of 
MeOH
The 'H NMR spectrum of 45 showed an upfield singlet signal integrating for two 
protons at 8 3.99 which was assigned to the methylene protons adjacent to the amino 
group, and a signal ascribed to the indolic NH was apparent at 5 13.63. The HRMS (El) 
data was consistent with the molecular formula of 45.
RCH,N2 1N3 r c h 2n h 2
Scheme 3-24 General scheme for the conversion of azides to amines using NaBH4 and 1,3-
propanedithiol as a catalyst
The azide reduction was reattempted following a method described by Pei120 using
NaBH4 and 1,3-propanedithiol as a catalyst in /-PrOH and TEA at room temperature.
Azides may be selectively reduced to amines by 1,3-propanedithiol which is oxidized to
the cyclic disulfide (Scheme 3-24). Sodium borohydride can then be used to reduce the
cyclic disulfide back to the 1,3-propanedithiol thus reducing the amount of 1,3-
propanedithiol required for complete reduction. Unfortunately, the reduction of the
azide 44 still gave a 3:1 mixture of the amine 45 and the unwanted cyclized product 46.
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 To avoid this unwanted cyclization, the reaction was undertaken at a lower 
temperature for a shorter time. The azide 44 was then successfully reduced by 1,3-
propanedithiol (3 eq.) and NaBH4 (15 eq.) in 35% MeOH in i-PrOH and TEA at 0oC for 
130 min to afford the amine 45 in 90% yield. 
 The other benzylamine derivative 48 was obtained from the benzyl azide 47 in 
91% yield in the same manner as for 45 (Scheme 3-25).  In the 1H NMR spectrum of 48, 
the methylene protons were assigned to the signal at δ 3.91, further upfield from the 
corresponding signal (δ 4.26) in the starting azide 47. 
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O2N CH2NH2
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44; R = H
47; R = OCH3
45; R = H, 90%
48; R = OCH3, 91%
NaBH4, i-PrOH/MeOH
TEA, HS(CH2)3SH
              0oC
 
Scheme 3-25 Reduction of the azides 44 and 47 to the amines 45 and 48, respectively 
 
 Since the palladium-induced oxidative cyclization of 22 gave 35 in low yield and 
two by-products 36 and 37, the synthesis of benzyloxy analogues of azide and amine 
derivatives was thus omitted.  Although the by-product 36 can be converted to 35, there 
is an extra step involved. 
 
3.3.4.7 Preparation of α-bromoacetamides 
 The final step in the preparation of the required alkylating agents was adapted 
from a literature precedent.121 The amine 45 was reacted with bromoacetyl chloride in 
DCM and TEA to afford the bromoacetamide 49 in 62% yield (Scheme 3-26).  The 1H 
NMR spectrum of 49 revealed the presence of two singlet signals integrating for two 
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protons each at δ 3.85 and 4.45 which were attributed to two groups of methylene 
protons in the molecule.  Further confirmation of the structure was obtained by the 
appearance of a signal ascribed to a carbonyl carbon at δ 167.2 in the 13C NMR 
spectrum, together with the HRMS (EI) spectrum which showed a molecular ion peak at 
m/z 389.0197, consistent with the molecular formula of 49.  
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Scheme 3-26 Preparation of bromoacetamides 49 and 50 
 
 The bromoactamide derivative 50 was prepared in 64% yield from the amine 48 in 
the same manner as for 49.  Analysis of the 1H NMR spectrum of 50 revealed two 
methylene proton signals as two singlets at δ 3.91 and 4.44, and the 13C NMR spectrum 
confirmed the presence of a carbonyl carbon signal at δ 167.1.  HRMS (EI) spectral 
analysis indicated a molecular ion at m/z 417.0332, supporting the molecular formula of 
50. 
 
3.3.4.8 Preparation of α-bromoesters 
 The α-bromoester derivatives 51 and 52 (Scheme 3-27) were prepared from the 
corresponding alcohol derivatives 41 and 42, respectively.  Following a literature 
procedure,122 the alcohol 41 was reacted with bromoacetyl chloride in TEA and THF at 
0oC for 2h.  As the formation of the desired bromoester 51 was not observed by TLC 
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analysis, the reaction was heated at 50oC for 5h to then afford 51 in 70% yield.  The 1H 
NMR spectrum of 51 revealed two singlet signals attributed to two groups of methylene 
protons at δ 3.97 and 5.31, together with a distinct signal ascribed to the carbonyl 
carbon in the 13C NMR at δ 167.0.  The mass spectral analysis HRMS (EI) showed a 
molecular ion at m/z 338.0056, consistent with the structure of 51. 
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Scheme 3-27 Preparation of bromoesters 51 and 52 
 
 The α-bromoester 52 was prepared in the same manner as the α-bromoacetamides 
49 and 50.  The desired product 52 was obtained in 39% yield with some starting 
material 42 still being present.  The 1H NMR spectrum of 52 showed a downfield 
singlet signal integrating for two protons at δ 5.17, which was attributed to the benzylic 
methylene protons, and a new signal integrating for two protons at δ 3.88 which was 
assigned to the bromomethyl group.  The 13C NMR spectrum of 52 had a signal at δ 
166.8 which was consistent with an ester carbonyl group.  
 
3.3.4.9 Preparation of indole benzyl bromide derivatives from the alcohols 
 Various methods for the conversion of alcohols into their corresponding alkyl 
bromides are known.  The most commonly used preparative route is the reaction of an 
alcohol with triphenylphosphine and carbon tetrabromide (Scheme 3-28).123,124 Thus the 
preparation of benzyl bromide 53 was conducted125 in anhydrous diethyl ether at room 
temperature for 2 days, but no reaction occurred. The reaction was therefore repeated at 
a higher temperature (40°C, 2 days) to push the bromination to completion. The desired 
benzyl bromide 53 was obtained in 41% yield together with triphenylphosphine oxide as 
a by-product (Scheme 3-29).
ROH
+ l +
Ph3P + CBr4 ------- - Ph3PBr ----- ► Ph3POR + CHBr3
CBr3 Br’
RBr + Ph3P = 0
Scheme 3-28 General scheme for the bromination of alcohols using carbon tetrabromide and 
triphenylphosphine126
The structure of 53 was confirmed by NMR spectroscopy, with the spectra being 
similar to the starting alcohol 41, while the formula was established from the HRMS 
(El) data.
Scheme 3-29 Bromination of the alcohol 41 into the benzyl bromide 53
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 In contrast, attempted bromination of alcohol 42 in the same manner as for the 
reaction with 41 (Scheme 3-29) failed to furnish the desired benzyl bromide 42a.  
Instead, the benzylphosphonium salt 54 was only obtained.  In the 1H NMR of 54, 15 
aromatic protons at δ 7.18-7.97 were present, plus two signal ascribed to methylene 
protons at δ 5.17.  The presence of a very weak singlet signal at δ 29.2 in the 13C NMR 
spectrum was attributed to the methylene carbon, although a doublet would be 
expected127 for this signal from coupling with the adjacent phosphorus atom.  This 
signal assignment was confirmed, by gHSQC and DEPT spectral analysis.  High 
resolution mass spectral analysis (ES) revealed a positive ion at m/z 543.1838, 
corresponding to the formula of the cation in the salt 54.  It is likely that the desired 
product 42a (Scheme 3-29) was formed in the reaction, but this then proceeded readily 
to give 54 on reaction with an excess of triphenylphosphine.  The bromide 42a would be 
further activated towards such a reaction by the para-methoxy group in the benzylic 
bromide.  Although undesired in this reaction, these conditions are common for making 
a phosphonium salt from an alkyl halide and phosphine.  Thus it was decided to make 
the undesired phosphonium salt 54 into a potentially useful alkene 55 (for cross 
metathesis reactions) via the Wittig reaction. 
N
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OCH3
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H
O2N
OCH3
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HCHO NH
O2N
OCH3
54a 55  
Scheme 3-30 Preparation of the alkene 55 via the Wittig reaction 
 The phosphonium salt 54 was treated with NaOH to generate ylid 54a, which was 
then reacted with formaldehyde to give the alkene 55 (Scheme 3-30).  Unfortunately, 
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the desired alkene 55 was obtained in only 3% yield together with an undesired alkyl 
derivative 56 as a major product in 49% yield.     
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Scheme 3-31 Possible mechanism for the formation of 56 
 
 The normal Wittig reaction (Scheme 3-30) would proceed via the phosphorus 
ylide 54a, being generated in turn by reaction of the phosphonium salt 54 with sodium 
hydroxide.  Subsequent reaction with formaldehyde would give 55.  It is proposed that 
an alternative pathway from 54 and sodium hydroxide could also occur via the indolyl 
anion 54c, which is stabilized by the electron-withdrawing nitro group.  Elimination of 
triphenylphosphine from 54c would afford 54d, which could be the re-aromatized to 
give product 56 via hydride transfer (from H2C(OH)O- formed in turn from HCHO and 
OH-).  A non-nucleophilic base could obviate this last step but this reaction was not 
examined further.  
 
3.3.4.10 Attempted N-protection of indole 42  
 In order to attempt to prevent the formation of undesired products during the 
formation of the benzylic bromide from 42,  protection of the indolic nitrogen of 42 was 
investigated.  It was hoped to Boc protect the indolic nitrogen and thus deactivate the 
ring before the bromination.  Accordingly, direct N-boc protection was attempted using 
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the alcohol 42 with (Boc)2O and DMAP.128 NMR spectroscopic analysis and mass 
spectrometry revealed that the O-acylated compound 58 (Scheme 3-32) was the major 
product, together with a small amount of 57, with no N-boc product.  
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Scheme 3-32 Attempted N-boc protection of 42  
 
 The 1H NMR spectrum of 58 showed the presence of a singlet signal at δ 1.52 
integrating for nine protons which was attributed to the t-butyl group.  A distinct singlet 
signal assigned to the NH proton at δ 9.99 confirmed that 58 was the O-boc and not the 
N-boc product.  In addition, the correlation of a methylene proton signal at δ 5.11 to a 
carbonyl carbon signal at δ 153.5 was seen in the gHMBC spectrum and mass spectral 
(CI) analysis confirmed the molecular ion peak at m/z 399 (C21H23N2O6, [MH]+), 
consistent with the molecular formula of 58.  
 
N
O2N
OO
OCH3
57; 7%
N
O2N
N
O2N
58a 58b
OCH3
OO
O
O
O
Ot-Bu
H+ Bu-t
H+
 
Scheme 3-33 Possible formation of the cyclized product 57 
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 As the alcohol 42 contains two acidic protons (NH and OH) with similar pKa 
values, which would be competitively deprotonated, the minor product 57 might be 
formed from an intermediate 58a and/or 58b (Scheme 3-33).  The 1H NMR spectrum of 
the minor product 57 showed a signal integrating for two protons at δ 4.91 as a broad 
doublet and this was attributed to the ring methylene group.  Mass spectral (CI) analysis 
confirmed the molecular formula of 57 via a base peak at m/z 325 (C17H13N2O5, [MH]+).    
 The N-protection of 42 was reattempted with a sulfonamide derivative which is 
less susceptible to nucleophilic attack than the carbamate type protecting groups.129 
However, reaction of the alcohol 42 with benzenesulfonyl chloride and n-BuLi at room 
temperature afforded only 59 in 8% yield (Scheme 3-34), without any of the desired N-
sulfonyl product.  
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Scheme 3-34 Attempted N-sulfonyl group protection of 42 
 
 Due to the unsuccessful selective N-protection of 42, the subsequent bromination 
step to achieve the alkyl bromide derivative 42a (Scheme 3-29) was not pursued further.  
It was decided to make a dual action drug 65 (Chapter 4, Scheme 4-5) in the next step 
using the alcohol 42 instead of 42a, as discussed in Chapter 4.  
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4 Chapter4:  
Synthesis of the berberine-indole dual action agents 
N
O
O
OMe
OMe
+
Y
N
H
O2N
R
Dual action prodrugs; Y = CH2OCOCH2-(C13), CH2NHCOCH2-(C13)
Dual action drugs;       Y = CH2
R = H, OCH3
13
 
Figure 4-1 The structures of the desired dual action agents 
 
 The aim of the synthetic work in this chapter was to synthesize berberine-indole 
dual action agents (Figure 4-1) based on the dual action prodrug and dual action drug 
concepts.  The hybrids consisted of berberine linked at its C-13 position by an ester, 
amide or alkyl group to a 2-aryl-5-nitroindole analogue.  Before the berberine and the 
indole derivatives were combined, a series of model compounds were produced, of 
which the first was 13-benzylberberine (Chapter 2, Section 2.2.2.2), with the benzyl 
group representing the 2-aryl-5-nitroindole moiety.  Eventually, synthesis of the desired 
berberine-indole molecules was achieved based on the two-step strategy of “model 
study 2” (Chapter 2, Section 2.2.2) as described in the following sections.   
 
4.1 Synthesis of the berberine-indole prodrugs with a cleavable 
linkage 
 The dual action prodrugs containing berberine and an indole were designed to link 
the berberine and indole moieties together via an ester or amide group.  These linkers 
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were expected to cleave under enzymatic action (by esterases or amidases) in the 
bacterial cells resulting in synchronous release in high concentration near the bacterial 
target sites.  The synthesis of the ester and amide-linked prodrugs is discussed in the 
following sections. 
 
4.1.1 Synthesis of the ester prodrug (60) 
 The ester bromide derivative of indole 51 was combined with the enamine 9 
following the “model study 2” coupling procedure (Chapter 2, Section 2.2.2).  The 
enamine 9, which was discussed in Chapter 2, was reacted with the bromoester 51 in 
dry CH3CN at 100oC for 2 days (Scheme 4-2).  Analysis of the crude reaction mixture 
by TLC (silica gel, 8% MeOH in DCM) showed product was formed which streaked up 
from the baseline.  The pure ester prodrug 60 was isolated in 19% yield after multiple 
preparative layer chromatography and recrystallization from 1% MeOH in DCM.  It is 
likely that some product was lost in the purification process due to it strong adsorption 
on silica gel. 
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Scheme 4-2 Preparation of a dual action prodrug 60 with an ester linkage  
 
 The structure of the ester prodrug 60 was confirmed by NMR spectroscopic 
analysis and mass spectrometry.  The 1H NMR spectrum in CDCl3 revealed the loss of 
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the signals attributed to the allyl substituent protons and the C-13 proton in the starting 
enamine 9, and the presence of a singlet signal ascribed to the C-8 proton appeared at δ 
9.91. The 1H NMR spectrum also verified the presence of the indole moiety, with a 
singlet signal attributed to the indolic NH proton at δ 12.19, the expected set of signals 
integrating for seven protons ascribed to the aromatic protons of the indole, and a 
characteristic singlet signal assigned to the C-3΄ proton at δ 6.74.  In addition, two 
singlet signals attributed to the methylene protons of the ester linking group at δ 4.48 
(CH2CO) and 5.39 (CH2O) were observed.  The carbonyl carbon of the ester group was 
confirmed by a signal in the 13C NMR spectrum at δ 170.3, and a downfield signal at δ 
145.8 was ascribed to the C-8 methine carbon in the berberine moiety.  Further support 
for the structural assignment was provided by HRMS (ES) with a signal at m/z 
664.2034, consistent with the formula of the quaternary ammonium ion component of 
60. 
 
4.1.2 Synthesis of the ester prodrug (61) 
 Under the same reaction conditions as for 60, the ester prodrug 61 was produced 
from enamine 9 and the bromoester 52 in CH3CN at 100oC for 2 days.  The ester 61 was 
obtained in 20% yield after extensive chromatographic treatment of the reaction 
mixture.  The 1H and 13C NMR spectra of 61 were similar to those of the ester 60 except 
for the absence of an aromatic proton signal attributed to the C-4΄΄ proton in the latter. 
Moreover, the presence of a signal at δ 3.84 integrating for three protons and attributed 
to the methoxy groups was observed in the 1H NMR spectrum, and for the methoxy 
carbon at δ 55.6 in the 13C NMR spectrum.  The HRMS (ES) spectrum showed a signal 
at m/z 674.2134, which was consistent with the positive ion component of compound 
61.  
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Scheme 4-3 Preparation of the dual action prodrug 61 with an ester linkage  
 
4.1.3 Synthesis of the amide prodrug (62) 
 The reaction conditions for the formation of the amide prodrug 62 were the same 
as those used to synthesize the ester prodrugs (60, 61) and the same purification 
problems, including the loss of some of the product 62, occurred due to the polarity of 
the molecule.  The enamine 9 was reacted with the bromoacetamide indole derivative 49 
in dry CH3CN at 100oC for 2 days.  The amide 62 was obtained in only 10% yield after 
recrystallization. 
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Scheme 4-4 Preparation of dual-action prodrug 62 with an amide linkage 
 
The 1H and 13C NMR spectra in CD3OD of amide 62 were almost the same as those for 
the ester 60, except for an upfield singlet signal attributed to the methylene protons 
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adjacent to the amide at δ 4.69 (CH2NH).  In the 13C NMR spectrum, an upfield signal 
at δ 42.0 was ascribed to the methylene carbon adjacent to the amide nitrogen atom.  
The HRMS (ES) showed a signal at m/z 643.2184, representing the positive ion 
component of compound 62.  
 
4.1.4 Synthesis of the amide prodrug (63) 
 A mixture of the enamine 9 and the bromoacetamide indole derivative 50 in dry 
CH3CN was heated at 100oC for 2 days.  After multiple chromatographic purification 
and recrystallization, 63 was obtained in 20% yield. 
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Scheme 4-5 Preparation of the dual-action prodrug 63 with an amide linkage  
 
Characteristic peaks in the 1H and 13C NMR spectra of 63 included an extra signal 
integrating for three protons at δ 3.87 ascribed to the methoxy group in the indole 
portion, as well as a further signal at δ 56.0 in the 13C NMR attributed to this group.  
The HRMS (ES) showed a peak at m/z 673.2305, representing the positive ion of 
compound 63.  
 
 97
4.1.5 Synthesis of the dual action drug (64) 
 The preparation of the dual action drug 64 used the same reaction conditions as 
those used in the synthesis of the other ester and amide prodrugs.  The enamine 9 and 
the bromide 53 in dry CH3CN were heated at 100oC for 1 day, to afford 64 in 34% 
yield.  The product was separated chromatographically but multiple development 
preparative layer chromatography was not required.  The structure of compound 64 was 
elucidated by NMR spectroscopy and mass spectrometry.  The 1H and 13C NMR spectra 
in CD3OD had signals representative of the berberine and 2-aryl-5-nitroindole moieties.  
In addition, signals attributed to the methylene linking group for those two moieties 
were observed at δ 4.84 in the 1H NMR spectrum and at δ 36.4 in the 13C spectrum.  The 
HRMS (ES) spectrum provided further evidence with a signal at m/z 586.1984, which 
was consistent with the positive ion component of compound 64.  
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Scheme 4-6 Preparation of the dual action drug 64 
 
4.1.6 Synthesis of the dual action drug (65) 
 Due to problems in the preparation of the para-methoxybenzyl bromide 5-
nitroindole derivative from 42 (Chapter 3), one pot procedures for the formation of 65 
from the alcohol 42 were investigated.  The first attempted synthesis of 65 (Scheme 4-7) 
was based on triphenylphosphine-carbon tetrabromide as the reagent combination to 
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generate the alkyl bromide in situ from the alcohol 42 in the first step, and then attack 
by the enamine 9 to ultimately afford the bromide salt of 65.  This reaction was carried 
out at 90oC for 20 hours and produced many products as indicated by TLC analysis.  
The only product isolated was the unwanted berberinium bromide (1) in 12% yield.  
Unfortunately there was no evidence for the expected bromide salt 65.  It seemed likely 
that the alkyl bromide derivative had been generated from the benzyl alcohol 42 and 
immediately cyclized to 46 (Scheme3-23; Section 3.3.4.6) instead of reacting with the 
enamine 9.  Hydrogen bromide, which may be generated in this reaction, could 
protonate the enamine 9 and then propene elimination would give the bromide salt 1. 
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Scheme 4-7 Attempted synthesis of the dual action drug 65 
 
 A further reaction was then attempted with the less reactive carbon tetrachloride 
in place of carbon tetrabromide.  A mixture of alcohol 42, enamine 9, and 
triphenylphosphine in CCl4 and DMF was heated at 90oC for 12 hours (Scheme 4-8).  
The crude reaction mixture was purified by multiple preparative layer chromatography 
and the product recrystallized to give the chloride salt 65 in 4% yield.  The 1H and 13C 
NMR spectra in CD3OD of 65 were similar to those of 64 except for one less aromatic 
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proton signal and the presence of signals which could be ascribed to the aromatic 
methoxy group (δ 3.83 in the 1H NMR; δ 56.0 in the 13C NMR).  The HRMS (ES) 
spectrum showed a signal at m/z 616.2090, which is consistent with the positive ion 
component of compound 65.  
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Scheme 4-8 Preparation of the dual action drug 65 
 
4.2 Attempted linking group expansion of berberine-indole 
hybrids  
 The purpose of expanding the length of the linking group of the berberine-indole 
hybrid was to create increased flexibility between the two moieties in the dual action 
drugs.  This would hopefully allow more successful attack on the bacterial target sites 
and hence increased antimicrobial activity.  
 
4.2.1 A ttem pted synthesis o f a berberine-indole hybrid via a cross 
m etathesis reaction
Cross metathesis is an important reaction in organic synthesis, in which two 
independent alkenes are combined into one molecule using appropriate catalysts (e.g. 
molybdenum, or ruthenium complexes) . 130,131 When two terminal alkenes are treated 
with a transition metal catalyst with the ability to catalyze the exchange of alkylidene 
groups of two independent alkenes, they produce a new compound linked via an alkene 
with the loss of ethylene.
Scheme 4-9 Schematic representation of the Ru-based cross metathesis mechanism132
The catalytic mechanism cycle proceeds via initial [2+2] cycloaddition and 
consequent cycloreversion to give the desired product (Scheme 4-9). Initially, the cycle 
is initiated by coordination of an alkene to the ruthenium metal to form a ruthenacycle 
(step A) which rapidly releases ethylene gas and gives a newly substituted alkylidene 
(step B). Then a cycloaddition reaction of the second alkene (step C) with the 
alkylidine from step B gives a metallacyclobutane in step D l, or D which is more
100
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preferred.  Cycloreversion of the metallacyclobutane results in the desired cross-
metathesis product and the active catalytic species is regenerated (step E). 
 Cross metathesis of alkenes with a ruthenium complex catalyst was chosen to 
carry out the linking group expansion in the berberine-indole hybrids.  Thus, the 
synthetic plan proposed the coupling of 13-allylberberine bromide 66 to the vinyl 
substituted 2-aryl-5-nitroindole analogue 55 via a cross metathesis reaction induced by 
polymer bound benzylidene-bis (tricyclohexylphosphine)-dichlororuthenium (Grubbs’ I 
catalyst) (Scheme 4-10).  The Grubbs’ II catalyst was not investigated due to time 
constraints. 
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Scheme 4-10 Attempted linking group expansion of the berberine-indole hybrid  
 
 The starting allyl berberine 66 was prepared by reaction of 8-
allyldihydroberberine 9 and excess neat allyl bromide at 100oC for 2 hours (Scheme 4-
11).  After chromatography, the allyl berberine 66 was obtained in 52% yield.  This 
compound had been made previously by Ikekawa et al., but they did not give any 
spectroscopic data in their patent.133 Confirmation of the structure of 66 was provided 
by NMR spectroscopic analysis and mass spectrometry.  The 1H and 13C NMR spectra 
showed the characteristic signals of 13-substituted berberinium salts as observed in 
compounds 60-65.  Additionally, the 1H NMR spectrum showed a set of distinctive 
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signals attributed to the allyl group at δ 3.90-4.01 (CH2CH=CH2) as a multiplet, 4.91 
and 5.43 (CH2CH=CH2) as broad doublets, and 6.31-6.42 (CH2CH=CH2) as a multiplet.  
The 13C NMR spectrum had signals that confirmed the structure of 66 including a set of 
signals attributed to an allyl group at δ 34.7 (CH2CH=CH2), 120.8 (CH2CH=CH2), and 
135.1 (CH2CH=CH2).  The HRMS (ES) spectrum provided additional evidence with a 
signal consistent with the positive ion of 66 at m/z 376.1548.  
 
CH2=CHCH2Br
100 oC, 52%
9
O
O N
OCH3
OCH3
O
O N
OCH3
OCH3
66
Br-
 
Scheme 4-11 Preparation of the allyl berberine salt 66 
 
 The other alkene component, 55 was prepared as discussed in Chapter 3 (Section 
3.3.4.9).  The cross metathesis reaction of 66 and 55 was catalyzed by 10 mol% of 
Grubbs’ I ruthenium catalyst (polymer bound) in dry DCM with heating at reflux for 2 
days under a nitrogen atmosphere.  After chromatography, two unidentified products 
were isolated and some of the starting materials 66 and 55 were also recovered. 
Unfortunately, none of the expected indole-berberine cross metathesis product was 
obtained and only trace amounts of the two isolated products were obtained which did 
not permit full spectroscopic identification.  The MS (CI) spectrum of the unknown 
products showed molecular ion peaks at m/z 208 in the first case and at m/z 313 in the 
second case.  These peaks did not correspond to possible homodimeric products. 
 The cross metathesis reaction shown in Scheme 4-10 was tested by changing the 
alkene 55 to another alkene derivative.  It was proposed that the vinyl group in 55 may 
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be too short, thus causing difficulty in coupling to 66 on steric grounds.  Thus, the allyl 
derivative 42a was designed to replace 55 for use in a cross metathesis reaction with 66.   
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Scheme 4-12 Unsuccessful O-alkylation of alcohol 42 
 
 In the attempted preparation of 42a, allyl bromide was used as the alkylating 
reagent, dry THF as a solvent, and TEA as a base to abstract the hydroxyl group proton 
in 42.  The reaction mixture was heated at 50oC for 30 hours under a nitrogen 
atmosphere, but none of the product 42a was obtained.  After chromatogryphy, only the 
starting alcohol 42 was recovered.  It seems likely that the electron-donating para-
methoxy substituent on the benzyl alcohol moiety decreased the acidity of the benzylic 
hydroxy proton.  Thus, a stronger base was indicated and NaH was used instead of TEA 
in the next trial.  Alcohol 42 was heated for 12 hours at 80oC in DMF with 1.3 mole 
equivalents of allyl bromide and 1.0 mole equivalent of NaH101 (Scheme 4-12).  After 
chromatography, the N-allyl product 67 was obtained in 21% yield together with two 
unidentified products which were lower in polarity than 67 (from TLC analysis).  It is 
likely that the indolic NH proton is more acidic than the benzylic hydroxy proton due to 
the presence of the 5-nitro group (electron withdrawing group).  The nitro group would 
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stabilize the indolyl anion through delocalization of the negative charge (Scheme 4-13), 
and hence N-alkylation would be preferred over O-alkylation. 
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Scheme 4-13 Resonance stabilization of 5-nitroindolyl anion 
 
The 1H NMR spectrum of 67 consisted of six aromatic proton signals with the expected 
splitting patterns, a singlet at δ 6.71 attributed to the C-3 proton of the indole nucleus, a 
singlet at δ 3.83 integrating for three protons ascribed to the methoxy group, and a 
singlet at δ 4.48 integrating for two protons and assigned to the methylene group.  
Moreover, the presence of an allyl group was indicated by characteristic signals at δ 
4.61 (CH2CH=CH2) as a doublet, 4.85 and 5.16 (CH2CH=CH2) as two doublets, and 
5.78-5.91 (CH2CH=CH2) as a multiplet; no signal which could be ascribed to the 
indolic NH proton was observed.  The 13C NMR spectrum and 2D analysis provided 
additional confirmation of the structure of 67.  The HMBC experimental data indicated 
that the methylene proton signal observed at δ 3.60 (allyl group) correlated with the 
signal at δ 139.6 (C-7a) and it also correlated with the signal at δ 131.3 (C-2).  This 
clearly indicated that the allyl group was attached to the nitrogen of the indole nucleus.  
The HRMS (CI) showed a signal at m/z 339.1349, consistent with the molecular ion of 
compound 67.  
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Scheme 4-14 Proposed alternative synthesis of a berberine-indole hybrid with an expanded linking 
group 
 At this point an alternative route to the more flexible hybrid molecules was 
devised based on an enamine alkylation reaction of 9 with 2-aryl-5-nitroindole 
derivatives containing longer side chains and a bromo substituent to act as an alkylating 
agent (Scheme 4-14).  The initial target was the bromide 55c.  The synthetic plan for 
55c (Scheme 4-15) involved a selective monoprotection of ethylene glycol (as its 
TBDMS ether), subsequent O-alkylation with the bromide 55 to produce 55a, then 
deprotection to give the free alcohol 55b, and bromination to eventually afford the 
bromide 55c.     
 
N
H
O2N CH2Br
O-alkylation
OHCH2CH2OSiMe2But
55
N
H
O2N CH2OCH2CH2OH
N
H
O2N CH2OCH2CH2OSiMe2Bu
t
N
H
O2N CH2OCH2CH2Br
55a
55b55c
Deprotection
Bromination
68
 
Scheme 4-15 Proposed synthesis of 55c 
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4.2.2 Synthesis of 2-(tert-butyldimethylsilanyloxy)ethanol (68)  
 The selective monosilylation of ethylene glycol was achieved following a 
literature procedure which described the synthesis of this compound.134  Ethylene glycol 
was treated with 1 equiv. of NaH to form a monosodium salt as an opaque white 
precipitate, and then  silylating with TBDMSCl.  After chromatography, the silyl 
alcohol 68 was obtained in 33% yield. 
OHCH2CH2OH OHCH2CH2OSiMe2Bu
tTBDMSClNaH, THF [OHCH2CH2Na]
RT, 33%RT 68  
Scheme 4-16 Monosilylation of ethylene glycol 
  
4.2.3 Attempted O-alkylation of 55a 
 The alkylation of 2-(tert-butyldimethylsilanyloxy)ethanol (68) with the previously 
prepared alkylating agent 55 was carried out using similar reaction conditions to those 
used for the synthesis of 67 (Scheme 4-12).  The monosilylated ethanol in DMF was 
treated with NaH to form a sodium alkoxide salt, and then the bromide 55 was added 
and the mixture heated at 80oC for 2 days.  The major product obtained (69% yield) was 
the cyclised compound 46 (see Chapter 3, Scheme 3-23); none of the required 
compound 55a was observed.  Due to time constraints, no further work on the extended 
linking chains was undertaken. 
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Scheme 4-17 Attempted O-alkylation of 2-(tert-butyldimethylsilanyloxy)ethanol (68) 
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4.3 Hydrolysis of the ester linked berberine-indole prodrug 
 An enzymatic hydrolysis experiment was undertaken only on the berberine-indole 
prodrug with an ester linkage, which was a model dual-action prodrug compound for 
enzymatic hydrolysis.  The enzyme used was the commercially available porcine liver 
carboxyl esterase (EC 3.1.1.1).  This experiment investigated the prodrug concept that 
two parent drugs would be released after enzymatic ester cleavage of the prodrug.   
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Figure 4-18 Enzymatic hydrolysis of ester prodrug 60 
 
 Following a general literature procedure,135  the ester prodrug 60 in DMSO was 
reacted with the porcine liver carboxyl esterase (EC 3.1.1.1) in the presence of Tris-HCl 
buffer solution (pH 7.2) at 37oC for 1 day.  After this time, organic products were 
extracted with DCM.  TLC analysis of this concentrated extract indicated the presence 
of trace amounts of the alcohol 41.  It is likely that the solubility of prodrug 60 in 
DMSO-Tris-HCl buffer solution may have been a problem, since formation of a 
suspension was noted after addition of the buffer solution to a solution of the ester 60 in 
DMSO.  When acetone was used instead of DMSO in the enzymatic reaction, a small 
amount of 41 was again detected.  These results provided some indication that the ester 
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prodrug 60 does hydrolyse in the presence of esterase or undergoes spontaneous 
hydrolysis slowly with time.  Further studies are needed to confirm these using bacterial 
esterases.  Also, the hydrolysis of the amide prodrug with hydrolases136 still needs to be 
investigated. 
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5 Chapter5: Biological test results   
 The biological activities of the test compounds were determined by antimicrobial 
assays against various microorganisms including bacteria, yeasts and a protozoan, but 
mainly bacteria. Subsequently, the most active compounds were assessed for 
cytotoxicity against human cancer cells.  The antibacterial testing was divided into two 
phases.  The first phase of testing was performed in the University of Wollongong to 
assess the initial antibacterial activity.  The second phase was performed in the 
Department of Biology, Northeastern University, Boston, USA, in collaboration with 
Prof. Kim Lewis and Mr. Anthony Ball, for more detailed systematic studies of both 
antibacterial and MDR pump inhibitory activities.  Additional antibacterial testing of a 
few active compounds was also done by Avexa Ltd., Melbourne, and antimalarial 
testing (protozoan; Plasmodium falciparum) of the most active antibacterial compound 
was done by Dr. Sumalee Kamchonwongpaisan, Protein-Ligand Engineering and 
Antimalarial Screening Laboratories, National Centre for Genetic Engineering and 
Biotechnology, National Science and Technology Development Agency (BIOTEC), 
Bangkok, Thailand.  Limited testing against the yeast, Saccharomyces cereavaesiae and 
the yeast-like fungus Candida albicans was also undertaken at Northeastern University.   
Details of the testing methodologies are given in Appendices I-V. 
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5.1 Preliminary antibacterial testing results against 
Staphylococcus aureus ACM844 and Escherichia coli 
ACM845 using a combination of FDA and antimicrobial (cell 
lysis/cell stasis) assays 
 The initial results of antibacterial testing of 7 berberine derivatives (3, 5-8, 10-11), 
2 indoles (38, 41), a potential dual action prodrug 60 and a dual action drug 64, together 
with MDR inhibitory testing of a mixture of 11 and 38, and 11 and 41, provided 
valuable initial information about the antibacterial activity against Gram-positive (S. 
aureus ACM844) and Gram-negative (E. coli ACM845) human pathogenic bacteria 
using a combination of fluorescein diacetate (FDA) and antimicrobial (cell lysis/cell 
stasis) assays137 (Table 5-1).  With the FDA assay, it is not possible to distinguish 
whether antimicrobial agents cause cell death or cell stasis, and thus the antimicrobial 
(cell lysis/cell stasis) assay was used after completion of the FDA assay to assess the 
ability of the cells to recover.  Therefore, the combination of both assays produced an 
accurate assessment of antimicrobial activity.137 The antimicrobial activity in the cell 
lysis/cell stasis assay was determined as the lowest concentration that caused over 90% 
cells unable to recover and is defined as the minimum inhibitory concentration (MIC).  
This value is given in µg/mL and in µM concentrations in Table 5-1. 
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Table 5-1 Minimum Inhibitory Concentration (MIC) values of berberine bromide, berberine 
derivatives, indole derivatives and a mixture of indole and berberine derivatives against S. aureus 
ACM844 and E.coli ACM845 using the combination of FDA and antimicrobial (cell lysis/cell stasis) 
assays.  NT indicates the sample was not tested.  * indicates result of antibacterial screening. 
  MIC, µg/mL (µM) 
Entry Compound S. aureus ACM844 E. coli ACM845 
1 1, Br 75.00(180.33) NT 
2 3 100.00(235.03) NT 
3 5 >100.00(>205.11) 100.00(205.11) 
4 6a 100.00(182.03) NT 
5 7 100.00(177.28) 100.00(177.28) 
6 8 100.00(191.82) 100.00(191.82) 
7 10 50.00(93.62) NT 
8 11 50.00(98.80) NT 
9 38 100.00(354.28) 100.00(354.28) 
10 41 50.00(186.38) <10.00(<37.28) 
11 11+38 (1:1 weight ratio ) 50.00 NT 
12* 11+41 (1:1 weight ratio ) 10.00-25.00 NT 
13 41 in the presence 
 of 11 at 0.5 MIC  10.00 NT 
14* 60 10.00-100.00(13.80-137.97) NT 
15 64 10.00(15.00) NT 
 
 The antibacterial activity results (Table 5-1) showed that compounds 3 and 5 had 
low antibacterial activity, and both were less active than 1.  Since it has been 
established11 that aromaticity in ring C is essential for protoberberine alkaloids to 
exhibit high antimicrobial activity (as discussed in Chapter 1, section 1.1), the low 
activity of tetrahydroberberines 3 and 5 was not unexpected although other variables 
could be involved.  Moreover, it has been reported that introduction of an ester group at 
the C-13 position (ring C) of 1 resulted in a decrease in the activity.9 Therefore, it was 
not surprising that the activities of 3 and 5 were lower than that of 1.   Similarly, 
compound 6a and 7 were slightly less active than 1 probably as the effect of the 
lipophilic ester group was introduced at the C-13 position.    
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 Introduction of a carboxylic acid group at the C-13 position of 1 caused a decrease 
in antibacterial activity (comparing 8 with 1).  Substitution of hydrogen at the C-13 
position of 1 by a lipophilic phenacyl group (10) or benzyl group (11) resulted in an 
increase in the activity.   
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 The related 13-substituted berberine derivatives 60 and 64, which were expected 
to have dual antimicrobial and MDR pump inhibitory activities, were both more active 
than 1, although the MIC for 60 was not accurately determined in these preliminary 
studies.  Compound 64, at least, was also more active than the benzyl analogue 11.  This 
evidence indicated that there was a significant advantage associated with a 2-phenyl-5-
nitro-1H-indole substituent at the C-13 position. 
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 The 2-phenyl-5-nitro-1H-indole analogues 38 and 41 had inherent antibacterial 
activity, with 38 being more active than 41.  Interestingly, 41 was more active against 
Gram-negative bacteria (E. coli ACM845) than Gram-positive bacteria (S. aureus 
ACM844).  In addition, 38 and 41 were tested in S. aureus in the presence of the 
antibacterial agent 11 (entry 11-13), and it was found that 41 was able to potentiate the 
antibacterial activity of 11 in line with 41 having MDR pump inhibitory activity.    
 The FDA and antimicrobial (cell lysis/cell stasis) assays provided preliminary 
results for the antibacterial agents (60 and 64) and the potential MDR pump blocking 
agents (38 and 41).  Therefore, systematic antimicrobial activity testing and MDR pump 
inhibitory activity testing of all target compounds were indicated and these tests were 
undertaken by microbiologists at Northeastern University, Boston.  The detailed results 
of the antimicrobial activity and MDR pump inhibitory activity are given in the next 
section. 
 
5.2 MDR pump inhibitory testing results   
 The initial antibacterial activity results in the previous section showed that 2-
phenyl-5-nitro-1H-indole derivatives may be NorA MDR pump inhibitors and 
potentiators of the antibacterial activity of berberine or berberine derivatives in S. 
aureus.  To confirm and quantify the MDR pump inhibitory activity of the 2-phenyl-5-
nitro-1H-indole derivatives, a set of these indoles was tested in the presence of a sub-
inhibitory concentration (no effect on bacteria at this concentration) of a NorA MDR 
pump-substrate and antibacterial agent which was either berberine (1) chloride or 
 114
ciprofloxacin.  The potentiating activity of the 2-phenyl-5-nitro-1H-indole derivatives 
on berberine 1 chloride in a wild type S. aureus strain 8325-4 was described by the 
fractional inhibitory concentration (FIC) index (Table 5-2), and the MDR pump 
inhibitor property was examined using this index as an indication of the activity.  In the 
case of the potentiating activity of these indoles on ciprofloxacin, the FIC index was not 
able to be calculated because the exact MICs for direct activity of the indoles against S. 
aureus K2361 (Table 5-4) were not available.  The MDR pump inhibitory activity 
results for the 2-phenyl-5-nitro-1H-indole derivatives are shown in Tables 5-3 and 5-4, 
and the direct activity (antibacterial activity) results for all test compounds (Figure 5-1; 
fold out sheet page 128) are shown in Tables 5-5 and 5-6 against strains expressing the 
MDR efflux pump in Gram-positive bacteria, Gram-negative bacteria and yeasts.  In all 
tests berberine 1 was used as its chloride salt.  
Table 5-2 Indicator of potentiating activity for 2-aryl-5-nitro-1H-indole derivatives with the 
antibacterial agent berberine (1) chloride using wild-type S. aureus 8325-4 which expresses the 
NorA MDR pump.   
  FIC indexa   FIC indexa 
Compound Berberine (1) chlorideCompound Berberine (1) chloride
38 1.12 44 0.24 
39 <0.37 45 0.13 
41 0.37 47 <0.14 
42 <0.37 48 <0.13 
43 <0.13 56 <0.15 
a The fractional inhibitory concentration (FIC) was calculated for each inhibitor and berberine (1) 
chloride in combination by using the following formulas: FIC of antibacterial agent = MIC of 
antibacterial agent in combination/MIC of antibacterial agent alone, FIC of inhibitor = MIC of inhibitor in 
combination/MIC of inhibitor alone, and FIC index = FIC of antibacterial agent + FIC of inhibitor.  
Potentiating activity was defined as an FIC index of <0.5.46    
  
 Most of the test compounds were synergistic with a sub-inhibitory concentration 
of 1.  The FIC indices (Table 5-2) for compounds 39, 41-45, 47, 48, and 56 had values 
 115
less than 0.5, which indicated that these compounds were synergistic in potentiating the 
antibacterial activity of 1 while compound 38 was not.  It appeared that the use of 1 in 
combination with an inhibitor of the MDR pump (41 - 45, 47, 48, and 56) significantly 
improved the efficacy of the antibacterial 1 by inhibiting its efflux.   
Table 5-3 Minimum Inhibitory Concentration (MIC) value for 2-phenyl-5-nitro-1H-indole 
derivatives (MDR pump inhibitory activity) against Gram-positive bacteria: Staphylococcus aureus 
K1758 (lacking NorA MDR pump), S. aureus 8325-4 (expressing NorA MDR pump), S. aureus 
K2361 (overexpressing the NorA MDR pump), Enterococcus faecalis V583, and E. faecium DO in 
the presence of sub-inhibitory concentration of berberine (1) chloride.  NT indicates the sample was 
not tested.  “-” indicates sample showed no activity when tested at a concentration of 50µg/mL. 
  MIC, µg/mL (µM) 
Compound S. aureus E. faecalis E. faecium
  K1758 8325-4 K2361 V583 DO 
  +1, 3µg/mL +1, 30µg/mL +1, 30µg/mL +1, 30µg/mL +1, 30µg/mL
38 
- 
 
- 
 
- 
 
- 
 
NT 
 
39 
12.50 
(40.03) 
12.50 
(40.03) 
12.50 
(40.03) 
- 
 
NT 
 
41 
6.25 
(23.30) 
12.50 
(46.59) 
12.50 
(46.59) 
- 
 
NT 
 
42 
3.13 
(10.49) 
12.50 
(41.90) 
6.25 
(20.95) 
- 
 
NT 
 
43 
0.39 
(1.04) 
0.39 
(1.04) 
0.78 
(2.08) 
- 
 
NT 
 
44 
0.78 
(2.66) 
6.25 
(21.31) 
3.13 
(10.67) 
- 
 
NT 
 
45 
<0.24 
(<0.90) 
0.39 
(1.46) 
12.50 
(46.77) 
12.50 
(46.77) 
25.00 
(93.53) 
47 
0.39 
(1.21) 
1.56 
(4.83) 
1.56 
(4.83) 
- 
 
NT 
 
48 
0.78 
(2.62) 
0.39 
(1.31) 
12.50 
(42.04) 
25.00 
(84.09) 
12.50 
(84.09) 
56 
0.39 
(1.38) 
1.56 
(5.53) 
- 
 
- 
 
NT 
 
INF55 
0.78 
(3.28) 
0.24 
(1.01) 
3.13 
(13.15) 
NT 
 
NT 
 
Note: inhibitors 41 and 44 were chosen for MDR inhibitory activity testing against Salmonella 
enterica Serovar Typhimurium SL1344R2 in the presence of either a fixed sub-inhibitory 
concentration of 30µg/mL berberine (1) or 50ng/mL ciprofloxacin.  The results showed that the 
MIC for 41 was 3.13µg/mL (11.67µM) in the presence of 1, but no activity in the presence of 
ciprofloxacin.  The MICs for 44 were 0.24µg/mL (0.82µM) in the presence of 1, and 3.13µg/mL 
(10.67µM) in the presence of ciprofloxacin.    
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 As shown in Table 5-3, alcohol analogue 43 (with benzyloxy substitution on the 
2-phenyl ring) showed the highest MDR inhibitory activity with an MIC of 0.78µg/mL 
(over 4-fold more potent than that of the parent INF55) in the presence of 1 against a 
mutant strain of S. aureus K2361 which overexpresses the NorA pump, but lower 
activity in the presence of ciprofloxacin with an MIC of 50.00µg/mL (Table 5-4).  The 
lipophilicity of the benzyloxy substituent and the weak acidity of the benzyl alcohol 
substituent (pKa ~ 12-13) might be of importance in mediating this synergistic activity. 
A similar pattern of synergy was shown with the other inhibitors 41-42, 44-45, 47-48 
and 56, which preferably potentiated the activity of 1 over ciprofloxacin (Tables 5-3 and 
5-4).  This would suggest that, compared to ciprofloxacin, 1 was a more preferred 
substrate for the NorA MDR pump, and that the less significant potentiating activity of 
those inhibitors with ciprofloxacin might relate to molecular hydrophilicity and 
structural characteristics of ciprofloxacin that may reduce recognition and efflux.   
 The azide analogues 44 and 47 bearing a methoxy substituent in the 2-aryl ring 
exhibited a 4- and 2-fold less blocking activity than 43, respectively, against S. aureus 
K2361.  In addition, the azide 44 was able to completely inhibit the Gram-negative 
bacterium Salmonalla enterica Serovar Typhimurium SL1344 R2 at MICs of 0.24 and 
3.13µg/mL (see Note, Table 5-3) in the presence of a sub-inhibitory concentration of 1 
and ciprofloxacin, respectively.  It might be noted that the dipolar azide functionality, 
N=N+=N-, seems to be associated with the ability of the molecule to inhibit the bacterial 
efflux pumps in both Gram-positive and Gram-negative bacteria.  However, one can not 
disregard the lipophilicity of the methoxy substituent in the azide 47, since this 
compound showed higher activity than 44 (which lacked the methoxy group) against S. 
aureus K 2361.  This is consistent with the effect of alkoxy substituents in the 2-aryl 
group on the activity of the alcohol analogues 41-43.  Without the alkoxy substituents 
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(41, 44), there was a 2- to 16-fold increase in MICs against S. aureus K 2361.  
Therefore, the substitution of a benzyloxy group in the 2-phenyl ring of the azide 
analogue might increase its MDR inhibitory activity in both S. aureus and S. enterica, 
and this would be of interest for future work.    
 Interestingly, two amine analogues, 45 and 48, had moderate activity in the 
presence of 1 against E. faecalis V583 and E. faecium DO, while the other analogues 
had no activity against these bacteria.  In addition, 45 and 48 also moderately 
potentiated the activity of either 1 (Table 5-3) or ciprofloxacin (Table 5-4) against S. 
aureus K2361. 
Table 5-4 Minimum Inhibitory Concentration (MIC) value for 2-phenyl-5-nitro-1H-indole 
derivatives (MDR pump inhibitory activity) against S. aureus K1758 (lacking NorA MDR pump), S. 
aureus 8325-4 (expressing NorA MDR pump), S. aureus K2361 (overexpressing NorA MDR pump) 
in the presence of sub-inhibitory concentration of ciprofloxacin (Cip.).  NT indicates the sample was 
not tested.  “-” indicates the sample showed no activity when tested at a concentration of 50µg/mL. 
  MIC, µg/mL (µM) 
Compound S. aureus 
  K1758 8325-4 K2361 
   +Cip., 40ng/mL +Cip., 500ng/mL 
38 NT - - 
39 NT - - 
41 NT - 50.00 (186.38) 
42 NT - - 
43 NT - 50.00 (133.55) 
44 NT - 12.50 (42.62) 
45 NT - 25.00 (93.53) 
47 NT - - 
48 NT - 12.50 (42.04) 
56 NT - - 
 
 Acid analogues 38 and 39 (with a methoxy substituent in the 2-aryl ring), were 
either inactive or were only slightly active against all test strains.  As shown in Table 5-
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2, 38 had no synergistic activity in potentiating the antibacterial activity of either 1 or 
ciprofloxacin; it is possible that 38 and 39 are competitive MDR substrates.  
 Since 43 was the most active NorA MDR inhibitor, a berberine (1) uptake assay 
in the presence of inhibitor 43 (5µg/mL) was performed.  As berberine is a planar 
cationic molecule, it fluoresces when located inside the cell and bound to DNA.  The 
uptake assay evaluated NorA pump inhibition by 43 through suppressing the berberine 
efflux.  The rate of berberine uptake (Figure 5-2) as measured by fluorescence emission 
showed a sharp increase in berberine accumulation within the cells over a period of 10 
minutes when in the presence of 43 compared to the parent NorA MDR inhibitor 
INF55.  43 is over 20-fold more active than INF55 over this period, and it potentiated 
the uptake of berberine in three strains of S. aureus: the wild-type 8325-4, the NorA 
knock out K1754, and the overexpressing NorA K2361.  
 
 
 
 
 
 
 
 
 
Figure 5-2 Uptake of berberine as potentiated by MDR inhibitors, 43 or INF55.  Fluorescence is 
given in relative fluorescence units (RFU).  The inhibitor concentration was 5µg/mL (for INF55 and 
43).  The background fluorescence of berberine was blanked to zero.  Cells were in HEPES buffer 
pH7 at OD 0.15.  The tests were done with S. aureus 8325-4, S. aureus K1754, and S. aureus K2361.  
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5.3 Antimicrobial testing results (Direct activity) 
 The set of 2-phenyl-5-nitro-1H-indole derivatives, the berberine carboxylic acid 
derivative (8), and dual-action prodrugs and dual-action drugs (60-65) (Figure 5-1; page 
128) were tested for direct antimicrobial activity against human pathogenic Gram-
positive and Gram-negative bacteria, and yeasts.  The data are shown in Tables 5-5 and 
5-6.   
 
5.3.1 Nitroindoles  
 In general, the 2-phenyl-5-nitroindole derivatives had weak or no intrinsic 
antimicrobial activity against S. aureus (Table 5-5).  Surprisingly, the amine 48 had 
moderate intrinsic antibacterial activity (12.5µg/mL) against the Gram-negative 
bacterium E. coli, which has an effective permeability barrier (outer membrane and 
MDR pumps) to hinder drug accumulation in its cells and also to transport unwanted 
molecules out of the cells.  Gram-positive bacteria lack this outer membrane which 
would restrict the access of amphipathic compounds into their cells.  Gram-negative 
bacteria are thus normally harder to kill than the Gram-positive ones.138,139 A similar 
result with the other Gram-negative bacterium S. enterica Serovar Typhimurium was 
seen with the alcohol derivative 43 (MIC, 12.5µg/mL).  This suggested that compounds 
43 and 48 might have another mode of antibacterial action in the Gram-negative 
bacteria, apart from the MDR pump inhibition and synergistic action with antibiotics. 
 120
 All compounds in the indole series were inactive against the Gram-positive 
bacterium E. faecalis, the Gram-negative bacterium P. aeruginosa, and the yeast, 
Saccharomyces cereavaesiae and the yeast-like fungus Candida albicans, (Table 5-5).   
 
Table 5-5 Minimum Inhibitory Concentration (MIC) value for indole derivatives (direct activity) 
against bacteria Gram-positive (Staphylococcus aureus; 3 strains) and Gram-negative (Escherichia 
coli, Salmonella enterica), and yeast (Saccharomyces cereavaesiae).  NT indicates the sample was not 
tested.  “-” indicates sample showed no activity tested at concentration 50µg/mL. 
  MIC, µg/mL (µM) 
Compd S. aureus E. coli
S. enterica 
Serovar Typhimurium S. cerevisiae
  K1758 8325-4 K 2361 K12 SL1344 R2 BY4742 
38 - - - - -  
39 NT - - - - - 
41 
50.00 
(186.38)  
50.00 
(186.38)  - - 
25.00 
(93.19) 
50.00 
(186.38) 
42 - - - - - - 
43 NT - - - 
12.50 
(33.39) - 
44 
3.13 
(10.67) 
50.00 
(170.48) -  - - - 
45 
50.00 
(187.07)  
50.00 
(187.07)  -  - 
25.00 
(93.53) -  
47 - - - - - - 
48 
25.00 
(84.09) 
- 
 
50.00 
(168.17)
12.50 
(42.04)
25.00 
(84.09) - 
56 - - - - - - 
INF55 
250.00 
(1050.42) 
250.00 
(1050.42) 
250.00 
(1050.42) NT NT NT 
Note: all compounds in Table 5-5 were additionally tested direct activity against Enterococcus faecalis 
V583, Pseudomonas aeruginosa PA1, Candida albicans F5, and Candida albicans F5 M432, which 
showed no direct activity at concentration of 50µg/mL. 
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5.3.2 Berberine derivatives 
 The ester prodrugs 60-61, the amide prodrugs 62-63 and the dual action drugs (or 
hybrid drugs) 64-65 were synthesized with the aim of increasing antibacterial potency 
of berberine or analogues 64 and 65 were obtained from a combination of berberine (1) 
and the 2-phenyl-5-nitro-1H-indole derivatives with a methylene linkage.  Similarly, the 
combination of 1 and the 2-phenyl-5-nitro-1H-indole derivatives with an ester linkage 
afforded 60 and 61, and those with an amide linking group also gave 62 and 63.  
Esterification of the berberine carboxylic acid derivative 8, which had 5- and 50-fold 
greater antibacterial activity than 1 (Table 5-6) against wild-type S. aureus 8325-4 and 
S. enterica Serovar Typhimurium, respectively, with the indole alcohol derivative 41 (or 
42) led to the corresponding ester prodrugs 60 (or 61).  Similarly, amidation of 8 with 
the indole amine derivative 45 (or 48) led to the corresponding amide prodrugs 62 (or 
63).  The prodrugs 60-63 required bacterial enzymatic hydrolysis (esterase and amidase) 
to release the MDR pump inhibitor component and berberine derivative 8 at or near 
target sites in bacterial cells.  These compounds were tested against human pathogenic 
bacteria (both Gram-positive and Gram-negative) and yeasts.  The data are shown in 
Table 5-6.  
 The ester prodrugs 60 and 61 exhibited moderate antibacterial activity against the 
NorA overexpressing strain of S. aureus K2361, with MICs of 25.00µg/mL for 60 and 
12.50µg/mL for 61, respectively.  The two amide prodrugs 62 and 63 were comparable 
in activity and more active than the esters 60 and 61; the amides 62 and 63 showed 2- to 
4-fold greater antibacterial activity at the same MIC values of 6.25µg/mL against the 
NorA overexpressing S. aureus strain.      
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Table 5-6 Minimum Inhibitory Concentration (MIC) value for berberine derivatives, dual action 
prodrugs and dual action drugs (direct activity) against Gram-positive (Staphylococcus aureus; 3 
strains, and Escherichia coli) and Gram-negative (Salmonella enterica).  NT indicates the sample 
was not tested.  “-” indicates sample showed no activity tested at a concentration of 50µg/mL. 
 MIC, µg/mL (µM) 
Compound S. aureus E. faecalis S. enterica Serovar 
 K1758 8325-4 K2361 V583 Typhimurium SL1344 R2
Ciprofloxacin 0.24 (0.72) 
1.00 
(3.00) 
4.00 
(12.00) NT NT 
1, Cl 15.60 (41.96) 
250.00 
(672.39) 
500.00 
(1344.77) 
500.00 
(1344.77)  
1250.00 
(3361.93) 
8 
50.00 
(95.92) 
50.00 
(95.92) 
NT 
 
- 
 
25.00 
(47.96) 
60 3.13 (4.32) 
16.00 
(22.07) 
25.00 
(34.49) 
50.00 
(68.98) 
1.56 
(2.15) 
61 3.13 (4.15) 
6.25 
(8.28) 
12.50 
(16.57) 
12.50 
(16.57) 
0.78 
(1.08) 
3.13 3.13 6.25 - 3.13 
62 (4.33) (4.33) (8.64)   (4.33) 
6.25 12.50 6.25 - 3.13 
63 (8.29) (16.59) (8.29)   (4.15) 
1.56 0.97 1.98 1.56 0.78 
64 (2.34) (1.46) (2.97) (2.34) (1.17) 
3.13 3.13 6.25 12.50 3.13 
65 (4.80) (4.80) (9.58) (19.17) (4.80) 
 Note: all compounds in Table 5-6 were additionally tested direct activity against Gram-negative bacteria 
(E. coli K12, Pseudomonas aeruginosa PA1) and yeasts (Saccharomyces cereavaesiae BY4742, Candida 
albicans F5, and Candida albicans F5 M432), which showed no direct activity at a concentration of 
50µg/mL. 
 
 The most active compound against S. aureus was the dual action drug 64 with an 
MIC against the mutant strain overexpressing the NorA pump at clinically useful 
concentrations (1.98µg/mL, over 250-fold more potent than the parent antibiotic 1).  
With this compound, it appeared that it had both strong NorA pump blocking activity as 
well as separate direct antibacterial potency.  A similar result was observed with the 
dual action drug 65, although it was 3-fold less active than 64 against the S. aureus 
strain K2361.  It seemed that the presence of a methoxy substituent in the aryl ring of 
the inhibitor moiety of 65, resulted in a decrease in the activity against S. aureus.  The 
MICs for 60-65 against S. aureus K2361 (the strain overexpressing the NorA pump) 
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compared with K1754 (the strain lacking the NorA pump) indicated that compounds 62-
65 completely inhibited the efflux activity of NorA pump in this bacterium as the MICs 
for these compounds in both strains were the same or similar (note that there was only a 
2-fold difference in the MICs with both strains, which might not be significant).  The 
MICs for compounds 60-61 in these two strains were quite different however, indicating 
that the NorA pump was partially inhibited by these ester prodrugs. 
 
 
 
Figure 5-3 Graphs showing the accumulation of compound 64 (5µg/mL) inside Staphylococcus 
aureus cells over a period of 10 minutes.  Fluorescence is given in relative fluorescence units (RFU). 
INF55 at 5µg/mL plus berberine 5µg/mL is not shown but would be represented by a horizontal 
line at –30 RFU’s.  The background fluorescence of berberine was blanked to zero.  Cells were in 
HEPES buffer pH7 at OD 0.15.  The tests were done with S. aureus 8325-4, S. aureus K1754, and S. 
aureus K2361.  
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 Verification of the dual action of the most active compound 64 was subsequently 
achieved by a direct uptake assay in 3 strains of S. aureus.47 The uptake assay measured 
the fluorescence generated by 64, a planar cationic species, when it interacted with 
DNA in the bacterial cells.  Due to the disabling of the MDR pumps, it led to an 
accumulation of 64 in the cells.  The fluorescence from the complex of 64-DNA (Figure 
5-3) was found to be increased compared with that from berberine plus INF55 (known 
NorA inhibitor, Figure 5-1 and Table 5-3).  This uptake study confirmed that 64 had a 
double action of MDR pump inhibition and antibacterial activity.   
N
H
O2N
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N
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H
O2N
64  
 Interestingly, with the Gram-positive bacterium E. faecalis, only the hybrid drug 
64 was able to completely inhibit the bacterial growth at a clinically useful 
concentration of 1.56µg/mL while the others were moderately active (61 and 65 with 
MICs of 12.5µg/mL) or inactive (60, 62, and 63). 
 Unexpectedly, the ester prodrug 61 and the hybrid drug 64 were extremely active 
against the Gram-negative bacterium S. enterica Serovar Typhimurium at the same MIC 
of 0.78µg/mL (over 1600-fold more potent than berberine 1).  The amine prodrugs 62 
and 63, and hybrid drug 65 were strongly active at the same concentration of 
3.13µg/mL against this bacterium while the ester prodrug 60 was more active at the 
concentration of 1.56µg/mL.  This data indicated that the ester prodrugs 60-61 had more 
specific efficacy for the Gram-negative bacterium S. enterica Serovar Typhimurium 
than for S. aureus.  The ester prodrug 60 and the hybrid 64 were also tested against the 
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other wild-type strain of S. aureus, ATCC 6538P, and 4 strains of Enterococcus 
faecium.  The hybrid drug 64 was strongly active against S. aureus, whereas the ester 
prodrug 60 was only moderately active.  As expected, both 60 and 64 were inactive 
against all strains of E. faecium, vancomycin resistant Enterococcus (VRE) strains due 
to unrelated resistance mechanisms to the MDR pump.  The resistance mechanism of 
these strains involves modification of the peptidoglycan drug target as discussed in 
Chapter1, section 1.3.2.  Moreover, 64 was tested for antimalarial activity in vitro 
against an anti-folate sensitive strain (TM4) and an anti-folate resistant strain (K1) of 
Plasmodium falciparum.  The result showed good activity with an IC50 of 1.66µg/mL 
against the anti-folate resistant strain, which possesses an efflux-related resistance 
phenotype.140  
 
Table 5-7 Additional Minimum Inhibitory Concentration (MIC) values for 60 and 64 (direct 
activity) against Staphylococcus aureus ATCC 6538P, 4 strains of Enterococcus faecium (VRE243 
and VRE987 are sensitive to vancomycin, and VRE449 and VRE820 are resistant to vancomycin), 
and 2 strains of Plasmodium falciparum (TM4 is an anti-folate sensitive strain and K1 is an anti-
folate resistant strain). 
 MIC, µg/mL (µM) IC50, µg/mL (µM)
Compd S. aureus E. faecium P. falciparum 
 ATCC 6538P VRE243 VRE449 VRE820 VRE987 TM4 K1 
60 
31.25 
(43.11) 
>125.00 
(>172.46)
>125.00 
(>172.46)
>125.00 
(>172.46)
>125.00 
(>172.46) NT NT 
64 
0.98 
(1.47) 
>125.00 
(187.54) 
125.00 
(187.54) 
125.00 
(187.54) 
>125.00 
(>187.54) 
7.93 
(11.90) 
1.66 
(2.49) 
 
 In summary, all compounds 60-65 showed moderate to strong direct antimicrobial 
activity and were much more potent than the parent berberine (1).  The MICs of 64 were 
near or below 1µg/mL against both S. aureus and S. enterica Serovar Typhimurium, 
which are clinically useful concentrations.  The hybrid drug 64 was the most potent 
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antimicrobial compound developed in this research, substantiating the principle of the 
hybrid molecule approach.  With the dual action prodrugs 60-63, there is evidence that 
antimicrobial berberine acid derivative (8) fragment and the MDR pump inhibitor 
fragment were possibly released by bacterial hydrolase enzymes.  Also this partial 
hydrolytic cleavage had been noted using commercially available pig liver esterase at 
pH 7.2 for 24h (Chapter 4, Section 4.3).  If it is assumed that the prodrugs 60-63 were 
hydrolysed completely by bacterial enzymes then they could release the two fragments 
expected in a 1:1 equimolar ratio as shown in Scheme 5-1. 
              1µmole                                                  1µmole                   1µmole 
N
O
O
OMe
OMe
+
X O
HN NO2
bacterial enzyme
N
O
O
OMe
OMe
+
COOH
Y
HN NO2
+
R
R
860: X = O, R = H
61: X = O, R = OCH3
62: X = NH, R = H
63: X = NH, R = OCH3
41: Y = OH, R = H
42: Y = OH, R = OCH3
45: Y = NH2, R = H
48: Y = NH2, R = OCH3
hydrolysis
  
Scheme 5-1 Potential release of 2 active components from the dual action prodrugs 60-63 by 
bacterial esterase or amidase as follows: 8 and 41 released from 60, 8 and 42 released from 61, 8 
and 45 released from 62, and 8 and 48 released from 63.  
 
  In order to prove the assumption of full hydrolysis, separate mixtures of the 
hydrolysis products, the berberine acid 8 and each of the indoles (41, 42, 45 or 47) in a 
1:1 ratio, were tested against both wild-type 8325-4 and mutant K1758 strains of S. 
aureus.  The results are shown in Table 5-8.  It should be noted that a 1:1 weight ratio 
was used in the testing instead of the more accurate 1:1 molar ratio. 
 The MIC value for a separate mixture of 8 and 41 in a 1:1 weight ratio in the 
antibacterial testing was compared with calculated MICs for the fragments 41 and 8 
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which would be generated from the prodrug 60 (MIC, 16.00µg/mL = 22.07µM) 
assuming complete bacterial enzymatic hydrolysis (Table 5-8). The calculated MICs 
showed that the concentration of 41 and 8 required for wild-type (8325-4) strain growth 
inhibition was only 5.92µg/mL (22.07µM) and 11.51µg/mL (22.07µM), respectively.  
The 1:1 mixture of 41 and 8 gave an experimental MIC of 6.25µg/mL.  
 
Table 5-8 Comparison of direct activity of co-administration of the MDR pump inhibitor and the 
berberine acid derivative 8 in a 1:1 weight ratio, to the dual action prodrugs (60-63). 
 MIC, µg/mL (µM)  MIC, µg/mL (µM) 
Compd S. aureus Compd S. aureus 
 8325-4 K1758  8325-4 K1758 
60 16.00 (22.07) 3.13 (4.32) 61 6.25 (8.28) 3.13 (4.15) 
8 + 41 
(calcd) 
8 = 11.51 (22.07) 
41 = 5.92 (22.07) 
8 = 2.25 (4.32) 
41 = 1.16 (4.32) 
8 + 42
(calcd)
8 = 4.32 (8.28) 
42 = 2.47 (8.28) 
8 = 2.16 (4.15) 
42 = 1.24 (4.15) 
8 + 41 
(exp.) 
8 = 6.25 (11.99) 
41 = 6.25 (23.30) 
8 = 3.13 (6.00) 
41 = 3.13 (11.67) 
8 + 42
(exp.)
8 = 6.25 (11.99) 
42 = 6.25 (20.95) 
8 = 6.25 (11.99) 
42 = 6.25 (20.95) 
62 3.13 (4.33) 3.13 (4.33) 63 12.50 (16.59) 6.25 (8.29) 
8 + 45 
(calcd) 
8 = 2.26 (4.33) 
45 = 1.16 (4.33) 
8 = 2.26 (4.33) 
45 = 1.16 (4.33) 
8 + 48
(calcd)
8 = 8.65 (16.59) 
48 = 4.93 (16.59) 
8 = 4.32 (8.29) 
48 = 2.46 (8.29) 
8 + 45 
(exp.) 
8 = 12.50 (23.98) 
45 = 12.50 (46.77) 
8 = 12.50 (23.98) 
45 = 12.50 (46.77) 
8 + 48
(exp.)
8 = 12.50 (23.98) 
48 = 12.50 (42.04) 
8 = 3.13 (6.00) 
48 = 3.13 (10.53) 
 
 These data indicated that the concentration of a separate mixture of 41 and 8 
required for bacterial growth inhibition corresponded approximately to the calculated 
maximum concentrations of fragments 41 and 8 which could be released from prodrug 
60.  Similar results were obtained with the other ester prodrug 61 and the amide prodrug 
63.   Therefore, the ester and amide prodrugs 60-61 and 63 seemed to be cleaved by 
bacterial hydrolytic enzymes as anticipated.  The calculated intracellular concentrations 
of the two fragments 8 and 45 released from the amide prodrug 62 were lower than the 
actual concentrations of a 1:1 separate mixture of 8 and 45 from antibacterial testing.  
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The amide prodrug 62 seemed to be stable in bacterial cells, and might have strong 
intrinsic antibacterial activity.   
 In order to fully establish bacterial esterase or amide hydrolysis in the prodrugs, it 
would be necessary to examine the effect of bacterial lysates on these compounds.  
Time constraints did not allow this to be undertaken.   
 
5.4 Cytotoxicity results 
 Only the inhibitor 41, the corresponding ester prodrug 60, and the hybrid drug 64 
were tested for cytotoxicity against human histiocytic lymphoma cells (cell line U937) 
by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H 
tetrazolium, inner salt (MTS) assay, and the results are shown in Table 5-9.  
Table 5-9 Preliminary minimum inhibitory concentration (MIC) of 40, 60, and 64 against human 
hystiocytic lymphoma cells (cell line U937). 
  Compound 
MIC 41 60 64 
µg/mL >100.00 >100.00 >100.00 
(µM) (327.76) (137.97) (>150.04) 
  
 The MIC value of each compound tested was greater than 100µg/mL, indicating 
they were only weakly or non-cytotoxic.  There was over 50-fold difference in the MIC 
of 60 and 64 for antimicrobial activity versus cytotoxicity.  
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6 Chapter6: Conclusions and Future Directions    
6.1 Conclusions  
The synthesis of a range of new 2-aryl-5-nitroindole derivatives as potent multidrug 
resistance pump (MDR) inhibitors was achieved using a palladium-mediated cyclisation 
to establish the crucial indole C2-aryl C bond formation.  Biological testing of these 
compounds showed that all compounds (39, 41-45, 47-48, and 56) apart from the acid 
derivative 38 potentiated the action of the antibacterial 
agent berberine (1) by blocking the NorA MDR pump 
in S. aureus.  The alcohol 43 was the most effective 
inhibitor in the 2-aryl-5-nitroindole series against all strains of Staphylococcus aureus, 
together with showing a moderate intrinsic activity against Salmonella enterica Serovar 
Typhimurium SL1344R2.  The novel alcohol 43 was thus a new dual action 
antibacterial agent.   
Other novel dual action antibacterial agents were designed and synthesized.  The 
lead compounds (60, 62, and 64) were based on a combination of berberine (1) and 2-
phenyl-5-nitroindole derivatives with enzymatically cleavable (ester and amide) and 
non-cleavable (methylene) linking groups.  The coupling of the two active components 
was achieved by a one-step synthesis.  This involved the reaction of 8-
allyldihydroberberine (9) with the appropriate alkylating agent from the 2-phenyl-5-
nitro-1H-indole derivative via an enamine alkylation/propene elimination strategy to 
afford the potential dual action prodrugs (60, 62) and the dual action drug (64) in low to 
moderate yields.  Similarly, methoxyaryl derivatives (61, 63, and 65) of these leads 
were synthesized and investigated for antibacterial activity.  Biological testing of the 
dual action prodrugs and dual action drugs (60-65) showed that all compounds were 
active as antibacterial agents.  The dual action drug 64 was the most active antibacterial 
N
H
O2N CH2OH
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agent against both Gram-positive and Gram-negative bacteria.  Compound 64 exhibited 
a 250-fold greater antibacterial activity than the parent antibacterial berberine (1) 
against a resistant strain of S. aureus, K2361, which overexpresses the NorA MDR 
pump.  Compound 64 also showed a 320-fold greater activity than 1 against 
Enterococcus faecalis V583, and a 1600-fold greater activity than 1 against Salmonella 
enterica Serovar Typhimurium SL1344R2. The methoxy substituted derivative of 64, 
the compound 65, was slightly less active than 64 against all strains tested.  Compound 
64 also showed good antimalarial activity (Plasmodium falciparum) in vitro.  An 
additional uptake assay against S. aureus for compound it was confirmed that 64 had 
dual activity as a NorA inhibitor and as an antibacterial.     
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 In the series of ester and amide dual action prodrugs 60-63, the amides 62 and 63 
had higher activities than the esters 60 and 61 against S. aureus strain K2361. However, 
the esters 60 and 61 were more potent than the amides 62 and 63 against S. enterica 
Serovar Typhimurium SL1344 R2.   
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 The ester 61 was the most active compound against the S. enterica strain SL1344 
R2 in the prodrug series, and was comparable in activity to the dual action drug 64 
(MIC; 0.78 µg/mL).  It is probable that the prodrugs 60-63 may have intrinsic 
antibacterial activity without enzymatic hydrolysis being involved.  As an amide bond 
has greater stability than an ester bond, the rate of bacterial enzymatic hydrolysis in 62 
or 63 might be slower than hydrolysis of the ester 60 or 61, resulting in slightly higher 
activities than the ester prodrugs against S. aureus K2361.  Thus, the dual action of the 
amide prodrugs may not require bacterial enzymatic action to generate the fragment 8 
and the corresponding MDR pump inhibitor (45 or 48).  On the other hand, the 
microbiological evidence pointed to hydrolysis of the esters 60 and 61 by bacterial 
esterase, with the fragments being the antibacterial berberine acid 8 and a corresponding 
MDR pump inhibitor (41 or 42) produced synchronously in high concentration. Partial 
hydrolysis of 60 was observed in the presence of pig liver esterase.    
 In summary, a potent dual action drug, 64, was found.  The dual action 
mechanism is thus a promising way to combat the problem of antibiotic resistance by 
drug efflux.  Also, compound 43 is the most potent NorA MDR pump inhibitor against 
S. aureus in the 2-aryl-5-nitro-1H-indole series.  Therefore, the variety of novel MDR 
pump inhibitors, dual action prodrugs and dual action drugs discovered in this project 
should provide a useful basis for future antimicrobial drug developments.    
 
6.2 Future directions  
 To verify ester or amide hydrolysis within bacterial cells, bacterial enzymatic 
hydrolysis experiments on the ester and amide prodrugs (60-63) is required in future 
work.   
 132
 Also, prior to in vivo antibacterial studies, plasma stability studies on the prodrugs 
need to be undertaken and modifications to the ester or amide groups made, if 
necessary, in order to avoid hydrolysis before delivery to the bacteria.  
 A combination of the most potent inhibitor 43 with berberine 1 should also be 
investigated.  Such a compound may be a novel triple action drug against the Gram-
negative pathogen Salmonella enterica.  
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7 Chapter7: Experimental   
7.1 General 
 All melting points were determined using a Reichert hot-stage melting point 
apparatus and are uncorrected.  
 The 1H and 13C NMR were determined at 299.92 and 75.42 MHz with a Varian 
Unity-300 spectrometer, and at 499.91 and 125.71 MHz with Varian Inova-500 
spectrometer.  Unless otherwise stated, the spectra were obtained from solutions in 
CDCl3 and referenced to TMS (proton) and the chloroform mid-line (77) (carbon).  
Chemical shifts of the outer peaks are given for specified multiplet patterns in the 1H-
NMR spectra.  The assignments were made by standard gradient correlation 
spectroscopy (gCOSY), gradient heteronuclear single quantum correlation (gHSQC) 
and gradient heteronuclear multiple bond correlation (gHMBC) spectroscopy. The same 
superscript assignments may be reversed for the signals designated in the same 
compound.  J values for mutually coupled systems were calculated from chemical shift 
differences and were the same or very close to being the same; coupling was confirmed 
from gCOSY spectra.   
 MS (CI) and (EI) were obtained using a Shimadzu QP-5000 spectrometer with 
isobutane as the ionising gas in the CI mode, and with a source temperature of 250oC.  
High resolution (CI) MS (for MH+) and (EI) MS (for M+) were run using a VG 
Autospec spectrometer operating at 70 eV and a source temperature of 250oC with PFK 
reference and methane as ionising gas in CI mode, and high resolution (ES) MS (for 
MH+) with a Micromass Qtof 2 mass spectrometer using a cone voltage of 30V and 
polyethylene glycol (PEG) as an internal reference.  
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  Elemental microanalyses were determined by Mr. G. Blazak at the University of 
Queensland.   
 Berberine chloride was obtained from the Sigma Chemical Company and dried 
over phosphorus pentoxide at 80oC under reduced pressure for 8 h before use.59 NBS 
was recrystallized from water and dried over phosphorus pentoxide before use.  
Solvents were purified and dried by standard techniques.141  
 Chromatography using Merck Kieselgel 60 silica gel (230-400 mesh) was 
performed under medium pressure or by vacuum liquid chromatography (VLC).  
Preparative TLC was done on Merck Silica gel 60 F254 and Aluminium oxide F254 with a 
thickness of 0.2 mm on aluminium sheet.  All chromatographic solvent proportions are 
volume for volume. Reactions were monitored by thin-layer chromatography (TLC) on 
Merck silica gel 60 F254 and Aluminium oxide F254 on aluminium sheets, and the 
compounds were detected by examination under ultraviolet light and by exposure to 
iodine vapour.  
 Organic solvents were dried with anhydrous sodium sulfate and removed under 
reduced pressure (in vacuo) by a Büchi rotary evaporator.   
 Microwave reactions were performed in a Milestone Ethos Sel Microwave 
Solvent Extractor, employing Easywave software, and using internal reaction 
temperature control.  Sealed Teflon reaction vessels were used and washed with 
concentrated nitric acid between uses.  Magnetic stirring was used to stir reaction 
mixtures. 
 
 
 
 
7.2 Dihydroberberine route to 13-substituted berberines 
(Chapter 2)
7.2.1 Preparation o f 9 ,10-D im eth oxy-5 ,8-d ihydro-6//-benzo[g]-l,3 -  
benzodioxolo[5,6-a]quinolizine (2)57,59
Method 1\ To a solution of dry berberine hydrochloride 
(1) (3.0g, 8.1mmol) in pyridine (18mL) was added sodium 
borohydride (360mg, 9.5mmol) and the mixture stirred at 
room temperature for 20min. More sodium borohydride
(300mg, 7.9mmol) was added and stirring was continued for 30min. The reaction 
mixture was then poured into ice water (200mL). The precipitated solid was filtered 
and dried to give the enamine 2 (2.6g, 96%) as a yellow solid, m.p. 123-125°C (Lit. 142 
157-158°C; recrystallised from DCM-MeOH). 'H-NMR (300MHz, CDC13): 8  2.88 (t, J  
= 5.9 Hz, 2H, H-5), 3.13 (t, J=  5.9 Hz, 2H, H-6 ), 3.85 (s, 6 H, OCH3), 4.32 (br.s, 2H, H- 
8 ), 5.94 (s, 2H, 0C H 20), 5.95 (s, IH, H-13), 6.58 (br.s, IH, H-11), 6.74 (s, 2H, H-12, 
H-4), 7.17 (s, IH, H-14). CIMS: m/z, [MH]+: 338 (50 %).
Method 2: To a solution of berberine hydrochloride.2.5 H20  (1) (0.7g, 1.7mmol) 
in methanol (25mL) was added K2CO3 (0.8g, 60mmol), and then sodium borohydride 
(24.0mg, 0.64mmol) was slowly added to the suspension which was then stirred at 0°C 
for 8 h. The mixture was concentrated and then added to ice water (200mL). The 
precipitated solid was filtered and washed thoroughly with water until the washing were 
neutral. The solid was then washed with MeOH (50mL) to remove starting material 1, 
and dried to give the enamine 2 (0.3g, 53%) as a yellow solid.
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7.2.2 Preparation of (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-
benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid  
          ethyl ester (3)  
Dry ethyl bromoacetate (30mL, 270.5mmol) was added 
dropwise with stirring to dihydroberberine 2 (2.62g, 
0.78mmol) at 0oC under a nitrogen atmosphere.  The solution 
was heated to 100oC for 1h to give a suspension.  Dry toluene 
(25mL) was added to the suspension, the precipitate filtered and then dried to give the 
iminium salt intermediate 2a (3.78g, 96%).  The unstable intermediate 2a  (3.78g, 
8.9mmol) was dissolved in absolute ethanol (50mL) and stirred at 0oC.  Sodium 
borohydride (400mg, 10.5mmol) was added to the suspension which was then stirred at 
room temperature for 20min.  More sodium borohydride (400mg, 10.5mmol) was added 
and further stirred for 1h.  The mixture was then concentrated by solvent evaporation in 
vacuo. Water (200mL) was added to the crude product and the mixture then extracted 
with diethyl diethyl ether (3 x 150mL).  The combined diethyl ether extract was washed 
with water, dried and evaporated.  The crude product was chromotographed on silica gel 
(DCM) to afford the ester 3 (2.8g, 88%) as a yellow solid, m.p. 103-104oC.  1H-NMR 
(300MHz, CDCl3): δ 1.15 (t, J = 7.2 Hz, 3H, CH3), 2.30 (dd, J = 15.6, 8.4 Hz, 1H, 
CH2CO), 2.44 (dd, J = 15.6, 8.4 Hz, 1H, CH2CO), 2.50-2.61 (m, 2H, H-5, H-6), 2.99-
3.13 (m, 2H, H-5, H-6), 3.52 (d, J = 16 Hz, 1H, H-8), 3.61-3.68 (m, 1H, H-13), 3.72 
(br.s, 1H, C-13a), 3.85 (s, 6H, OCH3), 3.98 (q, J =7 Hz, 2H, CH2CH3), 4.10 (d, J = 16 
Hz, 1H, H-8), 5.91 (d, J = 1.3 Hz, 1H, OCH2O), 5.92 (d, J = 1.3 Hz, 1H, OCH2O), 6.58 
(s, 1H, H-4), 6.74 (s, 1H, H-14), 5.76 (d, J = 8.4 Hz, 1H, H-11), 7.00 (d, J = 8.4 Hz, 1H, 
H-12).  13C NMR (75MHz, CDCl3): δ 14.11 (CH3), 29.8 (C5), 38.1 (CH2CO), 40.5 
(C13), 51.0 (C6), 54.2 (C8), 55.8 (OCH3), 60.0 (OCH3), 60.1 (CH2CH3), 63.0 (C13a), 
O
O N
OCH3
OCH3
EtOOCH2C
3
 137
100.8 (OCH2O), 105.9 (C4)a, 108.3 (C14)a, 110.6 (C12)b, 124.1 (C11)c, 128.4 (C13b)d, 
128.5 (C8a)e, 129.8 (C4a)d, 132.4 (C12a)e, 144.9 (C14a)f, 146.0 (C9), 146.4 (C3a)f, 
150.6 (C10), 173.6 (CO).  HMRS (EI); m/z calcd for C24H27NO6 [M]+: 425.1838; found: 
425.1837. 
 
7.2.3 Preparation of (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-
benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid(4)  
 Method 1: A solution of 3 (18.0mg, 0.04mmol) in 2M 
HCl  (1.5mL) was stirred for 30h at room temperature with 
shielding from light, and was then evaporated and added to 
ice water (20mL).  The mixture was neutralized by saturated NaHCO3 solution and then 
extracted with EtOAc (3 x 20mL).  The combined EtOAc extracts were washed with 
water, dried and evaporated to give only the starting material 3 (18.0mg).  The reaction 
conditions were, therefore, changed to use 1M H2SO4 in THF under the same procedure 
but no hydrolysis was observed.    
 Method 2: To a solution of 3 (521.0mg, 1.19mmol) in MeOH (30mL) was added a 
2% aqueous solution of lithium hydroxide (40mL) and the mixture heated at reflux for 1 
h. The cooled reaction mixture was then evaporated.   The crude product was added to 
ice water (200mL) and acidified to pH 1 with 1M HCl.  The precipitate was filtered, 
washed with water and dried to afford the acid 4 (460.1mg, 95%) as an opaque white 
solid, m.p. 202-205oC.  1H-NMR (300MHz, CDCl3): δ 2.59-2.85 (m, 4H, H-5, H-6, 
CH2CO), 3.18-3.34 (m, 2H, H-5, H-6), 3.42-3.50 (m, 1H, H-13), 3.73 (d, J = 15.6 Hz, 
1H, H-8), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.06 (d, J = 3.3 Hz, 1H, H-13a), 4.32 
(d, J = 15.6 Hz, 1H, H-8), 5.98 (s, 2H, OCH2O), 6.60 (s, 1H, H-4)a, 6.64 (s, 1H, H-14)a, 
6.86 (d, J = 8.7 Hz, 1H, H-12)b, 7.00 (d, J = 8.7 Hz, 1H, H-11)b.  13C NMR (75MHz, 
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DMSO-d6): δ 28.2 (C5), 37.8 (CH2CO), 43.3 (C13), 50.1 (C6), 53.0 (C8), 55.7 (OCH3), 
59.6 (OCH3), 62.2 (C13a), 100.8 (OCH2O), 105.6 (C4)c, 108.2 (C14)c, 111.6 (C12), 
123.9 (C11), 126.3 (C8a)d, 127.1 (C4a)e, 128.7 (C13b)e, 131.0 (C8a)d, 144.3 (C9)f, 
145.9 (C3a)g, 146.3 (C14a)g, 150.3 (C10)f, 173.6 (CO).  HRMS (EI); m/z calcd for 
C22H23NO6 [M]+: 397.1525; found: 397.1516. 
  
7.2.4 Preparation of (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-
benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid 
benzyl ester (5) 
 Method 1: To a mixture of the acid 4 (23.0mg, 
0.06mmol), HOBT (2mg, 0.01mmol) and DCC (15.0mg, 
0.07mmol) was added anhydrous DMF (1mL) at 0oC under a 
nitrogen atmosphere.  The mixture was then stirred at room 
temperature for 5 min.  A solution of 20% dry benzyl alcohol in anhydrous DMF 
(0.15mL, 0.29mmol) was then added and the mixture stirred at room temperature for 2 
days.  The reaction mixture was monitored by TLC (silica gel, 2%DCM in MeOH), but 
no reaction of the starting material 4 was observed. 
 Method 2: To a mixture of the acid 4 (23.0mg, 0.06mmol), DMAP (7.0mg, 
0.06mmol) and EDCI (9.2mg, 0.06mmol) was added anhydrous DMF (1mL) at 0oC 
under a nitrogen atmosphere.  The mixture was then stirred at room temperature for 5 
min.  A solution of 5% dry benzyl alcohol in anhydrous DMF (0.15mL, 0.08mmol) was 
then added and the mixture stirred at 40oC for 2 days.  The mixture was monitored by 
TLC (silica gel, 2%DCM in MeOH), but no reaction of the starting material 4 was 
observed. 
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Method 3: To a mixture of the acid 4 (115.0mg, 0.29mmol), DMAP (5mg, 
0.04mmol) and DCC (76.0mg, 0.37mmol) was added anhydrous DMF (1mL) at 0oC 
under a nitrogen atmosphere.  The mixture was then stirred at room temperature for 5 
min.  A solution of 20% dry benzyl alcohol in anhydrous DMF (0.15mL, 0.29mmol) 
was then added and the mixture stirred at 80oC for 30h.  The reaction mixture was 
evaporated in vacuo.  The residue was chromatographed on silica gel (0.5% MeOH in 
DCM) to afford the ester 5 (45.0mg, 32%) as a yellow solid, m.p.104-105oC.  1H-NMR 
(300MHz, CDCl3): δ 2.37 (dd, J = 15.5, 4.1 Hz, 1H, CH2CO), 2.52 (dd, J = 15.5, 8.9 
Hz, 1H, CH2CO), 2.48-2.60 (m, 2H, H-5, H-6), 2.94-3.32 (m, 2H, H-5, H-6), 3.50 (d, J 
= 15.9 Hz, 1H, H-8), 3.63-3.69 (m, 1H, H-13), 3.71 (br.s, 1H, H-13a), 3.83 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 4.18 (d, J = 16.2 Hz, 1H, H-8), 4.97 (d, J = 2.1, 2H, 
OCH2), 5.88 (d, J = 1.2 Hz, 1H, OCH2O), 5.89 (d, J = 1.5 Hz, 1H, OCH2O), 6.55 (s, 1H, 
H-4)a, 6.68 (d, J = 8.7 Hz, 1H, H-11)b, 6.74 (s, 1H, H-14)a, 6.90 (d, J = 8.4 Hz, 1H, H-
12)b, 7.19-7.35 (m, 5H, ArH).  13C NMR (75MHz, CDCl3): δ 29.8 (C5), 38.0 (CH2CO), 
40.7 (C13), 51.0 (C6), 54.2 (CH2O), 55.7 (OCH3), 60.0 (OCH3), 63.0 (C13a), 65.9 
(CH2O), 100.7 (OCH2O), 105.8 (C4)c, 108.2 (C14)c, 110.5 (C11)d, 124.0 (C12)d, 127.4 
(C8a)e, 127.8 (ArCH), 127.9 (2C, ArCH), 128.2 (C4a)f, 128.2 (2C, ArCH), 128.3 
(C13b)f, 132.0 (C12a)e, 135.9 (ArC), 144.8 (C9)g, 145.8 (C14a)h, 146.3 (C3a)h, 150.5 
(C10)g, 173.3 (CO).  HRMS (EI): m/z calcd for C29H29NO6  [M]+: 487.1995; found: 
487.1988.  
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7.2.5 Preparation of 13-(Ethoxycarbonylmethyl)-9,10-dimethoxy-5,6-
dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide 
(6a)58   
To a solution of the ester 3 (100.0mg, 0.24mmol) in absolute EtOH (10mL), was 
added iodine (179.2mg, 0.71mmol) and the mixture stirred at 60oC for 12 h.  More 
iodine (100.0mg, 0.39mmol) was then added and the mixture stirred for a further 12 h.  
The excess iodine was decomposed by the addition of sodium thiosulfate until the 
brown solution was changed to a yellow solution and a 
white precipitate was formed.  The insoluble substance was 
filtered and the filtrate was then evaporated.  The residue 
was crystallized from warm EtOH to afford the iodide salt 6a (125.5mg, 97%) as a 
yellow solid, m.p. 155-157oC  (Lit.58 165oC).  1H-NMR (300MHz, CDCl3): δ 1.35 (t, J 
= 7.2 Hz, 3H, CH3), 3.26 (br.s, 2H, H-5), 4.04 (s, 3H, OCH3), 4.25 (s, 2H, CH2CO), 
4.33 (q, J = 7.2 Hz, 2H, CH2CH3), 4.38 (s, 3H, OCH3), 5.09 (br.s, 2H, H-6), 6.08 (s, 2H, 
OCH2O), 6.87 (s, 1H, H-4), 7.21 (s, 1H, H-14), 7.70 (d, J = 9.0 Hz, 1H, H-11), 7.84 (d, 
J = 9.3 Hz, 1H, H-12), 10.34 (s, 1H, H-8).  
 
7.2.6 Preparation of 13-Benzyloxycarbonylmethyl-9,10-dimethoxy-5,6-
dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide  
(7a) and bromide (7b)  
Method 1, Iodide salt:  To a solution of ester 5 
(79.0mg, 0.16mmol) in ethanol (150mL) was added iodine 
(80.0mg, 0.32mmol).  The solution was heated at reflux for 
1h.  The excess iodine was decomposed by addition of 
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sodium thiosulfate until the brown solution was changed to a yellow solution and a 
white precipitate was formed.  The insoluble substance was filtered and the solvent was 
then evaporated.  The crude product was chromatographed on alumina by PLC (2% 
MeOH in DCM) to afford the quinolizinium iodide 7a (15.7mg, 16%) as a yellow solid. 
 Method 2, Bromide salt:  To a mixture of the ester 5 (30mg, 0.06mmol) and NBS 
(21.8mg, 0.12mmol) was added dry CHCl3 (2mL) and the solution stirred at room 
temperature for 1h.  The mixture was then washed with water (50mL).  The chloroform 
layer was dried and concentrated.  The residue was triturated with diethyl ether (10mL) 
and then filtered to afford the quinolizinium bromide 7b (38.2mg, 85%) as a yellow 
solid, m.p. 124-126oC.  1H-NMR (300MHz, CDCl3): δ 3.25 (t, J = 5.7 Hz, 2H, H-5), 
4.05  (s, 3H, OCH3), 4.31 (s, 2H, CH2CO), 4.39 (s, 3H, OCH3), 5.14-5.30 (br.m, 2H, H-
6), 5.31 (s, 2H, OCH2), 6.10 (s, 2H, OCH2O), 6.89 (s, 1H, H-4)a, 7.22 (s, 1H, H-14)a, 
7.39 (s, 5H, ArH), 7.57 (d, J = 9.3 Hz, 1H, H-11), 7.68 (d, J = 9.3 Hz, 1H, H-12), 10.56 
(s, 1H, H-8).  13C NMR (75MHz, CDCl3): δ 28.6 (C5), 37.2 (CH2CO), 57.0 (OCH3), 
57.4 (C6), 63.1 (OCH3), 68.0 (OCH2), 102.1 (OCH2O), 108.6 (C4)b, 109.1 (C14)b, 
119.1 (C13b)c, 119.6 (C11), 121.6 (C8a), 125.4 (C12), 125.7 (C12a)d, 128.7 (5C, 
ArCH), 133.2 (C13)d, 134.1 (C4a)c, 134.7 (ArC), 137.5 (C13a), 146.5 (C8), 147.2 (C9)e, 
147.3 (C14a), 150.1 (C3a), 150.5 (C10)e, 170.3 (CO).  HRMS (ES): m/z calcd for 
C29H26NO6  [M]+: 484.1760; found: 484.1735. Anal.Calcd. for C29H26NO6Br.1.5H2O: C, 
58.89 ; H, 4.94; N, 2.37%. Found: C, 58.70; H, 5.06; N, 2.26%. 
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7.2.7 Preparation of 13-Carboxymethyl-9,10-dimethoxy-5,6-dihydro-
benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide (8) 
To a solution of the ester 6a (90.0mg, 0.16mmol) in 
MeOH  (5mL), was added a 2% aqueous solution of LiOH 
(6mL) and the mixture was then heated at reflux for 30min.  
The cooled reaction mixture was then evaporated.  The crude 
product was added to ice water (100mL) and acidified to pH1 with 1M HCl.  The 
precipitate was filtered and washed with water.  The solid was dried and then 
recrystallized from 3% EtOH in DCM to afford the quinolizinium iodide 8 (47.4mg, 
53%) as a white solid, m.p. >250oC.  1H-NMR (300MHz, CD3OD): δ 3.12 (t, J = 5.7 
Hz, 2H, H-5), 4.09 (s, 3H, OCH3), 4.18 (s, 2H, CH2CO), 4.19 (s, 3H, OCH3), 4.80 (br.s, 
2H, H-6), 4.89 (s, 2H, OCH2O), 7.00 (s, 1H, H-4)a, 7.70 (s, 1H, H-14)a, 8.07 (d, J = 9.9 
Hz, 1H, H-11)b, 8.12 (d, J = 9.9 Hz, 1H, H-12)b, 9.78 (s, 1H, H-8).  13C NMR (125MHz, 
CD3OD): δ 29.1 (C5), 40.2 (CH2CO), 49.2 (OCH3), 57.5 (C6), 62.6 (OCH3), 103.6 
(OCH2O), 109.1 (C4)c, 111.1 (C14)c, 122.0 (C8a), 122.4 (C11)d, 123.0 (C12a), 127.2 
(C12)d, 132.1 (C4a), 134.8 (C13), 135.6 (C13a)e, 138.6 (C13b)e, 145.0 (C8), 146.1 
(C9)f, 148.8 (C3a)g, 151.4 (C14a)g, 151.7 (C10)f, 177.1 (CO).  HRMS (ES): m/z calcd 
for C22H20NO6 [M]+: 394.1291; found: 394.1282. 
 
7.3 8-Allyldihydroberberine route 
7.3.1 Preparation of 8-Allyl-9,10-dimethoxy-5,8-dihydro-6H-benzo[g]-
1,3-benzodioxolo[5,6-a]quinolizine (9)143 
 To a suspension of dry berberine chloride (1) (1.30g, 3.50mmol) in dry DCM 
(30mL) was added allyl tri-n-butyltin (3mL, 9.39mmol) in a sealed tube and the mixture 
O
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then heated to 100oC for 8h.  The resulting brown-yellow 
solution was cooled to room temperature and then 
concentrated.  The residue was crystallized from MeOH by 
placing the mixture in a freezer overnight.  The crystals were 
filtered, washed with cold MeOH and dried to give the allyl enamine 9 (1.12g) as a 
yellow crystalline solid.  The filtrate was concentrated and the residue recrystallized 
from MeOH to yield further 9  (0.10g) for a total yield of pure 9 of 1.22g (92%); m.p. 
109-110oC.  1H NMR (300MHz, CDCl3): δ 2.38-2.50 (m, 2H, CH2CH=CH2), 2.78-2.90 
(m, 2H, H-5), 3.28-3.36 (m, 1H, H-6), 3.44-3.58 (m, 1H, H-6), 3.84 (s, 3H, OCH3), 3.89 
(s, 3H, OCH3), 4.83-4.92 (m, 1H, H-8), 4.83-4.92 (m, 2H, CH2CH=CH2), 5.74-5.88 (m, 
1H, CH2CH=CH2), 5.80 (s, 1H, H-13), 5.94 (d, J = 3.3 Hz, 2H, OCH2O), 6.58 (s, 1H, 
H-4)a, 6.72 (d, J = 8.4 Hz, 1H, H-12), 6.76 (d, J = 8.4 Hz, 1H, H-11), 7.14 (s, 1H, H-
14)a.  13C NMR (75MHz, CDCl3): δ 30.6 (C5), 36.5 (CH2CH=CH2), 47.3 (C6), 56.0 
(OCH3), 58.3 (C8), 60.7 (OCH3), 94.6 (C13), 100.9 (OCH2O), 104.2 (C14)b, 107.7 
(C4)b, 116.6 (CH2CH=CH2), 111.7 (C12), 118.2 (C11), 123.0 (C12a), 125.8 (C4a)c, 
128.0 (C8a), 128.7 (C13b)c, 135.5 (CH2CH=CH2), 138.9 (C13a), 144.0 (C9)d, 146.4 
(C14a), 149.7 (C10)d, 147.0 (C3a).  HRMS (CI): m/z calcd for C23H24NO4 [MH]+: 
378.1705; found: 378.1703.  Anal.Calcd. for C23H23NO4: C, 73.19; H, 6.14; N, 3.71. 
Found: C, 73.33; H, 6.17; N, 3.60. 
 
7.3.2 Preparation of 13-Ethoxycarbonylmethyl-9,10-dimethoxy-5,6-
dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide 
(6b) from 8-Allyldihydroberberine (9) 
O
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OCH3
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 Dry ethyl bromoacetate (2mL, 18.03mmol) was added 
dropwise with stirring to 8-allyldihydroberberine (9) 
(50.5mg, 0.13mmol) at 0oC under a nitrogen atmosphere.  
The solution was then heated to 100oC for 2.5h to give a 
suspension.  Dry toluene (5mL) was added to the suspension, the mixture filtered and 
the filtrate was then evaporated to give 6b (57.3mg) as an orange-yellow amorphous 
solid.  The solid was recrystallized from 1% MeOH in DCM, and diethyl diethyl ether 
to give the quinolizinium bromide 6b (39.3mg, 59%) as yellow needles; m.p. 202-
204oC.  1H NMR (300MHz, CDCl3): δ 1.37 (t, J = 7.2 Hz, 3H, OCH2CH3), 3.20-3.35  
(br.t, 2H, H-5), 4.07 (s, 3H, OCH3), 4.27 (s, 2H, CH2CO), 4.36 (q, J = 7.2 Hz, 2H, 
OCH2), 4.41 (s, 3H, OCH3), 5.30-5.70 (br.m, 2H, H-6), 6.10 (s, 2H, OCH2O), 6.90 (s, 
1H, H-4), 7.24 (s, 1H, H-14), 7.71 (d, J = 9.3 Hz, 1H, H-11), 7.84 (d, J = 9.0 Hz, 1H, H-
12), 10.60 (s, 1H, H-8).  13C NMR (75MHz, CDCl3): δ 14.3 (CH2CH3), 28.5 (C5), 37.2 
(CH2CO), 57.0 (OCH3), 57.4 (C6), 62.3 (OCH2), 63.1 (OCH3), 102.1 (OCH2O), 108.6 
(C4), 109.0 (C14), 119.3 (C13b)a, 119.6 (C11), 121.6 (C8a), 125.6 (C4a)a, 125.8 (C12), 
133.2 (C13), 133.9 (C12a), 137.4 (C13a), 146.2 (C9)b, 146.9 (C14a), 147.3 (C8), 150.0 
(C3a), 150.5 (C10)b, 170.4, (CO).  HRMS (ES): m/z calcd for C24H24NO6  [M]+: 
422.1604; found: 422.1596.  Anal.Calcd. for C24H24NO6Br.0.2CH2Cl2: C, 55.97 ; H, 
4.74; N, 2.70%. Found: C, 55.83; H, 4.85; N, 2.54%.  
 
7.3.3 Preparation of 13-Benzyloxycarbonylmethyl-9,10-dimethoxy-5,6-
dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide 
(7b) from 8-Allyldihydroberberine (9) 
 Dry benzyl bromoacetate (1.5mL, 9.47mmol) was added dropwise with stirring to 
8- allyldihydroberberine (9) (36.4mg, 0.10mmol) at 0oC under a nitrogen atmosphere.  
O
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The solution was then heated to 100oC for 2.5h.  The reaction mixture was cooled, then 
adsorbed on celite and chromatographed on silica gel (4%MeOH in DCM) to give the 
quinolizinium bromide 7b (31.2mg, 57%) as a yellow solid. All spectroscopic data for 
7b was the same as that noted for this compound previously (Section 6.2.6). 
 
7.3.4 Preparation of 9,10-Dimethoxy-13-(2-oxo-2-phenyl-ethyl)-5,6-
dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide 
(10) 
To a solution of 8-allyldihydroberberine (9) (46mg, 
0.12mmol) in dry CH3CN (2mL) was added phenacyl 
bromide (46mg, 0.23mmol) under a nitrogen atmosphere.  
The mixture was refluxed for 4h, then concentrated and the 
residue chromatographed on silica gel (4% MeOH in DCM) to give the quinolizinium 
bromide 10 (35.6mg, 55%) as a yellow solid; m.p.181-183oC.  1H NMR (300MHz, 
CDCl3): δ 3.20-3.35 (br.m, 2H, H-5), 4.02 (s, 3H, OCH3), 4.33 (s, 3H, OCH3), 5.07 (s, 
2H, CH2CO), 5.10-5.30 (br.m, 2H, H-6), 5.99 (s, 2H, OCH2O), 6.90 (s, 2H, H-14 and 
H-4), 7.47 (d, J = 9.3 Hz, 1H, H-11), 7.62 (t, J = 7.8 Hz, 2H, ArH), 7.70-7.78 (m, 1H, 
ArH), 7.77 (d, J = 9.3 Hz, 1H, H-12), 8.19 (br.d, J = 7.5Hz, 2H, ArH), 10.46 (s, 1H, H-
8).  13C NMR (75MHz, CDCl3): δ 28.6 (C5), 42.03 (CH2CO), 57.0 (OCH3), 57.3 (C6), 
63.0 (OCH3), 102.0 (OCH2O), 108.4 (C4)a, 108.6 (C14)a, 119.8 (C4a), 119.9 (C11), 
121.7 (C8a), 125.7 (C12), 127.2 (C13b), 128.5 (2C, ArCH), 129.2 (2C, ArCH), 133.4 
(C13)b, 133.9 (C12a)b, 134.5 (ArCH), 135.2 (ArC), 137.6 (C13a), 146.0 (C9)c, 146.5 
(C8), 147.3 (C14a), 150.0 (C3a), 155.3 (C10)c, 196.7 (CO).  HRMS (ES): m/z calcd for 
C28H24NO5 [M]+: 454.1654; found: 454.1649.  Anal.Calcd. for 
C28H24NO5Br.1.4CH3OH: C, 60.96; H, 5.15; N, 2.42. Found: C, 60.69; H, 5.17; N, 2.39.  
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7.3.5 Preparation of 13-Benzyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-
1,3-benzodioxolo[5,6-a]quinolizinium bromide (11) 
Dry benzyl bromide (3.0mL, 25.26mmol) was added 
dropwise with stirring to 8-allyldihydroberberine (9) 
(205.0mg, 0.54mmol) at 0oC under a nitrogen atmosphere.  
The mixture was then heated to 100oC for 11h.  The resulting 
suspension was cooled to room temperature and dry toluene 
(ca 10mL) added.  The slurry was suction filtered to give yellow solids (270.0mg).  The 
solids were recrystallized from 1% MeOH in DCM, and diethyl ether, to give the 
quinolizinium bromide 11 (170.6mg, 62%) as yellow crystals; m.p. 223-225oC.  1H 
NMR (300MHz, CDCl3): δ 3.27 (t, J = 5.4 Hz, 2H, H-5), 4.02 (s, 3H, OCH3), 4.38 (s, 
3H, OCH3), 4.68 (s, 2H, CH2Ph), 5.20-5.35 (m, 2H, H-6), 6.00 (s, 2H, OCH2O), 6.95 (s, 
1H, H-14), 6.88 (s, 1H, H-4), 7.11 (br.d, J = 7.2 Hz, 2H, ArH), 7.26-7.42 (m, 3H, ArH), 
7.62 (d, J = 9.6 Hz, 1H, H-12)a, 7.71 (d, J = 9.6 Hz, 1H, H-11)a, 10.61 (s, 1H, H8).  13C 
NMR (75MHz, CDCl3 + CD3OD): δ 28.3 (C5), 36.4 (CH2Ph), 56.7 (OCH3), 56.8 (C6), 
62.6 (OCH3), 101.9 (OCH2O), 108.4 (C4)b, 108.6 (C14)b, 119.7 (C4a), 120.9 (C12)c, 
121.5 (C8a), 125.6 (C11)c, 127.0 (ArCH), 127.6 (2C, ArCH), 129.2 (2C, ArCH), 130.3 
(C13b), 133.3 (C13)d, 133.5 (C12a)d, 137.4 (C13a), 137.9 (ArC), 145.5 (C9)e, 145.6 
(C8), 147.0 (C14a), 149.8 (C3a), 150.1 (C10)e. HRMS(ES): m/z calcd for C27H24NO4  
[M]+: 426.1705; found: 426.1715.  Anal.Calcd. for C27H24NO4Br: C, 64.04; H, 4.78; N, 
2.77. Found: C, 63.65; H, 5.02; N, 2.55  
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7.4 Synthesis of natural bacterial pump blocking agents  
(Chapter 3) 
7.4.1 Preparation of 5,7-Deoxyhydnocarpin-D (12)144 
 To a mixture of 3´,4´-dihydroflavone (160.6mg, 0.63mmol) and coniferyl alcohol 
(98.5mg, 0.55mmol) were added dry benzene (12.5mL) and dry acetone (6.25mL) under 
a nitrogen atmosphere.  The mixture was warmed up to 60oC with stirring for 10min, 
and then silver carbonate (70.0mg, 0.25mmol) was added to the reaction mixture and 
further stirred vigorously for 10h. The mixture was then allowed to cool to room 
temperature, filtered through celite, and washed with 5% MeOH in DCM.  The filtrate 
was evaporated to give an orange-yellow oil.  The oil was then chromatographed on 
silica gel (DCM with a gradient elution to MeOH) to give a major fraction (57.2mg, 
eluent: 2% MeOH in DCM).  Further purification of this major fraction was achieved by 
multiple development PLC on silica gel (1% MeOH in DCM) to give 12 (29.0mg, 12%) 
as an opaque white solid, 13 (2.0mg, 1%) as an opaque white solid, and 14 (3.2mg, 1%) 
as an opaque white solid. 
12: 1H NMR (300MHz, CDCl3): δ 3.58 (dd, J = 12.8, 
3.5 Hz, 1H, H-11), 3.85 (dd, J = 12.6, 2.4 Hz, 1H, H-
11), 3.92 (s, 3H, OCH3), 4.08-4.14 (m, 1H, H-12), 5.00 
(d, J = 8.4 Hz, 1H, H-13), 5.83 (br.s, 1H, OH), 6.72 (s, 1H, H-3), 6.95 (d, J = 7.8 Hz, 
2H, H-5´´, H-6´´), 6.96 (s, 1H, H-2´´), 7.06 (d, J = 8.7 Hz, 1H, H-5´), 7.39 (ddd, J = 8.1, 
7.2, 0.9 Hz, 1H, H-7), 7.46 (dd, J = 8.4, 2.1 Hz, 1H, H-8), 7.49 (d, J = 9.0 Hz, 1H, H-
6´), 7.58 (d, J = 2.1 Hz, 1H, H-2´), 7.66 (ddd, J = 8.4, 7.2, 1.5 Hz, 1H, H-6), 8.20 (dd, J 
= 8.1, 1.2 Hz, 1H, H-5).  13C NMR (75MHz, CDCl3): δ 55.9 (OCH3), 60.9 (C11), 76.3 
(C13), 78.8 (C12), 105.9 (C3), 109.9 (C2´´), 114.9 (C2´), 115.3 (C5´´), 117.5 (C5´), 
O
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117.8 (C5), 120.0 (C6´), 120.5 (C6´´), 123.4 (C1´), 124.4 (C10), 125.2 (C8), 125.3 (C7), 
127.1 (C1´´), 133.8 (C6), 144.0 (C3´), 146.5 (C4´´), 146.0 (C3´´), 147.2 (C4´), 155.9 
(C9), 163.5 (C2), 178.8 (C4).  HRMS (CI); m/z calcd for C25H21O7 [MH]+: 433.1287; 
found: 433.1278. 
13: 1H NMR (300MHz, CDCl3): δ 3.55-3.63 (m, 1H, H-
11), 3.71-3.79 (m, 1H, H-11), 3.90 (s, 3H, OCH3), 4.57-
4.63 (m, 1H, H-13 of 13a or H-12 of 13b), 5.27 (d, J = 
3.0 Hz, 1H, H-12 of 13a or H-13 of 13b), 5.67 (s, 1H, 
OH), 6.74 (s, 1H, H-3), 6.89 (d, J = 6.9 Hz, 1H, H-5´´), 
6.91 (s, 1H, H-2´´), 6.95 (d, J = 8.7 Hz, 1H, H-6´´), 7.12 
(d, J = 8.4 Hz, 1H, H-5´), 7.40 (br.t, J = 8.1 Hz, 1H, H-7), 7.51 (dd, J = 8.4, 2.1 Hz, 1H, 
H-8), 7.53 (dd, J = 7.8 Hz, 1H, H-6´), 7.59 (d, J = 2.1 Hz, 1H, H-2´), 7.68 (ddd, J = 8.4, 
7.2, 1.8 Hz, 1H, H-6), 8.21 (dd, J = 8.1, 1.5 Hz, 1H, H-5).  HRMS (CI); m/z calcd for 
C25H21O7 [MH]+: 433.1287; found: 433.1281. 
14: 1H NMR (300MHz, CDCl3): δ 3.52-3.62 (m, 1H, H-
11), 3.85 (br.d, J = 13.2 Hz, 1H, H-11), 3.92 (s, 3H, 
OCH3), 4.07-4.10 (m, 1H, H-13), 5.03 (d, J = 8.4 Hz, 
1H, H-12), 5.72 (s, 1H, OH), 6.74 (s, 1H, H-3), 6.94 (d, 
J = 12.3 Hz, 2H, H-5´´, H-6´´), 6.97 (s, 1H, H-2´´), 7.08 (d, J = 8.7 Hz, 1H, H-5´), 7.40 
(br.t, J = 7.7 Hz, 1H, H-7), 7.49 (dd, J = 8.3, 2.6 Hz, 1H, H-8), 7.52 (d, J = 8.1 Hz, 1H, 
H-6´), 7.58 (d, J = 2.1 Hz, 1H, H-2), 7.68 (td, J = 7.8, 1.8 Hz, 1H, H-6), 8.22 (br.d, J = 
7.5 Hz, 1H, H-5). HRMS (CI); m/z calcd for C25H21O7 [MH]+: 433.1287; found: 
433.1284. 
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7.4.2 Acetylation of 5,7-Deoxyhydnocarpin-D144  
 To a solution of 5,7-deoxyhydnocarpin-D (12) 
(9.4mg, 0.02mmol) in dry pyridine (0.1mL) was 
added excess acetic anhydride (0.9mL) and the 
mixture stirred at room temperature for 12h. The 
mixture was evaporated and then chromatographed on silica gel by PLC (DCM) to give 
the diacetate product 15 (10.0mg, 89%) as an opaque white solid, m.p. 166-168oC 
(Lit.144 172-174oC).  1H NMR (300MHz, CDCl3): δ 2.06 (s, 3H, COCH3), 2.31 (s, 3H, 
COCH3), 3.85 (s, 3H, OCH3), 4.02 (dd, J = 12.3, 4.2 Hz, 1H, H-11), 4.26-4.36 (m, 1H, 
H-12), 4.38 (dd, J = 12.2, 3.2 Hz, 1H, H-11), 4.98 (d, J = 7.8 Hz, 1H, H-13), 6.73 (s, 
1H, H-3), 6.97 (dd, J = 7.8, 1.5 Hz, 1H, H-6´´), 6.99 (s, 1H, H-2´´), 7.09 (d, J = 8.4 Hz, 
2H, H-8, H-5´´), 7.39 (br.t, J = 8.1 Hz, 1H, H-7), 7.48-7.54 (m, 2H, H-5´, H-6´), 7.58 (d, 
J = 2.1 Hz, 1H, H-2´), 7.63-7.70 (m, 1H, H-6), 8.20 (dd, J = 7.8, 1.5 Hz, 1H, H-5).  13C 
NMR (75MHz, CDCl3): δ 20.7 (2C, COCH3), 55.0 (OCH3), 62.5 (C11), 75.9 (C12), 
76.4 (C13), 106.6 (C3), 110.5 (C2´´), 115.4 (C2´), 117.7 (C5´´), 117.9 (C5´)a, 119.7 
(C6´´), 120.3 (C6´)a, 123.3 (C1´), 123.8 (C8), 125.1 (C7), 125.3 (C1´´), 125.6 (C5), 
133.6 (C6), 133.9 (C10), 140.6 (C3´)b, 143.6 (C4´´), 145.8 (C4´)b, 151.6 (C3´´), 156.0 
(C9), 162.7 (C2), 168.5 (CO), 170.2 (CO), 178.2 (C4).  HMRS (EI); m/z calcd for 
C29H24O9 [M]+: 516.1420; found; 516.1419. 
 
7.5 Synthesis of synthetic bacterial pump blocking agents 
7.5.1 Attempted Fischer indole synthesis 
  Method 1: A mixture of 4-acetylbenzonitrile 
(145.0mg, 1.0mmol) and 4-nitrophenylhydrazine 
(153.0mg, 1.0mmol) in glacial acetic acid (1mL) and 1M HCl in diethyl ether (1mL) 
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was refluxed at 115oC under a nitrogen atmosphere for 1 h.  The solution was poured 
into ice (50g), then adjusted to pH 8 with saturated aqueous Na2CO3, and extracted with 
DCM (3 x 30mL).  The combined DCM extracts were dried, evaporated, and 
chromatographed on silica gel (DCM) to give the hydrazone 16 (181.0mg, 65%) as an 
orange solid.  1H NMR (300MHz, CDCl3): δ 3.35 (s, 3H, CH3), 7.40 (d, J = 9.3 Hz, 2H, 
H-2), 7.86 (d, J = 8.4 Hz, 2H, H-3´), 8.00 (d, J = 8.7 Hz, 2H, H-2´), 8.15 (d, J = 9.0 Hz, 
2H, H-3), 10.43 (s, 1H, NH).  EIMS: m/z, [M]+: 280 (50%).    
 Method 2:  To a solution of 4-acetylbenzonitrile (145.0mg, 1.0mmol) in 
isopropanol (10mL) and 1M HCl in diethyl ether (3mL), was added 4-
nitrophenylhydrazine (153.0mg, 1.0mmol) and refluxed at 80oC for 25min. The 
suspension was cooled to room temperature.  The precipitate was filtered, washed 
thoroughly with water, then hexane, and dried to give the hydrazone 16 (180.1mg, 
64%).  
 Method 3:  The hydrazone 16 (100.0mg, 0.36mmol) and 98-100% formic acid 
(1mL) were mixed in a microwave vessel which was irradiated at 110oC for 10min.  The 
mixture was allowed to cool down to room temperature, then poured into water (5mL) 
and boiled for 2min to hydrolyze any N-formyl derivative, which might have formed.  
The suspension was cooled to room temperature.   The precipitate was filtered, washed 
thoroughly with water, and dried to give only the hydrazone starting material 16.  
 Method 4:  The hydrazone 16 (1.12g, 4.0mmol) and zinc chloride powder (1.61g, 
16mmol) were mixed in a microwave vessel without solvent.  The solid mixture was 
irradiated at180oC for 1min using CH3CN for temperature probe vessel.  The mixture 
gave a black solid as carbonaceous residue. 
 Method 5:  A mixture of the hydrazone 16 (41.6mg, 0.15mmol) and p-
toluenesulfonic acid monohydrate (56.5mg, 0.30mmol) in xylene (3mL) was refluxed at 
 151
140oC for 5h.  The mixture was washed with water (5 x 3mL).  The xylene layer was 
dried and evaporated to give the hydrazone starting material 16. 
 Method 6:  To a solution of polyphosphoric acid (72.4mg) in xylene (3mL) at 
80oC, was added the hydrazone 16 (35mg, 0.13mmol) and heated at 110oC for 1 h.  The 
reaction was worked up in the same manner as in method 5 to give the hydrazone 
starting material 16. 
 Method 7: A mixture of the hydrazone 16 (100.0mg, 0.36mmol), 85% phosphoric 
acid (0.6mL) and toluene (2mL) was stirred vigorously at 100oC for 2h.  The toluene 
layer was decanted and fresh toluene (5mL) was added and further stirred for 4h.  The 
toluene was decanted again, then combined with the first toluene layer, dried, and 
evaporated to give the hydrazone starting material 16. 
 Method 8:  To a suspension of the hydrazone 16 (100.0mg, 0.36mmol) in glacial 
acetic acid (3mL), was added a solution of BF3-diethyl etherate and the mixture heated 
at reflux 110oC under a nitrogen atmosphere for 1h.  The reaction was cooled to room 
temperature and poured into iced water (100mL).  The suspension was filtered and dried 
to give a dark green solid.  The solid was dissolved in DCM and filtered.  The DCM 
filtrate was evaporated to give the hydrazone 16 and two other unidentified components 
in small amounts (these components on TLC analysis an silica gel did not give a brown 
colouration with iodine vapour).  
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7.5.2 N-Acylation reaction 
Acid chloride route 
7.5.2.1 Preparation of 1-Benzoyl-5-nitro-1H-indole (18)103 
To a suspension of sodium hydride (1.55g of 50% 
dispersion in mineral oil, 31.3mmol) in anhydrous DMF (24mL) 
at 0oC, was added, with stirring, a solution of 5-nitroindole (17) 
(2.90g, 17.9mmol) in DMF (50mL).  The mixture was stirred for 30min at 0oC.  The 
mixture was then warmed to room temperature and stirring continued for 2h.  Excess 
DMF (180mL) was added and then the mixture was cooled to –60oC in a dry 
ice/acetone bath.  A solution of benzoyl chloride (3mL, 25.9mmol) in DMF (12mL) was 
added dropwise to the cooled mixture, which was allowed to stir overnight with 
warming to 70oC.  The mixture was evaporated, added to ice water (700mL), and stirred 
vigorously for 4h.  The precipitate was filtered, washed with cold water, air dried, and 
washed with EtOAc (to remove traces of the starting material), yielding 18 (4.22g, 89%) 
as an opaque white solid, m.p. 158-159oC.  1H NMR (300MHz, CDCl3): δ 6.77 (dd, J = 
3.8, 0.5 Hz, 1H, H-3), 7.50 (d, J = 3.9 Hz, 1H, H-2), 7.54-7.62 (m, 2H, H-3´), 7.63-7.70 
(m, 1H, H-4´), 7.72-7.80 (m, 2H, H-2´), 8.26 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.47 (dd, J 
= 9.0, 0.6 Hz, 1H, H-7), 8.52 (d, J = 2.1 Hz, 1H, H-4).  HRMS (EI); m/z calcd for 
C15H10N2O3 [M]+: 266.0691; found: 266.0688. 
 
7.5.2.2 Preparation of 1-(4-Methoxybenzoyl)-5-nitro-1H-indole (19) 
To a solution of 17 (2.01g, 12.4mmol) in dry THF (250mL) at –60oC in a dry 
ice/acetone bath was added dropwise of 2M n-BuLi solution in cyclohexane (6.20mL, 
14.8mmol) and stirred for 30 min.  4-Methoxybenzoyl chloride (2.0mL, 14.8mmol) was 
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added to the reaction mixture which was further stirred for 3h. The mixture was then 
quenched with saturated NaHC03 solution (2mL), dried and evaporated to dryness. The 
residue was chromatographed on silica gel (40% DCM in PS) to afford 19 (1.62g,
44.2%) as a pale yellow solid, m.p,199-200°C. ‘H NMR 
(300MHz, CDCI3): 5 3.92 (s, 3H, OCH3), 6.76 (d, J =  3.8 
Hz, 1H, H-3), 7.05 (d, J  = 8 .8  Hz, 2H, H-3'), 7.55 (d, J  = 
3.8 Hz, 1H, H-2), 7.77 (dd, .7=7.0, 1.8 Hz, 2H, H-2'), 8.25 (dd, J=  9.1, 2.1 Hz, 1H, H- 
6 ), 8.41 (d, J =  9.1 Hz, 1H, H-7), 8.54 (d, J =  2.1 Hz, 1H, H-4). 13C NMR (75MHz, 
CDCI3): 5 55.6 (OCH3), 108.3 (C3), 114.2 (2C, C3'), 116.2 (C7), 117.2 (C4), 119.9 
(C6 ), 125.1 (C l'), 130.4 (C3a), 130.6 (C2), 132.0 (2C, C2'), 129.1 (C7a), 114.1 (C5), 
163.4 (C4'), 167.9 (CO). HRMS (El); m/z calcd for Q 6H12N2O4 [M]+: 296.0797; found: 
296.0796.
7.5.2.3 Preparation of l-(4-Benzyloxybenzoyl)-5-nitro-l//-indole (22)
Preparation o f acid chloride: To a suspension of /?-hydroxybenzoic 
9CH2ph acid (3.0g, 22.8mmol) and dry K2C 0 3 (7.0g, 50.0mmol) in dry DMF 
(60mL), was added dropwise of benzyl bromide (5.4mL, 45.8mmol) under a
COOCH2Ph
20 nitrogen atmosphere. The reaction mixture was heated at reflux at 80 C for 
6h. The mixture was evaporated, added to ice water (500mL), and acidified with 5M 
HC1 to pHl. The suspension was filtered, washed several times with H2O, then dried 
and chromatographed on silica gel by VLC (60% DCM in PS) to give benzyl 4- 
(benzyloxy) benzoate (20, 5.62g, 81%) as an off-white solid, m.p. 93-95°C. 'H NMR 
(300MHz, CDCI3): 5 5.09 (s, 2H, OCH2), 5.33 (s, 2H, COOCH2), 6.97 (d, J =  8.7 Hz, 
2H, H-3), 7.32-7.44 (m, 10H, ArH), 8.03 (d, J=  9.0 Hz, 2H, H-2).
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The suspension of 20 (5.0g, 15.7mmol) in MeOH (50mL) was added 30% 
aqueous solution of KOH (10mL) and heated at reflux for 6h.  The solvent was 
evaporated, added to ice water (300mL), and acidified to pH1.  The white precipitate 
was filtered and washed thoroughly with water and 20% DCM in PS (100mL) to 
remove unreacted dibenzylated starting material.  The precipitate was crystallized from 
diethyl ether to give 4-benzyloxybenzoic acid (21,106 3.25g, 91%) as white 
needles, m.p. 185-187oC (Lit.145 187-190oC).  1H NMR (300MHz, CDCl3 + 
CD3OD): δ 5.13 (s, 2H, OCH2), 7.00 (d, J = 9.0 Hz, 2H, H-3), 7.34-7.46 (m, 
5H, ArH), 8.01 (d, J = 9.0 Hz, 2H, H-2).  13C NMR (75MHz, CDCl3): δ 69.7 (OCH2), 
114.1 (2C, ArCH), 122.6 (ArC), 127.1 (2C, ArCH), 127.8 (ArCH), 128.3 (2C, C-3), 
131.5 (2C, C-2), 135.9 (C-1), 162.3 (C-4), 168.5 (CO).  
 The suspension of 21 (1.0g, 4.7mmol) in a 1:1 mixed solvent of THF/Benzene 
(10mL) was added dropwise of oxalyl chloride (1.28mL, 6.9mmol) at room temperature 
and stirred for 30h. The reaction mixture was monitored by alumina (2% MeOH in 
DCM).  The mixture was then concentrated to give crude of 4-(benzyloxy)benzoyl 
chloride, which was used in the next step immediately without purification because it 
was air sensitive. 
Preparation of acylated product: To a solution of 5-
nitroindole (0.3g, 2.0mmol) in dry THF (40mL) at –60oC in 
a dry ice/acetone bath was added dropwise 2M n-BuLi 
solution in cyclohexane (1.0mL, 2.0mmol) and the mixture then stirred for 30min.  The 
crude 4-(benzyloxy)benzoyl chloride (0.5g, 2.2mmol) was added to the reaction mixture 
and further stirred for 4.5h.  The mixture was then quenched with saturated NaHCO3 
solution (2mL), dried and evaporated to dryness.  The residue was chromatographed on 
silica gel by VLC (60% DCM in PS) to afford 22 (0.2g, 30%) as off-white needles, m.p. 
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177-179oC.  1H NMR (300MHz, CDCl3): δ 5.19 (s, 2H, OCH2), 6.77 (dd, J = 3.8, 0.8 
Hz, 1H, H-3), 7.12 (d, J = 9.0Hz, 2H, H-3´), 7.36-7.48 (m, 5H, ArH), 7.55 (d, J = 3.6 
Hz, 1H, H-2), 7.77 (d, J = 8.7 Hz, 2H, H-2´), 8.25 (dd, J = 9.3, 2.1 Hz, 1H, H-6), 8.41 
(d, J = 9.0 Hz, 1H, H-7), 8.54 (d, J = 2.1 Hz, 1H, H-4).  13C NMR (75MHz, CDCl3): δ 
70.3 (OCH2), 108.3 (C3), 115.0 (2C, C3´), 116.2 (C7), 117.2 (C4), 119.6 (C6), 125.4 
(C1´), 127.5 (2C, C3´´), 128.4 (2C, C4´´), 128.8 (C2´´), 130.4 (C3a), 130.5 (C2), 132.1 
(2C, C2´), 135.8 (C1´´), 139.1 (C7a), 144.2 (C5), 162.5 (C4´), 167.9 (CO).  HMRS (EI); 
m/z calcd for C22H16N2O4 [M]+: 372.1110; found; 372.1105. 
 
7.5.2.4 Preparation of 5-Nitro-1-phenylethanoyl-1H-indole (23)   
 To a suspension of sodium hydride (63.0mg of a 50% 
dispersion in mineral oil, 1.3mmol) in anhydrous DMF (1mL) at 
0oC, was added, with stirring, a solution of 17 (93.0mg, 
0.57mmol) in DMF (3mL).  The mixture was stirred for 30min at 0oC.  The mixture was 
then warmed to room temperature and further stirred for 2h.  Excess DMF (7mL) was 
added and then the mixture was cooled to –60oC in a dry ice/acetone bath.  A solution of 
phenyl acetyl chloride (0.1mL, 0.75mmol) in DMF (0.4mL) was added dropwise to the 
cooled mixture and then allowed to stir overnight with warming to 70oC.  The mixture 
was evaporated, then added to ice water (50mL), and stirred vigorously for 4h.  The 
precipitate was filtered, washed with cold water and air-dried.  The crude product was 
chromatographed on silica gel by VLC (4% EtOAc in PS) to give 23 (31.3mg, 19%) as 
an off white solid, m.p. 96-98oC.  1H NMR (300MHz, CDCl3): δ 4.29 (s, 2H, CH2CO), 
6.76 (dd, J = 3.8, 0.8 Hz, 1H, H-3), 7.29-7.42 (m, 5H, ArH), 7.68 (d, J = 3.9 Hz, 1H, H-
2), 8.24 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.46 (d, J = 2.4 Hz, 1H, H-4), 8.60 (dt, J = 9.3, 
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0.6 Hz, 1H, H-7).  13C NMR (75MHz, CDCl3): δ 43.0 (CH2), 109.8 (C3), 116.9 (C7), 
117.0 (C4), 120.5 (C6), 127.6 (C2), 127.8 (ArCH), 129.1 (4C, ArCH), 130.2 (C3a), 
132.5 (ArC), 138.8 (C7a), 144.4 (C5), 169.4 (CO).  HMRS (EI); m/z calcd for 
C16H12N2O3 [M]+: 280.0848; found: 280.0835. 
 
Preparation of N-Acyl Indoles 
7.5.2.5 Preparation of 1-Benzoyl-1H-indole (24) 
 To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP 
(24.4mg, 0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in dry 
DCM (2mL) at 0oC under a nitrogen atmosphere, was added a 
solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The solution was then warmed to 
room temperature and stirred for 15h.  The resulting suspension was evaporated and 
chromatographed on silica gel by PLC (5% EtOAc in PS) (multiple development) to 
give 24 (14.0mg, 32%) as an off-white solid, m.p. 63-64°C (Lit.96 59-60°C and 67-
68oC94).  1H NMR (300MHz, CDCl3): δ 6.57 (dd, J = 3.9, 0.6 Hz, 1H, H-3), 7.25 (d, J = 
3.9 Hz, 1H, H-2), 7.27-7.40 (m, 2H, H-5, H-6), 7.44-7.50 (m, 2H, H-3´), 7.52-7.60 (m, 
2H, H-4´, H-4), 7.68-7.73 (m, 2H, H-2´), 8.40 (dd, J = 8.4, 0.9 Hz, 1H, H-7).  HRMS 
(EI): m/z calcd for C15H11NO [M]+: 221.0841; found: 221.0843. 
 
7.5.2.6 Preparation of 1-(4-Methoxybenzoyl)-1H-indole (25)  
To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP 
(24.4mg, 0.2mmol) and p-methoxybenzoic acid (60.9mg, 
0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen 
atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The 
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solution was then warmed to room temperature and stirred for 15 h.  The resulting 
suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to 
give the acylated product 25 (23.0mg, 46%) as an off-white solid, m.p. 138-139°C 
(Lit.96 137-139°C).  1H NMR (300MHz, CDCl3): δ 3.82 (s, 3H, OCH3), 6.53 (dd, J = 
3.8, 0.8 Hz, 1H, H-3), 6.91-6.99 (m, 2H, H-3´), 7.18-7.32 (m, 3H, H-2, H-4, H-6), 7.51-
7.54 (m, 1H, H-5), 7.64-7.69 (m, 2H, H-2´), 8.26 (dd, J = 8.3, 1.1 Hz, 1H, H-7).  HRMS 
(EI): m/z calcd for C16H13NO2 [M]+: 251.0946; found: 251.0947.   
 
7.5.2.7 Preparation of 1-(2-Methoxybenzoyl)-1H-indole (26)  
To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP 
(24.4mg, 0.2mmol) and o-methoxybenzoic acid (60.9mg, 0.4mmol) 
in dry DCM (2mL) at 0oC under a nitrogen atmosphere, was added a 
solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The solution was then warmed to 
room temperature and stirred for 72h.  The resulting suspension was evaporated and 
chromatographed on silica gel (5% EtOAc in PS) to give the acylated product 26 
(17.1mg, 34%) as an off-white solid, m.p. 137-139°C.  1H NMR (300MHz, CDCl3): δ 
3.79 (s, 3H, OCH3), 6.55 (dd, J = 3.8, 0.9 Hz, 1H, H-3), 7.03 (d, J = 8.5 Hz, 1H, H-3´), 
7.07 (d, J = 3.3 Hz, 1H, H-2), 7.09 (td, J = 7.3, 0.9 Hz, 1H, H-5´), 7.33 (td, J = 7.6, 1.5 
Hz, 1H, H-5), 7.37 (td, J = 7.3, 1.5 Hz, 1H, H-6), 7.45 (dd, J = 7.6, 1.8 Hz, 1H, H-6´), 
7.51 (ddd, J = 8.5, 7.3, 1.8 Hz, 1H, H-4´), 7.57 (ddd, J = 7.6, 1.5, 0.6 Hz, 1H, H-4), 8.44 
(bd, J = 8.2 Hz, 1H, H-7). 13C NMR (75MHz, CDCl3): δ 55.7 (OCH3), 108.6 (C3), 
111.4 (C3´), 116.5 (C7), 120.7 (C5´)a, 120.8 (C4)a, 123.9 (C5), 124.8 (C1´), 124.9 (C6), 
127.4 (C2), 129.0 (C6´), 131.0 (C3a), 132.1 (C4´), 135.6 (C7a), 156.3 (C2´), 167.2 
(CO). HRMS (EI): m/z calcd for C16H13NO2 [M]+: 251.0946; found: 251.0955. 
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7.5.2.8 Preparation of 1-Benzoyl-5-methoxy-1H-indole (27) 
To a solution of 5-methoxy-1H-indole (29.4mg, 
0.2mmol), DMAP (24.4mg, 0.2mmol) and benzoic acid 
(48.8mg, 0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen 
atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The 
solution was then warmed to room temperature and stirred for 15h.  The resulting 
suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to 
give the acylated product 27 (14.0mg, 32%) as an off-white solid, m.p. 106-107°C 
(Lit.96 109-111°C).  1H NMR (300MHz, CDCl3): δ 3.88 (s, 3H, OCH3), 6.54 (dd, J = 
3.8, 0.8 Hz, 1H, H-3), 7.00 (dd, J = 9.2, 2.6 Hz, 1H, H-6), 7.06 (d, J = 2.4 Hz, 1H, H-4), 
7.26 (d, J = 2.1 Hz, 1H, H-2), 7.48-7.62 (m, 3H, H-3´, H-4´), 7.70-7.75 (m, 2H, H-2´), 
8.31 (d, J = 8.7 Hz, 1H, H-7).  HRMS (EI): m/z calcd for C16H13NO2 [M]+: 251.0946; 
found: 251.0950. 
 
7.5.2.9 Preparation of 5-Methoxy-1-(4-methoxybenzoyl)-1H-indole (28) 
To a solution of 5-methoxy-1H-indole (29.4mg, 
0.2mmol), DMAP (24.4mg, 0.2mmol) and p-
methoxybenzoic acid (60.9mg, 0.4mmol) in dry DCM 
(2mL) at 0oC under a nitrogen atmosphere, was added a solution of DCC (82.5mg, 
0.4mmol) in DCM (1mL).  The solution was then warmed to room temperature and 
stirred for 15h.  The resulting suspension was evaporated and chromatographed on silica 
gel (5% EtOAc in PS) to give 28 (7.7mg, 15%) as an off-white solid, m.p. 105-106°C.  
1H NMR (300MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.47 (dd, J = 
3.8, 0.6 Hz, 1H, H-3), 6.89 – 7.00 (m, 4H, H-4, H-6, H-3´), 7.26 (d, J = 3.8, 1H, H-2), 
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7.66 (tt, J = 9.7, 2.7 Hz, 2H, H-2´), 8.18 (d, J = 9.1 Hz, 1H, H-7). 13C-NMR (75MHz, 
CDCl3): δ 55.5 (OCH3), 55.7 (OCH3), 103.4 (C6), 108.0 (C3), 113.3 (C4), 113.8 (2C, 
C3´), 117.0 (C7), 126.6 (C1´), 128.4 (C2), 130.8 (C3a), 131.6 (2C, C2´), 131.6 (C7a), 
156.5 (C5), 162.6 (C4´), 167.9 (CO).  HRMS (EI): m/z calcd for C17H15NO3 [M]+: 
281.1052; found: 281.1053. 
 
7.5.2.10 Preparation of 1-Benzoyl-5-fluoro-1H-indole (29) 
To a solution of 5-fluoro-1H-indole (27.0mg, 0.2mmol), 
DMAP (24.4mg, 0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in 
dry DCM (2mL) at 0oC under a nitrogen atmosphere, was added a 
solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The solution 
was then warmed to room temperature and stirred for 24h.  The resulting suspension 
was evaporated and chromatographed on silica gel (5% EtOAc in PS) to give 29 
(42.7mg, 89%) as an opaque white solid, m.p. 65-66°C.  1H NMR (300MHz, CDCl3): δ 
6.50 (d, J = 3.8 Hz, 1H, H-3), 7.03 (td, J = 9.1, 2.3 Hz, 1H, H-6), 7.18 (dd, J = 8.8, 2.6 
Hz, 1H, H-4), 7.25 (d, J = 3.8 Hz, 1H, H-2), 7.46 (tt, J = 8.5, 1.5 Hz, 2H, H-3´), 7.54 (tt, 
1H, J = 6.2, 1.2 Hz, 1H, H-4´), 7.65 (dd, J = 8.8, 1.8 Hz, 2H, H-2´), 8.31 (dd, J = 9.1, 
5.3 Hz, 1H, H-7). 13C NMR (75MHz, CDCl3): δ 106.4 (d, J = 23.9 Hz, C4), 108.2 (d, J 
= 4.0 Hz, C3), 112.7 (d, J = 24.8 Hz, C6), 117.4 (d, J = 9.2 Hz, C7), 128.6 (2C, C3´), 
129.1 (C2), 129.1 (2C, C2´), 131.7 (d, J = 10.1 Hz, C3a), 132.0 (C4´), 132.4 (C1´), 
134.2 (C7a), 159.8 (d, J = 240.4 Hz, C5), 168.5 (CO). HRMS (EI): m/z calcd for 
C15H10NOF [M]+: 239.0746; found: 239.0738.  
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7.5.2.11 Preparation of 5-Fluoro-1-(4-methoxybenzoyl)- 1H-indole (30) 
  To a solution of 5-fluoro-1H-indole (27.0mg, 
0.2mmol), DMAP (24.4mg, 0.2mmol) and p-
methoxybenzoic acid (60.9mg, 0.4mmol) in dry DCM (2mL) 
at 0oC under a nitrogen atmosphere, was added a solution of 
DCC (82.5mg, 0.4mmol) in DCM (1mL).  The solution was then warmed to room 
temperature and stirred for 24h.  The resulting suspension was evaporated and 
chromatographed on silica gel (5% EtOAc in PS) to give 30 (47.0mg, 87%) as an 
opaque white solid, m.p. 133-135°C.  1H NMR (300MHz, CDCl3): δ 3.91 (s, 3H, 
OCH3), 6.57 (d, J = 3.8, 0.9 Hz, 1H, H-3), 7.02 (dt, J = 9.4, 2.6 Hz, 2H, H-3´), 7.09 (td, 
J = 9.1, 2.6 Hz, 1H, H-6), 7.25 (dd, J = 8.5, 2.3 Hz, 1H, H-4), 7.40 (d, J = 3.8 Hz, 1H, 
H-2), 7.74 (dt, J = 9.7, 2.9 Hz, 2H, H-2´), 8.32 (ddd, J = 9.3, 4.8, 0.6 Hz, 1H, H-7).  13C 
NMR (75MHz, CDCl3): δ 55.5 (OCH3), 106.3 (d, J = 23.9 Hz, C4), 107.7 (d, J = 3.7 
Hz, C3), 112.5 (d, J = 25.0 Hz, C6), 113.9 (2C, C3´), 117.2 (d, J = 9.2 Hz, C7), 126.2 
(C1´), 129.2 (C2), 131.5 (C3a), 131.7 (2C, C2´), 132.5 (C7a), 159.7 (d, J = 239.9 Hz, 
C5), 162.8 (C4´), 168.0 (CO).  HRMS (EI): m/z calcd for C16H12NO2F [M]+: 269.0852; 
found: 269.0854 
 
7.5.2.12 Preparation of 5-Fluoro-1-(2-methoxybenzoyl)- 1H-indole (31) 
To a solution of 5-fluoro-1H-indole (27.0mg, 0.2mmol), 
DMAP (24.4mg, 0.2mmol) and p-methoxybenzoic acid (60.9mg, 
0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen atmosphere, 
was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  
The solution was then warmed to room temperature and stirred for 3h.  The resulting 
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suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to 
give 31 (45.7mg, 85%) as a pale yellow solid, m.p. 100-101°C.  1H NMR (300MHz, 
CDCl3): δ 3.79 (s, 3H, OCH3), 6.50 (d, J = 3.8 Hz, 1H, H-3), 7.01 – 7.12 (m, 4H, H-3´, 
H-5´, H-2, H-6), 7.22 (dd, J = 8.2, 2.1 Hz, 1H, H-4) 7.44 (dd, J = 7.3, 2.3 Hz, 1H, H-6´), 
7.51 (td, J = 8.5, 1.8 Hz, 1H, H-4´), 8.44 (bdd, J = 8.8, 4.7 Hz, 1H, H-7). 13C NMR 
(75MHz, CDCl3): δ 55.6 (OCH3), 106.3 (d, J = 23.9 Hz, C4), 108.2 (d, J = 4.0 Hz, C3), 
111.4 (C3´), 112.4 (d, J = 24.8 Hz, C6), 117.5 (d, J = 9.2 Hz, C7), 120.8 (C5´), 124.4 
(C1´), 128.9 (C6´)a, 129.1 (C2)a, 131.9 (C3a)b, 132.0 (C7a)b, 132.3 (C4´), 156.3 (C2´), 
159.8 (d, J = 240.1 Hz, C5), 167.0 (CO).  HRMS (EI): m/z calcd for C16H12NO2F [M]+: 
269.0852; found: 269.0854. 
 
7.5.2.13 Preparation of 1-Benzoyl-5-nitro-1H-indole (18) 
 To a solution of 5-nitro-1H-indole (17) (32.4mg, 0.2mmol), DMAP (24.4mg, 
0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in dry DCM (2mL) at 0oC under a 
nitrogen atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  
The solution was then warmed to room temperature and stirred for 6h.  The resulting 
suspension was dried and to the crude residue was added MeOH (20mL).  The 
suspension was filtered and the precipitate then washed with cold MeOH and dried to 
give 18 (40.4mg) as an opaque white solid.  The filtrate was concentrated and 
recrystallized from MeOH to yield further 18 (8.0mg) for a total yield of pure product of 
48.4 mg (92%).  All spectroscopic data for 18 was the same as that noted for this 
compound previously (Section 6.5.2.1). 
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7.5.2.14 Preparation of 1-(4-Methoxybenzoyl)-5-nitro-1H-indole (19) 
 To a solution of 17 (32.4mg, 0.2mmol), DMAP (24.4mg, 0.2mmol) and p-
methoxy benzoic acid (60.9mg, 0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen 
atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The 
solution was then warmed to room temperature and stirred for 4h.  The resulting 
suspension was dried and to the crude residue was added MeOH (20mL). The 
suspension was filtered and the precipitate then washed with cold MeOH and dried to 
give 19 (45.7mg) as a pale yellow solid.  The filtrate was concentrated and 
recrystallized from MeOH to yield further 19 (10.4mg) for a total yield of pure product 
of 56.1mg (95%), m.p. 199-200oC.  All spectroscopic data for 19 was the same as that 
noted for this compound previously (Section 6.5.2.2).   
 
7.5.2.15 Preparation of 1-(2-Methoxybenzoyl)-5-nitro-1H-indole (32) 
To a solution of 17 (32.4mg, 0.2mmol), DMAP (24.4mg, 
0.2mmol) and o-methoxybenzoic acid (60.9mg, 0.4mmol) in dry 
DCM (2mL) at 0oC under a nitrogen atmosphere, which was 
added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).  The solution was then 
warmed to room temperature and stirred for 3h.  The resulting suspension was dried in 
vacuo and to the crude residue was added MeOH (20mL).  The suspension was filtered 
and the precipitate then washed with MeOH and dried to give 32 (38.1mg) as a slight 
yellow solid.  The filtrate was concentrated and recrystallized from MeOH to yield 
further 32 (9.2mg) for a total yield of pure product of 47.3mg (80%), m.p. 144-145oC.  
1H NMR (300MHz, CDCl3): δ 3.71 (s, 3H, OCH3), 6.61 (d, J = 3.5 Hz, 1H, H-3), 6.98 
(d, J = 8.5 Hz, 1H, H-3´), 7.05 (t, J = 7.5 Hz, 1H, H-5´), 7.17 (d, J = 3.5 Hz, 1H, H-2), 
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7.41 (d, J = 7.3 Hz, 1H, H-6´), 7.49 (t, J = 7.6 Hz, 1H, H-4´), 8.17 (t, J = 9.1 Hz, 1H, H-
6), 8.41-8.46 (m, 2H, H-4, H-7). 13C NMR (75MHz, CDCl3): δ 55.7 (OCH3), 108.7 
(C3), 111.5 (C3´), 116.5 (C7), 116.9 (C4), 120.1 (C6), 121.0 (C5´), 123.5 (C1´), 129.4 
(C6´), 130.3 (C2), 130.9 (C3a), 133.0 (C4´), 138.5 (C7a), 144.3 (C5), 156.4 (C2´), 
167.2 (CO). HRMS (EI): m/z calcd for C16H12N2O4 [M]+: 296.0797; found: 296.0804. 
 
7.5.2.16 Preparation of 5-nitro-1-phenylethanoyl-1H-indole (23) 
 A mixture of 17 (320.6mg, 1.98mmol), phenyl acetic acid (299.0mg, 2.20mmol), 
and boric acid (37.3mg, 0.60mmol) in mesitylene (30mL) was heated at reflux for 2 
days using a Dean-Stark water separator.  The reaction mixture was evaporated, 
triturated with PS, filtered, and washed thoroughly with PS to remove the mesitylene.  
The crude solid was chromatographed on silica gel by VLC (10% EtOAc in PS) to give 
the starting indole (200.0mg, 1.23mmol), and 23 (9.0mg, 4%). 
  
7.5.2.17 Preparation of 1-(4-benzyloxybenzoyl)-5-nitro-1H-indole (22) 
 To a solution of 17 (2.35g, 14.5mmol), DMAP (0.23g, 1.89mmol) and p-
benzyloxybenzoic acid (21, 4.00g, 18.6mmol) in dry DCM (150mL) at 0oC under a 
nitrogen atmosphere, was added a solution of DCC (3.89g, 18.6mmol) in DCM (50mL).  
The solution was then refluxed at 40oC for 2 days.  The resulting suspension was 
filtered and washed with DCM.  The filtrate was evaporated and then chromatographed 
on silica gel by VLC (40% DCM in hexane) to give the starting indole (510.0mg, 
3.15mmol) and 22 (2.80g, 52%). 
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7.5.3 Palladium Cyclization reactions 
7.5.3.1 Preparation of 2-Nitro-isoindolo[2,1-a]indol-6-one (33) 
Method 1: A solution of 18 (200mg, 0.75mmol) and 
palladium (II) acetate (167.8mg, 0.75mmol) in glacial acetic 
acid (20mL) was heated at 110oC under a nitrogen atmosphere 
for 11h.  The black suspension was filtered through celite and washed with acetone.  
The filtrate was then evaporated and added to ice water (200mL).  The precipitate was 
filtered, dried and chromatographed on silica gel by VLC (40-60% DCM in PS) to give 
33 (100.1mg, 50%) as yellow needles, m.p. 268.8oC (decomp.).  1H NMR (300MHz, 
CDCl3): δ 6.79 (d, J = 0.6 Hz, 1H, H-11), 7.43-7.49 (ddd, J = 8.4, 5.9, 2.6 Hz, 1H, H-9) 
7.62-7.65 (m, 2H, H-10, H-8), 7.84 (dt, J = 7.5, 0.9 Hz, 1H, H-7), 7.98 (d, J = 8.7 Hz, 
1H, H-4), 8.23 (dd, J = 8.7, 2.1 Hz, 1H, H-3), 8.41 (d, J = 2.1 Hz, 1H, H-1). 13C NMR 
(125MHz, DMSO-d6): δ 104.2 (C11), 112.6 (C4), 118.8 (C1), 121.8 (C3), 122.8 (C7), 
125.6 (C10), 130.2 (C9)a, 132.5 (C10a), 133.8 (C11a), 134.6 (C6a), 135.1 (C8)a, 136.1 
(C4a), 141.1 (C10b), 143.9 (C2), 162.0 (C6).  HRMS (EI); m/z calcd for C15H8N2O3 
[M]+: 264.0535; found: 264.0533. 
 Method 2: A solution of 18 (103.7mg, 0.38mmol), palladium (II) acetate (8.5mg, 
0.038mmol) and copper (II) acetate monohydrate (180mg, 0.99mmol) in glacial acetic 
acid (6mL) was heated at 95oC for 5 days.  The reaction was worked up as in method 1 
to give 33 (30.2mg, 29%).  All spectroscopic data were the same as those reported 
above.  
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7.5.3.2 Preparation of 9-Methoxy-2-nitro-isoindolo[2,1-a]indol-6-one (34) 
A solution of 19 (379mg, 1.28mmol) and palladium 
(II) acetate (287.3mg, 1.28mmol) in glacial acetic acid 
(80mL) was heated at 110oC under a nitrogen atmosphere 
for 16h.  The black suspension was filtered through celite and washed with acetone.  
The filtrate was then evaporated and added to ice water (200mL).  The precipitate was 
filtered, dried and chromatographed on silica gel by VLC (40–60% DCM in PS) to give 
34 (279.4mg, 74%) as yellow needles, m.p. 238-240oC.  1H NMR (300MHz, CDCl3 + 
CD3OD): δ 3.95 (s, 3H, OCH3), 6.77 (s, 1H, H-11), 6.91 (dd, J = 8.7, 2.1 Hz, 1H, H-8), 
7.11 (d, J = 2.7 Hz, 1H, H-10), 7.74 (d, J = 8.4 Hz, 1H, H-7), 7.95 (d, J = 8.7 Hz, 1H, 
H-4), 8.20 (dd, J = 8.7, 2.1 Hz, 1H, H-3), 8.40 (d, J = 2.1 Hz, 1H, H-1).  13C NMR 
(75MHz, CDCl3+CD3OD): δ 55.8 (OCH3), 103.0 (C11), 107.7 (C10), 112.6 (C4), 115.1 
(C8), 118.3 (C1), 121.7 (C3), 125.0 (C10a), 127.5 (C7), 134.1 (C11a), 136.3 (C4a), 
136.5 (C6a), 140.8 (C10b), 144.0 (C2), 162.3 (CO), 165.1 (C9).  HRMS (EI); m/z calcd 
for C16H10N2O4 [M]+: 294.0641; found: 294.0648. 
 
7.5.3.3 Preparation of 9-Benzyloxy-2-nitro-isoindolo[2,1-a]indol-6-one (35) 
 A solution of 22 (189.7mg, 0.51mmol) and palladium (II) acetate (120.7mg, 
0.54mmol) in glacial acetic acid (34mL) was heated at 110oC under a nitrogen 
atmosphere for 20h.  The black suspension was filtered through celite and then washed 
with acetone.  The filtrate was then evaporated and added to ice water (100mL).  The 
precipitate was filtered, dried and then chromatographed on silica gel by VLC (PS with 
gradient elution to DCM and then MeOH) to give 35 (35.0mg, 20%, eluent: 40-60% 
DCM in PS) as pale yellow needles, and the more polar fraction (eluent: 2% MeOH in 
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DCM) which gave two colors (gray and brown) in the same spot on TLC after exposure 
to iodine vapor.  This fraction was added to 2% MeOH in DCM and then filtered to 
afford 9-hydroxy-2-nitro-isoindolo[2,1-a]indol-6-one (36) (32.3mg, 22%) as a pale 
yellow solid, and the filtrate was evaporated to give 1-(4-hydroxybenzoyl)-5-nitro-1H-
indole (37) (50.1mg, 35%) as a pale yellow solid. 
35: m.p. >250oC, 1H NMR (300MHz, CDCl3 + 
CD3OD): δ 5.21 (s, 2H, OCH2), 6.79 (s, 1H, H-11), 
7.01 (dd, J = 8.7, 2.1 Hz, 1H, H-8), 7.22 (d, J = 2.1 
Hz, 1H, H-10), 7.43-7.50 (m, 5H, ArH), 7.76 (d, J = 8.7 Hz, 1H, H-7), 7.97 (d, J = 8.7 
Hz, 1H, H-6), 8.22 (dd, J = 8.7, 2.4 Hz, 1H, H-3), 8.42 (d, J = 2.1 Hz, 1H, H-1).  13C 
NMR (75MHz, CDCl3 + CD3OD or DMSO-d6) spectrum showed only methine and 
methylene carbon signals without quaternary carbon signals due to precipitating whilst 
the experiment was underway.  HRMS (EI); m/z calcd for C22H14N2O4 [M]+: 370.0954; 
found: 370.0944. 
36: m.p. 199-201oC, 1H NMR (300MHz, DMSO-d6): δ 6.82 
(dd, J = 8.6, 2.3 Hz, 1H, H-8), 7.07 (s, 1H, H-11), 7.16 (d, J 
= 2.1 Hz, 1H, H-10), 7.60 (d, J = 8.7 Hz, 1H, H-7), 7.81 (d, J 
= 9.0 Hz, 1H, H-4), 8.13 (dd, J = 8.7, 2.4 Hz, 1H, H-3), 8.45 (d, J = 1.8 Hz, 1H, H-1).  
13C NMR (75MHz, DMSO-d6): δ 103.6 (C11), 109.6 (C10), 112.1 (C4), 116.7 (C8), 
118.6 (C1), 121.5 (C3), 122.7 (C10), 127.6 (C7), 134.1 (C11a), 135.9 (C4a), 136.2 
(C6a)a, 140.6 (C10b)a, 143.4 (C2), 161.6 (CO), 163.9 (C9).  HRMS (EI); m/z calcd for 
C15H8N2O4 [M]+: 280.0484; found: 280.0480. 
37: m.p. 201-203oC, 1H NMR (300MHz, DMSO-d6): δ 6.92 
(d, J = 3.3 Hz, 1H, H-3), 6.91-6.93 (m, 2H, aromatic), 7.64-
7.67 (m, 2H, ArH), 7.73 (d, J = 3.3 Hz, 1H, H-2), 8.17 (dd, J 
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= 9.3, 2.4 Hz, 1H, H-6), 8.27 (d, J = 9.0 Hz, 1H, H-7), 8.60 (d, J = 1.8 Hz, 1H, H-4), 
10.53 (br s, 1H, OH).  13C NMR (75 MHz, DMSO-d6): δ 108.1 (C3), 115.6 (2C, 
ArCH), 115.8 (C7), 117.3 (C1´), 119.3 (C6), 123.0 (C4), 130.3 (C2), 131.7 (C3a), 132.5 
(2C, ArCH), 138.6 (C7a), 143.4 (C5), 162.0 (C4´), 167.6 (CO).  HRMS (EI); m/z calcd 
for C15H10N2O4 [M]+: 282.0641; found: 282.0638. 
 
7.5.3.4 Conversion of 36 to 35:  
 To a suspension of 36 (200.0mg, 0.71mmol) and cesium carbonate (230.0mg, 
0.70mmol) in dry DMF (20mL), was added dropwise with stirring of benzyl bromide 
(0.1mL, 0.84mmol).  The reaction was heated at 80oC under a nitrogen atmosphere for 
7h.  The reaction was allowed to cool to room temperature and then filtered.  The 
precipitate was washed thoroughly with water and dried to give 35 as a pale yellow 
solid (196.1mg, 74%).   
 
7.5.4 Ring opening reactions 
7.5.4.1 Preparation of 2-(5-Nitro-1H-indol-2-yl)benzoic acid (38) 
A solution of t-BuOH (192mL) and H2O (19.2mL) 
containing t-BuOK (4.25 g, 37.9mmol) was added to 33 (1g, 
3.79mmol) and heated at 82oC for 12h.  The mixture was 
evaporated and added to ice water (400mL).  The solution was acidified to pH1 with 5M 
HCl.  The solution was stirred vigorously with solid NaCl for 2h, and then extracted 
with diethyl ether (3 x 400mL).  The combined diethyl ether extracts were dried and 
evaporated to give 38 (1.016g, 95%) as a pale yellow solid, m.p. 250-252oC.  1H NMR 
(300MHz, DMSO-d6): δ 6.98 (s, 1H, H-3), 7.33-7.45 (m, 2H, H-4´, H-5´), 7.52 (d, J = 
N
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9.0 Hz, 1H, H-7), 7.67 (br.d, J = 7.2 Hz, 1H, H-3´), 7.75 (br.d, J = 7.5 Hz, 1H, H-6´), 
7.94 (dd, J = 9.03, 2.4 Hz, 1H, H-6), 8.52 (d, J = 2.4, 1H, H-4).  13C NMR (75MHz, 
DMSO-d6): δ 102.2 (C3), 117.8 (C7), 116.3 (C6), 116.8 (C4), 127.5 (C3a), 127.8 (C5´), 
128.5 (C2), 128.7 (C4´), 128.9 (C6´), 129.9 (C3´), 138.5 (C2´), 139.3 (C7a), 140.5 (C5), 
142.2 (C1´), 171.7 (CO).  HRMS (EI); m/z calcd for C15H10N2O4 [M]+: 282.0641; 
found: 282.0643. 
 
7.5.4.2 Preparation of 4-Methoxy-2-(5-nitro-1H-indol-2-yl)benzoic acid (39) 
A solution of t-BuOH (88.5mL) and H2O (8.9mL) 
containing t-BuOK (1.98g, 17.7mmol) was added to 34 
(520.0mg, 1.77mmol) and heated at 82oC for 12h.  The reaction 
mixture was evaporated and added to ice water (200mL).  The solution was acidified to 
pH1 with 5M HCl.  The solution was stirred vigorously with solid NaCl for 2h, and then 
extracted with diethyl ether (3 x 200mL).  The combined diethyl ether extracts were 
dried and evaporated to give 39 (520.0g, 94%) as a pale yellow solid, m.p. 206-208oC.  
1H NMR (300MHz, DMSO-d6): δ 3.86 (s, 3H, OCH3), 6.78 (dd, J = 2.1, 0.6 Hz, 1H, H-
3), 7.08 (dd, J = 7.8, 2.7 Hz, 1H, H-5´), 7.11 (s, 1H, H-3´), 7.50 (d, J = 8.7 Hz, 1H, H-
7), 7.89 (d, J = 7.8 Hz, 1H, H-6´), 8.00 (dd, J = 9.0, 2.4 Hz, 1H, H-6), 8.55 (d, J = 2.4 
Hz, 1H, H-4), 12.07 (s, 1H, NH).  13C NMR (75MHz, DMSO-d6): δ 55.7 (OCH3), 103.3 
(C3), 111.5 (C7), 114.0 (C5´), 116.4 (C3´), 116.7 (C6), 117.1 (C4), 123.8 (C2), 127.4 
(C3a), 132.3 (C6´), 134.1 (C1´)a, 139.6 (C7a), 140.7 (C5), 141.5 (C2´)a, 161.3 (C4´), 
167.9 (CO).  HRMS (EI); m/z calcd for C16H12N2O5 [M]+: 312.0746; found: 312.0749. 
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7.5.4.3 Preparation of 4-Benzyloxy-2-(5-nitro-1H-indol-2-yl)-benzoic acid 
(40) 
A solution of t-BuOH (22.5mL) and H2O (2.3mL) 
containing t-BuOK (503.5mg, 4.49mmol) was added to 35 
(166.0mg, 0.45mmol) and heated at 82oC for 12h.  The 
reaction mixture was evaporated and added to ice water (70mL).  The solution was 
acidified to pH1 with 5M HCl.  The solution was stirred vigorously with solid NaCl for 
2h, and then extracted with diethyl ether (3 x 50mL).  The combined diethyl ether 
extracts were dried and evaporated to give 40 (167.0mg, 96%) as a pale yellow solid, 
m.p. 233-235oC.  1H NMR (300MHz, DMSO-d6): δ 5.24 (s, 2H, OCH2), 6.78 (s, 1H, H-
3), 7.16 (dd, J = 8.6, 2.6 Hz, 1H, H-5´), 7.24 (d, J = 2.7 Hz, 1H, H-3´), 7.30-7.50 (m, 
5H, ArH), 7.52 (d, J = 9.0 Hz, 1H, H-7), 7.85 (d, J = 8.7, 1H, H-6´), 8.00 (dd, J = 8.9, 
2.3 Hz, 1H, H-6), 8.55 (d, J = 2.4 Hz, 1H, H-4), 12.20 (s, 1H, NH), 12.57 (s, 1H, 
COOH).  13C NMR (75MHz, DMSO-d6): δ 69.6 (OCH2), 103.2 (C3), 111.5 (C7), 114.6 
(C5´), 116.6 (C6), 117.0 (C3´), 117.1 (C4), 124.1 (C2), 127.3 (C3a), 127.7 (2C, ArCH), 
128.0 (ArCH), 128.4 (2C, ArCH), 132.1 (C6´), 133.8 (C2´), 136.4 (ArC), 139.6 (C7a), 
140.6 (C5), 141.1 (C1´), 160.2 (C5´), 167.9 (CO).  HRMS (EI); m/z calcd for 
C22H16N2O5 [M]+: 388.1059; found: 388.1069. 
 
7.5.5 Reduction reactions 
7.5.5.1 Preparation of [2-(5-Nitro-1H-indol-2-yl)-phenyl]-methanol (41) 
To a solution of 38 (997.0mg, 3.54mmol) in dry THF 
(90mL) was slowly added 1M BH3-THF complex solution 
(7.1mL, 7.1mmol) at 0oC under a nitrogen atmosphere. After 
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vigorous stirring at room temperature for 2h, the excess hydride was carefully destroyed 
by adding a solution of 50% THF in H2O (20mL) until the gas bubbling ceased.  The 
aqueous layer was saturated with anhydrous K2CO3.  The THF layer was separated and 
the aquoeus layer was extracted with diethyl ether.  The combined THF and diethyl 
ether extracts were dried, then evaporated, and chromatographed on silica gel by VLC 
(2% MeOH in DCM) to give 41 (940.5mg, 99%) as bright yellow needles, m.p.132-
134oC.  1H NMR (300MHz, CDCl3): δ 4.77 (s, 2H, CH2O), 6.91 (d, J = 1.2 Hz, 1H, H-
3), 7.36-7.47 (m, 4H, H-7, ArH), 7.79 (br.d, J = 7.8 Hz, 1H, ArH), 8.12 (dd, J = 8.9, 2.4 
Hz, 1H, H-6), 8.61 (d, J = 2.4 Hz, 1H, H-4 ), 10.92 (s, 1H, NH).  13C NMR (75MHz, 
CDCl3): δ 65.1 (CH2), 103.5 (C3), 111.2 (C7), 117.5 (C6), 117.6 (C4), 127.8 (C3a), 
128.8 (ArCH), 129.4 (ArCH), 130.3 (ArCH), 131.1 (ArCH), 132.8 (C2), 135.8 (C2´), 
139.6 (C7a), 141.4 (C1´), 141.8 (C5). HRMS (EI); m/z calcd for C15H12N2O3 [M]+: 
268.0848; found: 268.0838. 
 
7.5.5.2 Preparation of [4-Methoxy-2-(5-nitro-1H-indol-2-yl)-phenyl]- 
  methanol (42) 
 To a solution of 39 (520.0mg, 1.67mmol) in dry THF 
(50mL) was slowly added 1M BH3-THF complex solution 
(3.3mL, 3.3mmol) at 0oC under a nitrogen atmosphere. After 
vigorous stirring at room temperature for 2h, the excess hydride 
was carefully destroyed by adding a solution of 50% THF in H2O (10mL) until the gas 
bubbling ceased.  The aqueous layer was saturated with anhydrous K2CO3.  The THF 
layer was separated and the aquoeus layer was extracted with diethyl ether.  The 
combined THF and diethyl ether extracts were dried, then evaporated, and 
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chromatographed on silica gel by VLC (2% MeOH in DCM) to give 42 (470.7mg, 
95%) as bright yellow needles, m.p. 206-208oC.  1H NMR (300MHz, CDCl3): δ 3.89 (s, 
3H, OCH3), 4.70 (s, 2H, CH2), 6.91 (d, J = 1.8 Hz, 1H, H-3), 6.92 (dd, J = 8.4, 2.7 Hz, 
1H, H-5´), 7.30 (d, J = 2.7 Hz, 1H, H-3´), 7.34 (d, J = 8.7 Hz, 1H, H-6´), 7.46 (d, J = 8.7 
Hz, 1H, H-7), 8.10 (dd, J = 8.7, 2.1 Hz, 1H, H-6), 8.62 (d, J = 2.1 Hz, 1H, H-4), 11.02 
(s, 1H, NH).  13C NMR (75MHz, CDCl3): δ 55.5 (OCH3), 64.6 (CH2O), 103.5 (C3), 
111.3 (C7), 113.9 (C5´), 115.7 (C3´), 117.6 (C6), 117.7 (C4), 127.7 (C3a), 128.3 (C2), 
132.6 (C6´), 134.2 (C1´)a, 139.6 (C2´)a, 141.4 (C7a), 141.8 (C5), 160.1 (C4´).  HRMS 
(EI); m/z calcd for C16H14N2O4 [M]+: 298.0954; found: 298.0941. 
 
7.5.5.3 Preparation of [4-Benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol 
(43) 
  To a solution of 40 (200.0mg, 0.52mmol) in dry 
THF (15mL) was slowly added 1M BH3-THF complex 
solution (1.0mL, 1.0mmol) at 0oC under a nitrogen 
atmosphere. After vigorous stirring at room temperature for 2h, the excess hydride was 
carefully destroyed by adding a solution of 50% THF in H2O (2mL) until the gas 
bubbling ceased.  The aqueous layer was saturated with anhydrous K2CO3.  The THF 
layer was separated and the aquoeus layer was extracted with diethyl ether.  The 
combined THF and diethyl ether extracts were dried, then evaporated, and 
chromatographed on silica gel by VLC (2% MeOH in DCM) to give 43 (163.5mg, 
85%) as bright yellow needles, m.p. 70-72oC.  1H NMR (300MHz, CDCl3): δ 4.63 (s, 
2H, CH2OH), 5.08 (s, 2H, OCH2), 6.80 (dd, J = 2.0, 0.8 Hz, 1H, H-3), 6.90 (dd, J = 8.4, 
2.7 Hz, 1H, H-5´), 7.23-7.42 (m, 8H, H-7, H-3´, H-6´, ArH), 8.03 (dd, J = 9.0, 2.1 Hz, 
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1H, H-6), 8.54 (d, J = 2.4 Hz, 1H, H-4), 10.92 (s, 1H, NH).  13C NMR (75MHz, 
CDCl3): δ 64.6 (CH2OH), 70.2 (OCH2), 103.5 (C3), 111.3 (C7), 114.7 (C5´), 116.7 
(C6´), 117.6 (C6), 117.7 (C4), 112.4 (2C, ArCH), 127.7 (C2), 128.2 (ArCH), 128.5 
(C3a), 128.7 (2C, ArCH), 132.6 (C3´), 134.2 (ArC), 136.4 (C2´), 139.6 (C7a), 141.3 
(C5), 141.9 (C1´), 159.3 (C4´).  HRMS (EI); m/z calcd for C22H18N2O4 [M]+: 374.1267; 
found: 374.1256. 
 
7.5.6 Amination reactions 
7.5.6.1 Preparation of 2-(2-Azidomethyl-phenyl)-5-nitro-1H-indole (44) 
 A mixture of 41 (285.0mg, 1.06mmol), sodium azide 
(75.5mg, 1.16mmol) and  triphenyl phosphine (546.0mg, 
2.08mmol) in a solution of 25% CCl4 in DMF (10mL) was 
heated at 90oC under a nitrogen atmosphere for 5h.  The reaction mixture was then 
cooled to room temperature, quenched by adding H2O (10mL), and stirred for 10min.  
The mixture was diluted with diethyl ether (40mL) and washed thoroughly with H2O.  
The organic layer was dried, then concentrated, and chromatographed on silica gel by 
VLC (30% DCM in PS) to give 44 (231.0mg, 74%) as bright yellow needles, m.p. 146-
148oC.  1H NMR (300MHz, CDCl3): δ 4.40 (s, 2H, CH2N3), 6,86 (dd, J = 2.1 Hz, 0.6 
Hz, 1H, H-3), 7.44-7.54 (m, 4H, H-7, ArH), 7.69 (dd, J = 6.2, 1.7 Hz, 1H, ArH), 8.13 
(dd, J = 9, 2.1 Hz, 1H, H-6), 8.61 (d, J = 2.1 Hz, 1H, H-4), 9.53 (s, 1H, NH).  13C NMR 
(75MHz, CDCl3,): δ 54.0 (CH2N3), 104.7 (C3), 111.1 (C7), 117.8 (C6), 117.9 (C4), 
127.8 (C3a), 129.2 (ArCH), 129.5 (ArCH), 130.7 (ArCH), 131.2 (ArCH), 132.1 (C2), 
132.3 (C1´), 139.4 (C7a), 140.0 (C2´), 142.1 (C5).  HRMS (CI); m/z calcd for 
C15H12N5O2 [MH]+: 294.0991; found: 294.0987. 
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7.5.6.2 Preparation of 2-(5-Nitro-1H-indol-2-yl)-benzylamine (45) 
 Method 1: To a mixture of 44 (260.0mg, 0.89mmol) and sodium borohydride 
(25.0mg, 0.66mmol) in dry THF (10mL) heated at reflux, was slowly added MeOH 
(1.0mL) and the mixture stirred for 2h.  Further sodium borohydride (25.0mg, 
0.66mmol) was then added and stirring continued for 3 days.  The mixture was cooled 
to room temperature and then 1M HCl (3mL) was added until the gas bubbling ceased.  
The mixture was basified to pH11 with a saturated NaOH solution and then extracted 
with DCM (3 x 20mL).  The combined DCM extracts were dried, concentrated and then 
chromatographed on silica gel by VLC (PS by gradient elution to DCM, then MeOH 
and TEA) to give starting material 44 (70.2mg, 0.24mmol; eluent: 30% DCM in PS), 2-
nitro-6H-isoindolo[2,1-a]indole 46 (30.1mg, 14%; eluent: 40% DCM in PS) as a 
yellow solid, and the benzylamine 45 (70.6 mg, 30%; eluent: 30:1:2 DCM/MeOH/TEA) 
as a brown solid.  
45: m.p. 127-129oC, 1H NMR (300MHz, CDCl3): δ 3.99 (s, 
2H, CH2), 6.87 (br.s, 1H, H-3), 7.26-7.46 (m, 4H, H-7, ArH), 
7.78 (d, J = 7.5 Hz, 1H, ArH), 8.08 (dd, J = 8.7, 2.4 Hz, 1H, H-
6), 8.61 (d, J = 2.1 Hz, 1H, H-4), 13.63 (s, 1H, NH).  13C NMR (75MHz, CDCl3): δ 46.0 
(CH2), 102.5 (C3), 111.2 (C7), 117.1 (C6), 117.6 (C4), 127.9 (C3a), 128.5 (ArCH), 
128.7 (ArCH), 130.3 (ArCH), 131.4 (ArCH), 133.1 (C2), 136.4 (C2´), 139.6 (C7a), 
141.4 (C5), 142.7 (C1´).  HRMS (EI); m/z calcd for C15H13N3O2 [M]+: 267.1008; found: 
267.0995. 
46: m.p. 234-236oC, 1H NMR (300MHz, CDCl3): δ 5.12 (s, 2H, 
H-6), 6.75 (s, 1H, H-11), 7.33 (d, J = 9.0 Hz, 1H, H-4), 7.38-
7.51 (m, 3H, ArH), 7.74 (d, J = 7.2 Hz, 1H, ArH), 8.09 (dd, J = 
9.0, 2.1 Hz, 1H, H-3), 8.58 (d, J = 2.1 Hz, 1H, H-1).  13C NMR (75MHz, CDCl3): δ 48.8 
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(C6), 93.6 (C11), 108.8 (C4), 117.3 (C3), 118.7 (C1), 121.6 (ArCH) 123.7 (ArCH), 
128.3 (ArCH), 128.6 (ArCH), 132.0 (C10b), 136.6 (C11a), 141.3 (2C, C6a, C10a), 
141.6 (C2), 147.1 (C4a).  HRMS (EI); m/z calcd for C15H10N2O2 [M]+: 250.0742; found: 
250.0732. 
 Method 2: To a solution of 44 (99.6mg, 0.34mmol), TEA (0.09mL, 0.68mmol), 
and 2 drops of 1,3-propanedithiol (ca. 0.1mL, 1.0mmol) in 35% MeOH in i-PrOH 
(12mL), was added sodium borohydride (128.6mg, 3.4mmol) at 0oC.  After 2h, more 
sodium borohydride (64mg, 1.7mmol) was added and the mixture stirred for a further 
10min to complete the reaction.  The reaction mixture was evaporated, then added to 
H2O (50mL) and extracted with 40% Et2O in PS (2 x 40mL).  The aqueous layer was 
basified to pH11 with a saturated NaOH solution and extracted with DCM (3 x 50mL).  
The combined DCM extract was dried, concentrated and then chromatographed on 
silica gel by VLC (4% MeOH in DCM) to give the amine 45 (81.6mg, 90%) as a brown 
yellow solid after washing with 40% diethyl ether in PS to remove traces of 1,3-
propanedithiol. 
 
7.5.6.3 Preparation of 2-(2-Azidomethyl-5-methoxyphenyl)-5-nitro-1H-
indole (47) 
  A mixture of 42 (298.0mg, 1.0mmol), sodium azide 
(65.0mg, 1.0mmol) and triphenylphosphine (524.6mg, 
2.0mmol) in a solution of 25% CCl4 in DMF (9mL) was heated 
to 90oC under a nitrogen atmosphere for 5h.  The reaction mixture was cooled to room 
temperature, quenched by adding H2O (10mL), and stirred for 10min.  The mixture was 
diluted with diethyl ether (40mL) and washed thoroughly with H2O.  The organic layer 
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was dried, concentrated, and chromatographed on silica gel by VLC (40% DCM in PS) 
to give 47 (198.0mg, 61%) as bright yellow needles, m.p. 138-140oC.  1H NMR 
(300MHz, CDCl3): δ 3.79 (s, 3H, OCH3), 4.26 (s, 2H, CH2), 6.78 (dd, J = 2.1, 0.9 Hz, 
1H, H-3), 6.89 (dd, J = 8.7, 2.7 Hz, 1H, H-4´), 7.12 (d, J = 2.7 Hz, 1H, H-6´), 7.29 (d, J 
= 8.7 Hz, 1H, H-3´), 7.37 (d, J = 8.4 Hz, 1H, H-7), 8.03 (dd J = 9.0, 2.1 Hz, 1H, H-6), 
8.52 (d, J = 2.1 Hz, 1H, H-4), 9.77 (s, 1H, NH).  13C NMR  (75MHz, CDCl3): δ 53.6 
(CH2), 55.5 (OCH3), 104.6 (C3), 111.2 (C7), 114.2 (C5´), 116.1 (C6´), 117.7 (C4), 
117.9 (C6), 124.6 (C2), 127.7 (C3a), 132.6 (C3´), 133.5 (C1´)a, 139.5 (C7a), 140.0 
(C2´)a, 142.3 (C5), 160.1 (C5´). HRMS (EI); m/z calcd for C16H13N5O3 [M]+: 323.1018; 
found: 323.1024. 
 
7.5.6.4 Preparation of 4-Methoxy-2-(5-nitro-1H-indol-2-yl)-benzylamine 
(48) 
To a solution of 47 (109.0mg, 0.34mmol), TEA (0.09mL, 
0.68mmol), and 2 drops of 1,3-propanedithiol (ca. 0.1mL, 
1.0mmol) in i-PrOH (9mL) and MeOH (3mL), was added 
sodium borohydride (128.6mg, 3.4mmol) at 0oC.  After 2h, 
more sodium borohydride (64mg, 1.7mmol) was added and stirring continued for 
10min.  The reaction mixture was evaporated, then added to H2O (50mL) and extracted 
with 40% diethyl ether in PS (2 x 40mL).  The aqueous layer was basified to pH11 with 
a saturated NaOH solution and extracted with DCM (3 x 50mL).  The combined DCM 
extracts were dried, concentrated and then chromatographed on silica gel by VLC (4% 
MeOH in DCM) to give 48 (91.0mg, 91%) as a yellow solid after washing with 40% 
diethyl ether in PS to remove traces of 1,3-propanedithiol, m.p. 170-178oC.  1H NMR 
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(300MHz, CDCl3): δ 3.86 (s, 3H, OCH3), 3.91 (s, 2H, CH2), 6.84 (br.s, 1H, H-3), 6.86 
(dd, J = 7.9, 2.6 Hz, 1H, H-5´), 7.23 (d, J = 8.1 Hz, 1H, H-6´), 7.28 (s, 1H, H-6´), 7.40 
(d, J = 9.3 Hz, 1H, H-7), 8.06 (dd, J = 9.3, 2.4 Hz, 1H, H-6), 8.59 (d, J = 2.1 Hz, 1H, H-
4), 13.66 (s, 1H, NH).  13C NMR (75MHz, DMSO-d6): δ 42.5 (CH2), 55.3 (OCH3), 
103.4 (C3), 111.9 (C7), 114.1 (C5´), 114.6 (C3´), 116.7 (C6), 117.0 (C4), 127.6 (C3a), 
129.0 (C2), 131.8 (C6´), 132.9 (C1´)a, 139.6 (C2´)a, 140.7 (C5), 141.4 (C7a), 158.6 
(C4´).  HRMS (EI); m/z calcd for C16H15N3O3 [M]+: 297.1113; found: 297.1101. 
 
7.5.7 N-Alkylation reactions 
7.5.7.1 Preparation of 2-Bromo-N-[2-(5-nitro-1H-indol-2-yl)benzyl]-
acetamide (49) 
To a solution of 45  (70.6mg, 0.26mmol) and TEA 
(0.17mL, 1.2mmol) in dry DCM (4mL), was added 
bromoacetyl chloride (0.1mL, 1.2mmol) at 0oC under a 
nitrogen atmosphere, and stirred for 15min.  The reaction mixture was then added to 
H2O (20mL) and extracted with DCM (3 x 20mL).  The combined DCM extracts were 
dried, concentrated and then chromatographed on silica gel (60% DCM in PS) to give 
49 (63.8mg, 62%) as a yellow solid, m.p.181-183oC.  1H NMR (300MHz, CDCl3): δ 
3.85 (s, 2H, CH2Br), 4.45 (d, J = 6.6 Hz, 2H, CH2N), 6.65 (d, J = 1.5 Hz, 1H, H-3), 
7.28-7.50 (m, 6H, H-7, NHCO, ArH), 8.02 (dd, J = 8.9, 2.3 Hz, 1H, H-6), 8.51 (d, J = 
2.4 Hz, 1H, H-4), 11.36 (s, 1H, NH-indole).  13C NMR (75MHz, CDCl3): δ 28.7 
(CH2Br), 42.3 (CH2N), 104.4 (C3), 111.3 (C7), 117.5 (2C, C-4, C-6), 127.9 (C3a), 
128.3 (ArCH), 129.3 (ArCH), 129.5 (ArCH), 131.1 (ArCH), 131.6 (C2), 134.7 (C2´), 
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139.7 (C7a), 140.9 (C1´), 141.7 (C5), 167.2 (CO).  HRMS (EI); m/z calcd for 
C17H14N3O3Br [M]+: 389.0198; found: 389.0197. 
 
7.5.7.2 Preparation of 2-Bromo-N-[4-methoxy-2-(5-nitro-1H-indol-2-yl)-
benzyl)-acetamide (50) 
To a solution of 48 (80mg, 0.27mmol) and TEA 
(0.1mL, 0.27mmol) in dry DCM (8mL), was added 
bromoacetyl chloride (0.05mL, 0.60mmol) at 0oC under a 
nitrogen atmosphere for 15min.  The reaction mixture was then added to H2O (10mL) 
and extracted with DCM (3 x 10mL).  The DCM extracts were dried, concentrated and 
then chromatographed on silica gel (50% DCM in PS) to give 50 (72.0mg 64%) as a 
yellow solid, m.p.176-179oC.  1H NMR (300MHz, CDCl3): δ 3.84 (s, 3H, OCH3), 3.91 
(s, 2H, CH2Br), 4.44 (d, J = 6 Hz, 2H, CH2), 6.72 (dd, J = 2.1, 0.8 Hz, 1H, H-3), 6.96 
(dd, J = 8.4, 3.0 Hz, 1H, C-4´), 7.04 (d, J = 2.7 Hz, 1H, C-6´), 7.30 (d, J = 8.4 Hz, 1H, 
H-3´), 7.33 (br s, 1H, NHCO), 7.47 (d, J = 9.0 Hz, 1H, H-7), 8.09 (dd, J = 9.0, 2.4 Hz, 
1H, H-6), 8.58 (d, J = 2.4 Hz, H-4), 11.52 (s, 1H, NH-indole).  13C NMR (75MHz, 
CDCl3): δ 28.8 (CH2Br), 41.9 (CH2N), 55.5 (OCH3), 104.4 (C3), 111.3 (C7), 115.5 
(C6´), 115.6 (C4´), 117.6 (2C, C4, C6), 126.8 (C2), 127.8 (C3a), 131.0 (C3´), 132.9 
(C1´)a, 139.7 (C7a), 141.0 (C2´)a, 141.9 (C5), 159.2 (C5´), 167.1 (CO).  HMRS (EI); 
m/z calcd for C18H16N3O4Br [M+]: 417.0324; found; 417.0332. 
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7.5.8 O-Alkylation reactions 
7.5.8.1  Preparation of Bromoacetic acid 2-(5-nitro-1H-indol-2-yl)-benzyl 
ester (51) 
To a solution of 41 (200mg, 0.75mmol), anhydrous 
TEA (0.21mL, 1.5mmol) and dry THF (25mL), was 
slowly added a solution of bromoacetyl chloride (0.13mL, 1.5mmol) in THF (5mL) at 
0oC under a nitrogen atmosphere and the mixture then heated at 50oC for 5h.  The 
reaction mixture was then filtered and concentrated.  The resulting residue was added to 
water (50mL), extracted with EtOAc (3 x 30mL) and washed with H2O.  The combined 
EtOAc extracts were dried and chromatographed on silica gel by VLC (20% EtOAc in 
PS) to give 51 (160.0mg, 70%) as yellow needles, m.p. 139-141oC.  1H NMR (300MHz, 
CDCl3): δ 3.97 (s, 2H, CH2Br), 5.31 (s, 2H, CH2O), 6.83 (d, J = 1.8 Hz, 1H, H-3), 7.44-
7.64 (m, 5H, H-7, ArH), 8.13 (dd, J = 9.0, 1.8 Hz, 1H, H-6), 8.62 (d, J = 1.8 Hz, 1H, H-
4), 9.63 (s, 1H, NH).  13C NMR (75MHz, CDCl3): δ 40.9 (CH2Br), 66.4 (CH2O), 104.9 
(C3), 111.1 (C7), 117.7 (C6), 117.8 (C4), 127.8 (C3a), 129.1 (ArCH), 129.5 (ArCH), 
130.3 (ArCH), 131.2 (ArCH), 132.2 (C2), 132.5 (C2´), 139.6 (C7a), 139.7 (C1´), 142.0 
(C5), 167.0 (CO).  HRMS (EI); m/z calcd for C17H13N2O4Br [M]+: 338.0059; found: 
338.0056. 
 
7.5.8.2  Preparation of Bromoacetic acid 4-methoxy-2-(5-nitro-1H-indol-2-
yl)phenyl)-benzyl ester (52) 
To a solution of 42 (220mg, 0.74mmol), anhydrous 
TEA (0.1mL, 0.74mmol) and dry DCM (20mL), was 
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slowly added a solution of bromoacetyl chloride (0.13mL, 1.5mmol) at 0oC under a 
nitrogen atmosphere, and the mixture then stirred for 15min.  The reaction mixture was 
added to water (30mL), then extracted with DCM (3 x 30mL) and washed with H2O.  
The combined DCM extracts were dried and chromatographed on silica gel by VLC (PS 
by gradient elution to DCM and then MeOH) to give the starting material 42 (31.1mg, 
0.1mmol; eluent: 2% MeOH in DCM) and 52 (120.0mg, 39%; eluent: 60% DCM in PS) 
as an amorphous solid.  1H NMR (300MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 3.88 (s, 2H, 
CH2CO), 5.17(s, 2H, CH2O), 6.76 (dd, J = 2.1, 0.9 Hz, 1H, H-3), 6.91 (dd, J = 8.4, 2.7 
Hz, 1H, H-5´), 7.06 (d, J = 2.7 Hz, 1H, H-3´), 7.40 (d, J = 9.3 Hz, 1H, H-7), 7.44 (d, J = 
8.4 Hz, 1H, H-6´), 8.06 (dd, J = 9.0, 2.4 Hz, 1H, H-6), 8.54 (d, J = 2.4 Hz, 1H, H-4), 
9.59 (s, 1H, NH). 13C NMR (75MHz, CDCl3): δ 25.9 (CH2Br), 55.5 (OCH3), 66.6 
(CH2O), 104.9 (C3), 111.1 (C7), 114.6 (C5´), 115.8 (C6´), 117.8 (C4), 118.0 (C6), 
124.2 (C2), 127.8 (C3a), 133.5 (C6´), 134.2 (C1´)a, 139.5 (C7a), 140.0 (C2´)a, 142.2 
(C5), 160.3 (C4´), 166.8 (CO).  HRMS (EI); m/z calcd for C18H15N2O5Br [M]+: 
420.0144; found: 420.0151. 
 
7.5.9 Bromination reactions 
7.5.9.1 Preparation of 2-(2-Bromomethylphenyl)-5-nitro-1H-indole (53) 
A yellow suspension of 41 (200mg, 0.75mmol), 
triphenylphosphine (390mg, 1.5mmol) and carbon tetrabromide 
(490mg, 1.5mmol) in dry diethyl ether (60mL) was stirred with 
warming at 40oC under a nitrogen atmosphere for 2 days.  The reaction mixture was 
then filtered and the filtrate concentrated.  The residual yellow oil was chromatographed 
on silica gel by VLC (20% EtOAc in PS) to give 53 (102.3mg, 41%) as a yellow solid, 
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m.p. 164-166oC.  1H NMR (300MHz, CDCl3,): δ 4.64 (s, 2H, CH2Br), 6.93 (d, J = 1.2 
Hz, 1H, H-3), 7.43-7.58 (m, 5H, H-7, ArH), 8.16 (dd, J = 9.0, 2.1 Hz, 1H, H-6), 8.64 (d, 
J = 2.1 Hz, 1H, H-4), 9.14 (s, 1H, NH).  13C NMR (75MHz, CDCl3): δ 33.0 (CH2Br), 
105.1 (C3), 111.1 (C7), 117.8 (C4), 118.6 (C6), 127.9 (C3a), 129.4 (ArCH), 129.6 
(ArCH), 130.5 (ArCH), 131.7 (ArCH), 131.8 (C2), 135.6 (C1´), 139.3 (C7a), 139.6 
(C2´), 142.3 (C5).  HRMS (EI); m/z calcd for C15H11N2O2Br [M]+: 330.0003; found: 
329.9982. 
 
7.5.9.2  Attempted bromination of the benzyl alcohol 42 
  Method 1: A yellow suspension of 42 (510mg, 
1.7mmol), triphenylphosphine (472mg, 1.8mmol) and carbon 
tetrabromide (597.0mg, 1.8mmol) in dry diethyl ether (80mL) 
was stirred at room temperature under a nitrogen atmosphere 
for 3 days.  The reaction mixture was filtered and then concentrated. The residue was 
chromatographed on silica gel by VLC (1% MeOH in DCM) to give [4-methoxy-2-(5-
nitro-1H-indol-2-yl)-triphenyl-phosphonium bromide (54) (500.0mg, 47%) as an orange 
solid. 1H NMR (300MHz, CDCl3,): δ 3.71 (s, 3H, OCH3), 5.17 (d, J = 11.7 Hz, 2H, 
CH2), 5.95 (s, 1H, H-3), 6.57 (d, J = 7.8 Hz, 1H, H-5´), 6.78 (d, J = 6.9 Hz, 1H, H-6´), 
6.91 (br.s, 1H, H-3´), 7.18-7.97 (m, 15H, ArH), 7.80 (br.d, J = 9.3 Hz, 1H, H-7), 7.93 
(br.d, J = 9.0 Hz, 1H, H-6), 8.30 (d, J = 1.5 Hz, 1H, H-4), 12.03 (s, 1H, NH).  13C NMR 
(75MHz, CDCl3,): δ 29.2 (CH2, very weak signal), 55.4 (OCH3), 103.6 (C3), 112.5 
(C7), 114.8 (C4´), 116.2 (d, J = 35.4 Hz, 3C, ArC), 116.4 (C2)a, 116.8 (C6´), 116.9 
(C4), 117.2 (C6), 117.5 (C1´)a, 127.1 (C3a), 130.0 (d, J = 49.2 Hz, 6C, ArCH), 133.2 
(C3´), 133.5 (d, J = 38.7 Hz, 6C, ArCH), 134.9 (3C, ArCH), 139.3 (C2´)a, 140.0 (C7a), 
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141.4 (C5), 159.7 (C5´).  HRMS (ES): m/z calcd for C34H28N2O3P [M]+: 543.1838; 
found: 543.1838. 
 
7.5.9.3 Preparation of 2-(5-Methoxy-2-vinylphenyl)-5-nitro-1H-indole (55) 
  To a solution of 54 (355.0mg, 0.57mmol) in DCM (20mL) 
was added 40mg/mL aqueous solution of formaldehyde (2mL, 
2.66mmol).  The reaction mixture was stirred vigorously, 0.1% 
aqueous NaOH (23mL, 0.57mmol) was added slowly over 10min at room temperature.  
Stirring of the reaction mixture was continued for 40min.  The mixture was then washed 
sequentially with water (30mL), 1M HCl (30mL), water (30mL), and brine (30mL).  
The DCM layer was dried, evaporated and then chromatographed on silica gel (50% 
DCM in hexane) to give 55 (5.0mg, 3%) as a yellow solid and 2-(5-methoxy-2-methyl-
phenyl)-5-nitro-1H-indole (56) (82.7mg, 49%) as bright yellow needles. 
55: m.p. 151-153oC, 1H NMR (300MHz, CDCl3,): δ 3.87 (s, 3H, OCH3), 5.29 (dd, J = 
11.0, 1.4 Hz, 1H, C=CH2), 5.68 (dd, J = 17.3, 1.4 Hz, 1H, C=CH2), 6.69 (dd, J = 2.1, 
0.9 Hz, 1H, H-3), 6.88 (dd, J = 17.6, 11.0 Hz, 1H, CH=CH2), 6.98 (dd, J = 8.4, 2.7 Hz, 
1H, H-4´), 7.03 (d, J = 2.4 Hz, 1H, H-6´), 7.44 (d, J = 8.7 Hz, 1H, H-7), 7.58 (d, J = 8.4 
Hz, 1H, H-3´), 8.13 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.61 (d, J = 1.8 Hz, 2H, H-4, NH).  
13C NMR (75MHz, CDCl3,): δ 55.5 (OCH3), 105.2 (C3), 110.8 (C7), 114.2 (C6´), 115.0 
(C4´), 115.3 (CH=CH2), 117.7 (C4), 117.9 (C6), 127.9 (C3a), 128.4 (C3´), 129.4 (C2´)a, 
131.2 (C2), 134.8 (CH=CH2), 139.1 (C7a), 140.1 (C1´)a, 142.1 
(C5), 159.3 (C5´).  HRMS (EI); m/z calcd for C17H14N2O3 [M]+: 
294.1004; found: 294.0988. 
56: m.p. 194-196oC, 1H NMR (300MHz, CDCl3 + CD3OD): δ 
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2.43 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 6.75 (d, J = 0.9 Hz, 1H, H-3), 6.89 (dd, J = 8.5, 
2.6 Hz, 1H, H-4´), 7.05 (d, J = 2.7 Hz, 1H, H-6´), 7.25 (d, J = 8.4 Hz, 1H, H-3´), 7.44 
(d, J = 8.1 Hz, 1H, H-7), 8.10 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.59 (d, J = 2.4 Hz, 1H, H-
4).  13C NMR (75MHz, CDCl3 + CH3OD): δ 20.0 (CH3), 55.4 (OCH3), 104.3 (C3), 
110.7 (C7), 113.8 (C4´), 114.4 (C6´), 117.4 (C6), 117.5 (C4), 127.9 (C3a), 128.3 (C2), 
132.1 (C3´), 132.3 (C2´)a, 139.2 (C1´)a, 140.7 (C7a), 141.6 (C5), 157.6 (C5´).  HRMS 
(CI); m/z calcd for C16H15N2O3 [MH]+: 283.1083; found: 283.1092. 
 
7.5.9.4 Attempted N-protection of the benzyl alcohol 42 
 Method 1: A mixture of 42 (20.0mg, 0.067mmol), (Boc)2O (14.65mg, 
0.067mmol) and DMAP (8.2mg, 0.067mmol) in dry DMF (2mL), was stirred under a 
nitrogen atmosphere at room temperature for 24h.  The mixture was evaporated and 
then diethyl ether (10mL) was added.  The ethereal solution was washed with 10% citric 
acid, dried and then evaporated.  The residue was chromatographed on silica gel by PLC 
(70% DCM in PS) to give the cyclized product 57 (1.5mg, 
7%) as an opaque white solid and the O-Boc product 58 
(11.5mg, 43%) as a yellow solid. 
57: 1H NMR (300MHz, CDCl3): δ 3.83 (s, 3H, OCH3), 4.91 
(br.d, J = 9.6 Hz, 2H, OCH2), 6.67 (s, 1H, H-13), 6.86 (d, J = 2.7 Hz, 1H, H-12), 6.97 
(dd, J = 8.6, 2.6 Hz, 1H, H-10), 7.43 (d, J = 9.0 Hz, 1H, H-9), 8.23 (dd, J = 9.5, 2.3 Hz, 
1H, H-3), 8.40 (d, J = 9.3 Hz, 1H, H-4), 4.48 (d, J = 2.4 Hz, 1H, H-1).  MS (CI): m/z 
325 (M+1, 100 %). 
58: 1H NMR (300MHz, CDCl3): δ 1.52 (s, 9H, CH3), 
3.87 (s, 3H, OCH3), 5.11 (s, 2H, OCH2), 6.81 (d, J = 1.5 
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Hz, 1H, H-3), 6.97 (dd, J = 8.4, 2.7 Hz, 1H, H-5´), 7.11 (d, J = 2.7 Hz, 1H, H-3´), 7.45 
(d, J = 9.0 Hz, 1H, H-7), 7.53 (d, J = 8.7 Hz, 1H, H-6´), 8.13 (dd, J = 8.9, 2.3 Hz, 1H, 
H-6), 8.61 (d, J = 2.4 Hz, 1H, H-4), 9.99 (s, 1H, NH).  13C NMR (75MHz, CDCl3): δ 
27.8 (3C, CH3), 55.5 (OCH3), 66.9 (OCH2), 83.2 (OCMe3), 104.6 (C3), 111.1 (C7), 
114.6 (C5´), 115.5 (C3´), 117.7 (2C, C4, C6), 124.9 (C1´)a, 127.8 (C3a), 133.3 (C6´), 
133.7 (C2), 139.4 (C7a), 140.4 (C2´)a, 142.0 (C5), 153.5 (CO), 160.0 (C4´).  MS (CI): 
m/z 399 (M+1, 50 %), 299 (50 %), 281 (100 %). 
 Method 2: To a solution of 42 (30.0mg, 0.1mmol) in dry THF (1mL) at –60oC in a 
dry ice/acetone bath under a nitrogen atmosphere, was added dropwise 2M n-BuLi 
solution in cyclohexane (0.05mL, 0.1mmol).  The cooling bath was removed and the 
reaction mixture stirred for 45min while warming to 0oC.  The reaction mixture was 
then re-cooled to –60oC, and a solution of benzenesulfonyl chloride (20.8mg, 
0.15mmol) in dry THF was added (1mL).  The mixture was allowed to warm slowly to 
room temperature and stirring continued overnight.  A 5% NaHCO3 solution (1mL) was 
added to the mixture which was then extracted with DCM (3 x 5mL).  The combined 
DCM extracts were washed with 5% NaHCO3, water and 
then brine.  The solution was dried, evaporated, and then 
chromatrographed on silica gel by PLC (50% DCM in 
hexane) to give the dibenzenesulfonyl indole 59  (4.5mg, 8%) as an opaque white solid.  
1H NMR (300MHz, CDCl3): δ 3.89 (s, 3H, OCH3), 5.33 (s, 2H, OCH2), 6.76 (d, J = 0.6 
Hz, 1H, H-3), 6.91 (dd, J = 8.4, 2.1 Hz, 1H, H-6), 6.94-7.01 (m, 1H, ArH), 7.00 (d, J = 
8.4 Hz, 1H, H-4´), 7.11 (d, J = 1.8 Hz, 1H, H-6´), 7.12-7.22 (m, 2H, ArH), 7.32-7.42 
(m, 3H, H-3´, ArH), 7.52-7.59 (m, 2H, ArH), 7.76 (d, J = 8.7 Hz, 1H, H-7), 7.98 (d, J = 
8.7 Hz, 1H, ArH), 8.17-8.25 (m, 2H, ArH), 8.42 (d, J = 1.8 Hz, 1H, H-4).  MS (CI): m/z 
579  (M+H, 1%), 295 (100%).    
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7.6 Alkylation reactions (Chapter 4) 
7.6.1 Preparation of 9,10-Dimethoxy-13-[2-(5-nitro-1H-indol-2-yl)-
benzyloxycarbonyl-methyl]-5,6-dihydrobenzo[g]-1,3-
benzodioxolo[5,6-a]quinolizinium bromide (60) 
A solution of the dihydroberberine 9 (100.0mg, 
0.26mmol) and the bromoester 51 (108.8mg, 0.32mmol) in 
dry CH3CN (8mL), was heated at reflux for 48h under a 
nitrogen atmosphere.  The reaction mixture was then 
concentrated by evaporation of the CH3CN.  The residue 
was chromatographed on silica gel (4% MeOH in DCM), followed by PLC (multiple 
development, silica gel, 4% MeOH in DCM) of the main fraction from the column.  
Subsequently, the polar fraction was crystallized from 1% MeOH in DCM to give 60 
(66.6mg, 35%) as a yellow solid; m.p. 212-214oC.   1H NMR (300MHz, DMSO-d6): δ 
3.03 (br.t, J = 5.1 Hz, 2H, H-5), 4.04 (s, 3H, OCH3), 4.07 (s, 3H, OCH3), 4.48 (s, 2H, 
CH2CO), 4.78 (br.s, 2H, H-6), 5.39 (s, 2H, CH2O), 6.14 (s, 2H, OCH2O), 6.74 (s, 1H, 
H-3´), 7.07 (s, 1H, H-4)a, 7.13 (s, 1H, H-14)a, 7.42-7.62 (m, 5H, H-7´, ArH), 7.87 (d, J 
= 9.3 Hz, 1H, H-11)b, 8.00 (d, J = 8.1 Hz, 1H, H-6´), 8.03 (d, J = 9.3 Hz, 1H, H-12)b, 
8.48 (s, 1H, H-4´), 9.91 (s, 1H, H-8), 12.19 (s, 1H, NH).  13C NMR (75MHz, DMSO-
d6): δ 27.4 (C5), 36.5 (CH2CO), 56.9 (C6), 57.1 (OCH3), 61.2 (OCH3), 65.5 (CH2O), 
102.3 (OCH2O), 104.3 (C3´), 108.7 (C4)c, 108.8 (C14)c, 111.9 (C7´), 117.2 (2C, C4´, 
C6´), 119.8 (C4a), 121.0 (C8a)d, 121.1 (C11)e, 126.0 (C12a)d, 126.2 (C12)e, 127.6 
(C3a´), 129.0 (2C, C4´´, C5´´), 129.8 (C3´´)f, 130.2 (C6´´)f, 131.6 (C2´), 132.8 (C13), 
133.2 (C2´´), 134.3 (C13b), 137.2 (C13a), 139.6 (C1´´), 139.9 (C7a´), 141.0 (C5´), 
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144.4 (C9)g, 145.8 (C8), 146.9 (C3a)h, 149.6 (C14a)h, 150.4 (C10)g, 170.3 (CO).  
HRMS (ES): m/z calcd for C37H30N3O8 [M]+: 644.2033; found: 644.2034. 
 
7.6.2 Preparation of 9,10-Dimethoxy-13-[4-methoxy-2-(5-nitro-1H-
indol-2-yl)-benzyloxycarbonylmethyl]-5,6-dihydrobenzo[g]-1,3-
benzodioxolo[5,6-a] quinolizinium bromide (61) 
A solution of the dihydroberberine 9 (91.0mg, 
0.24mmol) and the bromoester 52 (100.0mg, 
0.24mmol) in dry CH3CN (14mL) was heated at reflux 
for 48h under a nitrogen atmosphere.  The reaction 
mixture was then concentrated by evaporation of the 
CH3CN.  The residue was chromatographed on silica gel (4% MeOH in DCM), 
followed by PLC (multiple development, silica gel, 4% MeOH in DCM) of the main 
fraction from the column.  Subsequently, the polar fraction was crystallized from 1% 
MeOH in DCM to give 61 (40.7mg, 22%) as a yellow solid; m.p. 230oC (decomp.).  1H 
NMR (500MHz, DMSO-d6): δ 3.03 (t, J = 5.5 Hz, 2H, H-5), 3.84 (s, 3H, OCH3), 4.04 
(s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.47 (s, 2H, CH2CO), 4.78 (s, 2H, H-6), 5.31 (s, 2H, 
CH2O), 6.14 (s, 2H, OCH2O), 6.72 (s, 1H, H-3´), 7.05 (dd, J = 5.1, 1.5 Hz, 1H, H-5´´), 
7.08 (s, 1H, H-4)a, 7.13 (s, 1H, H-14)a, 7.16 (d, J = 1.5 Hz, 1H, H-3´´), 7.51 (d, J = 9.3 
Hz, 1H, H-6´´), 7.54 (d, J = 9.6 Hz, 1H, H-7´), 7.85 (d, J = 5.7 Hz, 1H, H-11)b, 8.01 (dd, 
J = 9.3, 1.2 Hz, 1H, H-6´), 8.03 (d, J = 5.7 Hz, 1H, H-12)b, 8.46 (d, J = 1.2 Hz, 1H, H-
4´), 9.90 (s,1H, H-8), 12.24 (s, 1H, NH).  13C NMR (125MHz, DMSO-d6): δ 27.3 (C5), 
36.5 (CH2CO), 55.6 (OCH3), 56.9 (C6), 57.0 (OCH3), 62.1 (OCH3), 65.4 (CH2O), 102.3 
(OCH2O), 104.2 (C3´), 108 6 (C4)c, 108.7 (C14)c, 111.9 (C7´), 114.4 (C5´´), 114.6 
(C3´´), 117.1 (2C, C4´, C6´), 119.8 (C4a), 120.9 (2C, C12, C8a)d, 125.0 (C2´), 126.1 
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(2C, C11, C12a)d, 127.4 (C3a´), 132.7 (2C, C13, C6´´), 133.2 (C1´´)e, 134.2 (C13b), 
137.2 (C13a), 139.4 (C2´´)e, 139.8 (C7a´), 140.9 (C5´), 144.3 (C9)f, 145.7 (C8), 146.8 
(C3a)g, 149.5 (C14a)g, 150.3 (C10)f, 159.5 (C4´´), 170.3 (CO).  HRMS (ES): m/z calcd 
for C38H32N3O9 [M]+: 674.2139; found: 674.2134. 
 
7.6.3 Preparation of 9,10-Dimethoxy-13-{[2-(5-nitro-1H-indol-2-yl)-
benzylcarbamoyl]-methyl}-5,6-dihydrobenzo[g]-1,3-
benzodioxolo[5,6-a]quinolizinium bromide (62) 
A solution of the dihydroberberine 9 (22.5mg, 
0.06mmol) and the bromoamide 49 (25.0mg, 0.07mmol) in 
dry CH3CN (3mL) was heated at reflux for 48h under a 
nitrogen atmosphere.  The reaction mixture was then 
concentrated by evaporation of the CH3CN. The residue 
was chromatographed on silica gel (4% MeOH in DCM), 
followed by PLC (multiple development, silica gel, 4% MeOH in DCM) of the polar 
fraction from the column.  Subsequently, the polar fraction was crystallized from 1% 
MeOH in DCM to give 62 (5.0mg, 12%) as a yellow solid; m.p. 209-211oC.  1H NMR 
(500MHz, CD3OD): δ 3.11 (br.t, J = 4.8 Hz, 2H, H-5), 4.03 (s, 3H, OCH3), 4.19 (s, 3H, 
OCH3), 4.33 (s, 2H, CH2CO), 4.69 (s, 2H, CH2N), 4.88 (br.s, 2H, H-6), 6.12 (s, 2H, 
OCH2O), 6.83 (s, 1H, H-3´), 7.02 (s, 1H, H-4)a, 7.40 (s, 1H, H-14)a, 7.46-7.63 (m, 5H, 
H-7´, ArH), 7.82 (d, J = 9.6 Hz, 1H, H-11)b, 7.98 (d, J = 9.6 Hz, 1H, H-12)b, 8.06 (dd, J 
= 9, 2.1 Hz, 1H, H-6´), 8.52 (d, J = 2.1 Hz, 1H, H-4´), 9.84 (s, 1H, H-8).  13C NMR 
(125MHz, CD3OD): δ 27.8 (C5), 37.3 (CH2CO), 42.0 (CH2N), 56.2 (OCH3), 57.3 (C6), 
61.2 (OCH3), 102.5 (C2), 104.1 (C3´), 108.3 (C4)c, 109.3 (C14)c, 111.0 (C7´), 116.9 
(C7´), 117.1 (C4´), 120.0 (C4a), 120.4 (C11)d, 121.7 (C8a)e, 126.2 (C12)d, 127.8 
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(C12a)e, 127.9 (ArCH), 128.1 (C3a´), 128.8 (ArCH), 129.4 (ArCH), 129.8 (ArCH), 
131.8 (C2´), 134.1 (2C, C13b, C13), 136.0 (C1´´)f, 138.2 (C13a), 139.2 (C2´´)f, 140.7 
(C5´), 141.3 (7a´), 144.9 (C8), 145.1 (C9)g, 147.9 (C3a)h, 150.2 (C14a)h, 150.7 (C10)g, 
170.8 (CO).   HRMS (ES): m/z calcd for C37H31N4O7 [M]+: 643.2193; found: 643.2184. 
 
7.6.4 Preparation of 9,10-Dimethoxy-13-{[4-methoxy-2-(5-nitro-1H-
indol-2-yl)-benzylcarbamoyl]-methyl}-5,6-dihydrobenzo[g]-1,3-
benzodioxolo[5,6-a]quinolizinium bromide (63) 
 A solution of the dihydroberberine 9 (58.0mg, 
0.15mmol) and the bromoamide 50 (70.0mg, 
0.16mmol) in dry CH3CN (3mL) was heated at 
reflux for 48h under a nitrogen atmosphere.  The 
mixture was then concentrated and the residue 
triturated with diethyl ether.  The precipitate was 
filtered and washed with diethyl ether.  The solid was chromatographed on silica gel 
(4% MeOH in DCM), and the product was crystallized from 1% MeOH in DCM to give 
63 (25.4mg, 22%) as a yellow solid; m.p. >250oC.  1H NMR (300MHz, CD3OD): δ 3.12 
(br t, J = 5.7 Hz, 2H, H-5), 3.87 (s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.19 (s, 3H, OCH3), 
4.30 (s, 2H, CH2CO), 4.62 (s, 2H, CH2N), 4.79 (br.t, J = 5.7 Hz, 2H, H-6), 6.12 (s, 2H, 
OCH2O), 6.83 (d, J = 0.9 Hz, 1H, H-3´), 7.02 (s, 1H, H-4)a, 7.06 (dd, J = 8.6, 2.9 Hz, 
1H, H-5´´), 7.14 (d, J = 2.4 Hz, 1H, H-3´´), 7.4 (s, 1H, H-14)a, 7.48 (d, J = 9.0 Hz, 1H, 
H-7´), 7.52 (d, J = 8.4 Hz, 1H, H-6´´), 7.80 (d, J = 9.3 Hz, 1H, H-12)b, 7.94 (d, J = 9.3 
Hz, 1H, H-11)b, 8.04 (dd, J = 9.2, 2.3 Hz, 1H, H-6´), 8.49 (d, J = 2.1 Hz, 1H, H-4´), 
9.82 (s, 1H, H-8).  13C NMR (75MHz, CD3OD): δ 29.1 (C5), 38.5 (CH2CO), 42.9 
(CH2N), 56.0 (OCH3), 57.5 (OCH3), 58.7 (C6), 62.7 (OCH3), 103.8 (C2), 105.2 (C3´), 
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109.4 (C4)c, 110.5 (C14)c, 112.3 (C7´), 115.7 (C5´´), 116.0 (C3´´), 118.2 (C4´), 118.3 
(C6´), 121.4 (C12)d, 121.5 (C11)d, 122.8 (C8a)e, 127.4 (C4a), 128.9 (C12a)e, 129.0 
(C2´), 129.3 (C3a´), 132.6 (C6´´), 134.2 (C1´´)f, 135.1 (C13), 135.2 (C13b), 139.4 
(C13a), 141.2 (C2´´)f, 141.5 (C7a´), 142.9 (C5´), 146.3 (C9)g, 146.4 (C8), 148.9 (C3a)h, 
151.7 (C14a)h, 151.8 (C10)g, 160.7 (C4´´), 171.9 (CO).  HRMS (ES): m/z calcd for 
C38H33N4O8 [M]+: 673.2298; found: 673.2305. 
 
7.6.5 Preparation of 9,10-Dimethoxy-13-[2-(5-nitro-1H-indol-2-
yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-
a]quinolizinium bromide (64) 
 A solution of the dihydroberberine 9 (91.0mg, 
0.24mmol) and the benzyl bromide 53 (102.3mg, 
0.30mmol) in dry CH3CN (7mL) was heated at reflux for 
24h under a nitrogen atmosphere.  The mixture was then 
concentrated and the residue triturated with diethyl ether.  The precipitate was filtered 
and washed with diethyl ether.  The solid was chromatographed on silica gel (6% 
MeOH in DCM) to give 64 (55.0mg, 35%) as a yellow solid; m.p. 206oC (decomp.).  1H 
NMR (300MHz, CD3OD): δ 3.03 (t, J = 5.5 Hz, 2H, H-5), 4.01 (s, 3H, OCH3), 4.17 (s, 
3H, OCH3), 4.80 (br.s, 2H, H-6), 4.84 (s, 2H, CH2Ph), 5.96 (s, 2H, OCH2O), 6.72 (s, 
1H, H3´), 6.86 (s, 1H, H-4)a, 6.90 (s, 1H, H-14)a, 6.96 (d, J = 7.8 Hz, 1H, H-6´´), 7.27 
(td, J = 7.7, 1.5 Hz, 1H, H-5´´), 7.37 (br.t, J = 7.5 Hz, 1H, H-4´´), 7.42 (d, J = 9.0 Hz, 
1H, H-7´), 7.58 (dd, J = 7.7, 1.1 Hz, 1H, H-3´´), 7.78 (d, J = 9.3 Hz, 1H, H-11)b, 7.88 
(dd, J = 9.0, 2.4 Hz, 1H, H-6´), 7.94 (d, J = 9.3 Hz, 1H, H-12)b, 8.34 (d, J = 2.1 Hz, 1H, 
H-4´), 9.8 (s, 1H, H-8).  13C NMR (75MHz, CD3OD): δ 29.1 (C5), 36.4 (CH2Ar), 57.5 
(OCH3), 58.8 (C6), 62.7 (OCH3), 103.6 (OCH2O), 105.6 (C3´), 109.3 (C4)c, 109.8 
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(C14)c, 112.3 (C7´), 118.2 (C6´), 118.3 (C4´), 121.4 (C4a), 122.5 (C11)d, 122.9 (C8a)e, 
127.3 (C12)d, 128.6 (C4´´), 129.2 (C3a´), 130.4 (2C, C6´´, C5´´), 131.8 (C3´´), 132.8 
(C12a)e, 133.4 (C2´), 135.0 (C13b), 135.1 (C13), 138.6 (C1´´)f, 139.0 (C13a), 141.2 
(C7a´), 141.5 (C2´´)f, 142.9 (C5´), 146.1 (C8), 146.2 (C9)g, 148.6 (C3a)h, 151.4 
(C14a)h, 151.7 (C10)g.  HRMS (ES): m/z calcd for C35H28N3O6 [M]+: 586.1978; found: 
586.1984. 
 
7.6.6 Preparation of 9,10-Dimethoxy-13-[4-methoxy-2-(5-nitro-1H-
indol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-
a]quinolizinium chloride (65) 
Method 1: A suspension of 42 (30.0mg, 0.10mmol), 
dihydroberberine 9 (37.9mg, 0.1mmol), 
triphenylphosphine (52.5mg, 0.20mmol), and carbon 
tetrabromide (331.6mg, 1.0mmol) in DMF (1mL) was 
heated at 90oC for 20h under a nitrogen atmosphere.  The 
mixture was then evaporated and the residue chromatographed on silica gel (6% MeOH 
in DCM) to give a yellow solid (9.4mg).  The solid was crystallized from 2% MeOH in 
CHCl3 to give berberine bromide (5.1mg, 12.2%) as a yellow solid. 
 Method 2: A solution of 42 (20.0mg, 0.07mmol), dihydroberberine 9 (25.0mg, 
0.07mmol), and triphenylphosphine (35.1mg, 0.13mmol) in 25% CCl4 in DMF (1mL) 
was heated at 90oC for 12h under a nitrogen atmosphere.  The mixture was then 
evaporated and the residue chromatographed on silica gel (4% MeOH in DCM), 
followed by multiple development PLC on silica gel (4% MeOH in DCM).  An almost 
pure fraction was crystallized from hot MeOH to give 65 (1.8mg, 4%) as a yellow solid; 
m.p. 230oC (decomp.). 1H NMR (500MHz, CD3OD): δ 3.04 (t, 5.9 Hz, 2H, H-5), 3.83 
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(s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.19 (s, 3H, OCH3), 4.78 (s, 2H, H-6 ), 4.80 (s, 2H, 
CH2Ph), 6.00 (s, 2H, 0CH 20), 6.78 (s, IH, H-3'), 6.84-6.91 (m, 2H, H-6 " , H-5"), 6.92 
(s, IH, H-4)a, 7.00 (s, IH, H-14)a, 7.22 (d, J =  2.4 Hz, IH, H-3"), 7.48 (d, J =  8.7 Hz, 
IH, H-7'), 7.81 (d, J=  9.6 Hz, IH, H-12)b, 8.00 (d, J=  9.5 Hz, IH, H-1 l)b, 8.02 (dd, J=  
8.9, 2.2 Hz, IH, H-6 '), 8.47 (d, J =  2.1 Hz, IH, H-4'), 9.81 (s, IH, H-8 ). 13C NMR 
(125MHz, CD3OD): 5 29.0 (C5), 35.7 (CH2Ph), 56.0 (OCH3), 57.5 (OCH3), 58.8 
(OCH3), 62.7 (C6 ), 103.6 (0CH 20), 105.7 (C3'), 109.3 (C4)c, 109.8 (C14)c, 112.3 
(C7'), 115.5 (C5"), 117.3 (C3"), 118.3 (2C, C4', C6 '), 121.4 (C4a), 122.6 (C12)d, 
122.9 (C8 a)e, 127.3 (C11 )d, 129.2 (C3a'), 130.3 (C2'), 131.6 (C3"), 133.1 (Cl3b),
134.3 (C l" ) f, 135.0 (C12a)e, 135.2 (C13), 138.9 (C13a), 141.1 (2C, C7a',C2"f), 142.9 
(C5'), 146.0 (C9)g, 146.2 (C8 ), 148.6 (C3a)h, 151.4 (C14a)h, 151.7 (C10)g, 160.2 (C4"). 
HRMS (ES): m/z calcd for C36H30N3O7 [M]+: 616.2084; found: 616.2090.
7.7 Attempted synthesis to increase the bond length between 
berberine and pump blocker (Chapter 4)
7.7.1 Preparation o f 13-A llyl-9,10-dim ethoxy-5,6-dihydrobenzo[g]-l,3  
benzodioxolo[5,6-a]quinolizinium  brom ide (66)133
A suspension of the dihydroberberine 9 (380.0mg,
l.Olmmol) and allyl bromide (2mL) was refluxed at 100°C under
a nitrogen atmosphere for 2h. Diethyl ether (lOmL) was added 
66
to the reaction until no further precipitate formed. The 
precipitate was filtered and then chromatographed on silica gel (3% MeOH in DCM) to 
give 6 6  (241.Omg, 52%) as a yellow solid. 'H  NMR (300MHz, CDCI3 + CD3OD): 8 
3.23 (t, J =  5.9 Hz, 2H, H-5), 3.90-4.01 (m, 2H, CH2CH=CH2), 4.06 (s, 3H, OCH3),
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4.36 (s, 3H, OCH3), 4.91 (br.d, J = 17.4 Hz, 1H, CH2CH=CH2), 5.24 (br.s, 2H, H-6), 
5.43 (br.d, J = 10.5 Hz, 1H, CH2CH=CH2), 6.07 (s, 2H, OCH2O), 6.31-6.42 (m, 1H, 
CH2CH=CH2), 6.87 (s, 1H, H-4)a, 7.34 (s, 1H, H-14)a, 7.82 (s, 2H, H-11, H-12), 10.53 
(s, 1H, H-8).  13C NMR (75MHz, CDCl3 + CD3OD): δ 28.5 (C5), 34.7 (CH2CH=CH2), 
57.0 (OCH3), 57.6 (C6), 63.2 (OCH3), 102.0 (OCH2O), 108.4 (C4)b, 108.8 (C14)b, 
119.3 (C12)c, 120.0 (C13b)d, 120.8 (CH2CH=CH2), 121.7 (C8a)e, 125.4 (C11)c, 129.7 
(C4a)d, 133.3 (C13), 133.5 (C12a)e, 135.1 (CH2CH=CH2), 136.9 (C13a), 145.9 (C9)f, 
146.4 (C14a)g, 147.0 (C8), 149.7 (C3a)g, 150.3 (C10)f.  HRMS (ES): m/z calcd for 
C23H22NO4 [M]+: 376.1549; found: 376.1548. 
 
7.7.2 Attempted cross metathesis reaction of 66 
 A mixture of 66 (5.1mg, 0.01mmol), indole 55 (4.0mg, 0.01mmol) and polymer 
bound benzylidine-bis(triscyclohexylphosphine)-dichlororuthenium 0.1mmol/g (1.4mg, 
0.001mmol), in dry DCM (5mL) was stirred and heated at refluxed for 2 days under a 
nitrogen atmosphere.  The catalyst was then removed by filtration of the mixture.  The 
filtrate was then evaporated.  The residue was chromatographed on silica gel (3% 
MeOH in DCM) to give a two component mixture of product (5.2mg), which could not 
be identified.  MS (CI) of the mixture: m/z, [MH]+ showed 208 (100%) and 313 (100%). 
 
7.7.3 Attempted O-alkylation of 42  
 Method 1:  To a solution of the benzyl alcohol 42 (13.0mg, 0.05mmol) in 10% 
TEA in THF (2mL) was added 10% allyl bromide in THF (0.1mL, 0.01mmol) at 0oC 
under a nitrogen atmosphere.  The solution was then heated at 50oC for 30h.  The 
reaction mixture was then evaporated and the residue chromatographed on silica gel by 
VLC (1% MeOH in DCM) to give only starting material 42 (10.0mg).  
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Method 2:  To a suspension of sodium hydride (5.0mg of 
a 50% dispersion in mineral oil, 0.1mmol) in anhydrous DMF 
(1mL) at 0oC, was added a solution of 42 (30.0mg, 0.1mmol) in 
DMF (2mL) and the mixture then stirred for 30min.  The 
mixture was warmed to room temperature and stirred for a further 2h.  Excess DMF 
(2mL) was added and then the mixture was cooled to –60oC in a dry ice/acetone bath.  
A solution of 10% allyl bromide in DMF (0.1mL, 0.13mmol) was added dropwise to the 
cooled mixture and then allowed to stir overnight at 80oC.  The mixture was evaporated 
and the residue added to ice water (20mL), and the mixture stirred vigorously for 4h.  
The precipitate was filtered, washed with cold water, and dried.  The residue was 
chromatographed on silica gel by PLC (50% DCM in hexane) to give 67 (7.0mg, 21%) 
as an amorphous solid.  1H NMR (300MHz, CDCl3): δ 3.83 (s, 3H, OCH3), 4.48 (s, 2H, 
CH2), 4.61 (d, J = 3.6 Hz, 2H, CH2CH=CH2), 4.85 (d, J = 17.1 Hz, 1H, CH2CH=CH2), 
5.16 (d, J = 10.5 Hz, 1H, CH2CH=CH2), 5.78-5.91 (m, 1H, CH2CH=CH2), 6.71 (s, 1H, 
H-3), 6.87 (d, J = 2.4 Hz, 1H, H-6´), 7.04 (dd, J = 8.7, 2.4 Hz, 1H, H-4´), 7.35 (d, J = 
9.3 Hz, 1H, H-7), 7.52 (d, J = 8.4 Hz, 1H, H-3´), 8.13 (dd, J = 8.9, 2.0 Hz, 1H, H-6), 
8.59 (d, J = 1.8 Hz, 1H, H-4).  13C NMR (75MHz, CDCl3): δ 46.7 (CH2CH=CH2), 55.4 
(OCH3), 62.4 (CH2OH), 104.9 (C3), 110.2 (C7), 115.3 (C4´), 116.2 (C6´), 117.2 
(CH2CH=CH2), 117.4 (C6), 117.7 (C4), 127.1 (C3a), 130.4 (C3´), 131.3 (C2), 132.6 
(C1´)a, 132.7 (CH2CH=CH2), 139.6 (C7a), 141.6 (C2´)a, 141.9 (C5), 158.7 (C5´).  
HRMS (CI): m/z calcd for C19H19N2O4 [MH]+: 339.1345; found: 339.1349. 
 Method 3:  To a suspension of sodium hydride (50% dispersion in mineral oil, 
1.6g, 36.0mmol, after being washed with dry diethyl ether) in dry THF (30mL) was 
added ethylene glycol (2mL, 36.0mmol) at room temperature and the mixture stirred for 
1h.  After this time, tert-butyldimethylsilyl chloride (5.4g, 36.0mmol) was slowly added 
N
O2N
OCH3
CH2OH
67
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to the mixture and vigorous stirring was continued for 45min.  The mixture was poured 
into diethyl ether (200mL), and then washed with 10% aqueous K2CO3 solution (60mL) 
and brine (60mL).  The diethyl ether layer was dried, concentrated and then 
chromatographed on silica gel by VLC (20% EtOAc in hexane) to give 2-(tert-
butyldimethylsilanyloxy)ethanol (1.13g, 33%) as a pale yellow oil.  1H NMR134 
(300MHz, CDCl3): δ 0.01 (s, 6H, Si(CH3)2), 0.82 (s, 9H, C(CH3)3), 2.71 (br s, 1H, OH), 
3.51-3.64 (m, 4H, CH2).  CIMS: m/z 177 ([MH]+, 100%).  
 To a suspension of sodium hydride (11.0mg of a 50% dispersion in mineral oil, 
0.23mmol) in anhydrous DMF (1mL) at 0oC, was added a solution of 2-(tert-
butyldimethylsilanyloxy)ethanol  (49.0mg, 0.28mmol) in DMF (1mL) and the mixture 
stirred for 30min.  The mixture was then warmed to room temperature and stirred for a 
further 2h.  Excess DMF (3mL) was added and then the mixture was cooled to –60oC in 
a dry ice/acetone bath.  A solution of benzyl bromide 53 (75.9mg, 0.23mmol) in DMF 
(4mL) was added dropwise to the cooled mixture and then the mixture was allowed to 
stir for 2 days at 80oC.  The mixture was evaporated, then added to ice water (30mL), 
and stirred vigorously for 4h.  The precipitate was filtered, then washed with cold water, 
and dried.  The residue was chromatographed on silica gel by PLC (30% DCM in 
hexane) to give the cyclised product 46 (39.6mg, 69%).  All spectroscopic data for 46 
was the same as that noted for this compound previously (Section 6.5.6.2). 
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7.8  Enzymatic hydrolysis of 9,10-Dimethoxy-13-[2-(5-nitro-1H-
indol-2-yl)-benzyloxycarbonyl-methyl]-5,6-dihydrobenzo[g]-
1,3-benzodioxolo[5,6-a]quinolizinium bromide (60) 
 To a solution of 60 (4.7mg, 0.006mmol) in DMSO (30µL), was added a 
suspension of porcine liver carboxyl esterase (EC 3.1.1.1, 1mg, 46units: one unit 
represents 1µmol product produced per min) in Tris-HCl buffer solution at pH7.2 
(1mL).  The buffer solution was prepared as follows: 0.2M trishydroxymethyl-
aminomethane (25mL) was mixed with 0.1M HCl (45mL), then adjusted to pH7.2, and 
the volume made up to 100mL with water.  The reaction mixture was warmed to 37oC, 
and stirred at this temperature for 24 h.  The suspension was then extracted with DCM 
(3 x 3mL) and the DCM extract washed with water (10mL).  The DCM extract was 
dried and evaporated to give a residue in which the benzyl alcohol 41 was identified by 
TLC analysis (silica gel, DCM) and comparison with the authentic alcohol.  
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APPENDIX I 
Antibacterial activity testing using Fluorescein Diacetate (FDA) 
and Antimicrobial (cell lysis/ cell stasis) assays137 
 
Materials and Methods 
Maintenance and preparation of microbial cultures 
 Stock cultures of S. aureus ACM844 and E. coliACM845 were obtained from the 
Culture Collection at the University of Queensland and maintained at –78oC in 15% 
glycerol.  The cultures were prepared by streaking onto Nutrient Agar (NA) (Oxoid 
CM3; pH 7.4).  After an overnight incubation, single colonies were used to inoculate 
sterile liquid media.  The broth consisted of yeast extract (5g; ICN 103303-17), peptone 
(10g; Oxoid L37), and NaCl (5g, ICN 102892) in distilled water (1L).  Inoculated 
broths were placed on an orbital shaker (150rpm) and incubated overnight at 37oC.   
 
FDA assay 
 The overnight cultures of the microorganisms were diluted to an absorbance of 
0.12 (600nm) and grown to 0.18 (ca 30min; 37oC; 150rpm).  The wells of a 96 well 
tissue culture plate (3072 Microtest III, Becton Dickinson) were filled with 175µL of 
the culture.  To each well 20µL of the test compound or appropriate control was added.  
Three replicates were made at each test concentration.  The microtiter plate was 
incubated for 30min at 37oC before 5µL FDA (0.2% solution in acetone) was added.  
Incubation was continued for a further 2h or until the production of fluorescein was 
easily visible under an ultraviolet lamp (λ 254nm).  The results were simply recorded as 
positive or negative according to the detection of fluorescence. 
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Test compounds used in the assay were dissolved in acetone (100%, AR Grade) and 
tested at a maximum concentration of 10mg/mL.  Two procedural controls, consisting 
of 20µL of acetone and 20µL of Milli Q water with FDA, were added to each test plate 
(three replicates) to determine any effects of the acetone on the viability of the cells.  
Additional procedural controls included 20µL of test substance in 175µL of broth with 
FDA, to ascertain whether the test compound hydrolysed FDA, and 195µL of broth with 
FDA to check for contamination in the broth. 
 
Antimicrobial (cell lysis/ cell stasis) assay 
 After the FDA assay was completed, 20µL of culture (four replicates) from all the 
wells that did not show fluorescence, were spread on to agar to determine if the cells 
could recover.  The plates were incubated overnight at 37oC.  Counts of visibly growing 
colonies were performed and compared to a dilution series of a control culture from the 
FDA plate containing acetone. 
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APPENDIX II 
Antibacterial activity and MDR inhibitory activity testing using 
turbidometric assay56 (performed by Lewis, K. and Ball, A., 
Northeastern University, USA) 
 
Materials and Methods 
 Microbial strains used for antimicrobial activity testing were Gram-positive 
bacteria: S. aureus 8325-4 (wild-type strain which expresses NorA MDR pump), S. 
aureus K1758 (NorA mutant strain lacking the NorA MDR pump), S. aureus K2361 
(resistance strain which overexpresses the NorA MDR pump), E. faecalis V583, and E. 
faecium DO; Gram-negative bacteria:  E. coli K12, S. enterica Serovar Typhimurium 
SL1344R2, and P. auerginosa PA1; and Yeast: S. cerevisiae BY4742, C. albicans F5, 
and C. albicans F5 M432. 
 
Cell Culturing and Susceptibility Testing 
 Growth of microbe and susceptibility measurements were performed according to 
the National Center for Clinical Laboratory Standards Recommendations.  All strains 
were cultured in Mueller-Hinton (MH) broth overnight with aeration at 37oC.  Cells 
were then inoculated into fresh MH medium at a 1:10 dilution and were allowed to 
grow for 1h.  This suspension was dilute 1:2000 into MH broth and 0.05 mL was 
dispensed per well of microtiter plates.  For measurements of direct antimicrobial 
activity, test compounds were dissolved in DMSO at 10mg/mL and then serially diluted 
with water.  The final volume of a well was 0.2 mL, and the cell concentration was 105 
cells/mL.  All tests were done in triplicate.  Minimum inhibitory concentrations (MICs) 
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were determined by serial 2-fold dilution of test compounds.  Two procedural controls 
were used.  One contained cells and MH broth to observe the normal growth rate of 
microorganisms within the wells.  Another one contained only MH broth to observe any 
contamination.  MIC was defined as a concentration (µg/mL) of an antimicrobial that 
completely prevented cell growth during an 18h incubation at 37oC.  Growth was 
assayed with a microtiter plate reader (Bio-Rad) by absorption at 600nm.   
 Test for MDR inhibitory activity were done in similarly, but with antibiotic 
(Berberine chloride or Ciprofloxacin) present at a sub-inhibitory concentration 
throughout.  The test substance was then serially diluted 2-fold, and MIC for test 
substances was then defined as their minimal concentration that completely inhibited 
cell growth in the presence of sub-inhibitory concentration of antibiotic. 
 
Effect of NorA inhibitors on antibacterial accumulation in 
bacterial cells using uptake assay (performed by Lewis, K. and 
Ball, A., Northeastern University, USA) 
 
Materials and Methods 
 Microbial strains used for antimicrobial activity testing were Gram-positive 
bacteria: S. aureus 8325-4 (wild-type strain which expresses NorA MDR pump), S. 
aureus K1758 (NorA mutant strain lacking the NorA MDR pump), S. aureus K2361 
(resistance strain which overexpresses the NorA MDR pump). 
  Cells were grown to an OD of 1.5 (600nm) in 1 milliliter of MH broth. Cells were 
centrifuged at 12,000 Rpm for two minutes and washed in 20mM HEPES/KOH buffer 
pH 7 twice. Cells were resuspended to an OD of 0.6 in 20mM HEPES/KOH buffer 
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containing 10mM sucrose and incubated for 1h. Cells were centrifuged and washed with 
20mM HEPES buffer and resuspended to an OD 0.3.  Cells were then added to 96 well 
microtiter plates at an OD of 0.15.  Uptake of berberine can be measured due to its 
ability to intercalate with DNA. Accumulation of berberine 30µg/mL was measured by 
fluorescence (λ 355nm excitation, λ 517nm emission) in the presence or absence of 
inhibitor 10µg/mL.  
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APPENDIX III 
Antibacterial activity testing146 (performed by Avexa Ltd., 
Australia) 
 
Materials and Methods 
 The bacterial strains were used S.  aureus ATCC 6538P, and 4 strains of E. 
faecium VRE243, VRE449, VRE820 and VRE987. It should be noted that, VRE243 
and 987 were sensitive to vancomycin and VRE449 and VRE820 were resistant to 
vancomycin.  
 
Antimicrobial assay 
 The Mueller-Hinton Broth (MHB) Medium culture media was prepared with final 
concentrations of 1 µg/mL MgCl2 and 2 µg/mL CaCl2 and was pre-warmed for 2-3 h at 
37oC before use. Mueller-Hinton Agar (MHA) Medium culture media was prepared 
with final concentrations of 1.5% Agar (Merck Agar 1.01614). S. aureus was streaked 
onto MHA and the plate was incubated overnight at 37oC. From this plate, 10 cryovial 
were prepared by looping several colonies into 0.5 mL of 20% glycerol solution and 
were immediately stored at −140oC. A cryovial was removed from −140oC storage and 
thawed at room temperature. The MHA plate was streaked with a loopful of bacterial 
suspension and incubated overnight at 37oC to create a parent plate (P1). The parent 
plate was stored at 4oC. A daughter plate (D1) was incubated overnight at 37oC and its 
loop of colony was used to inoculate a 125 mL flask containing 20 mL of MHB 
containing 25 µg/mL CaCl2.2H2O) and 12.5 µg/mL MgCl2.6H2O. The flask was shaken 
at 260 rpm for 18 h at 37oC on an orbital incubator shaker. The parent plates 1 and 2 
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were each used twice to generate two daughter plates (D1 and D2) before being 
discarded. 
 The standardised inocula for assays was prepared as 1/10 dilution of seed cultures 
by adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette and the 
required dilution factor was calculated by dividing the observed OD650. Sufficient 
volumes of the final inoculum cultures were prepared in pre-warmed MHB (37oC) by 
diluting the standardised cultures to the required final concentration (108 dilution). 
 
Assay Procedure for 96-well Microtitre Plates 
 To each well of the 96-well microtitre plate was added 50 µL of liquid medium 
and 50 µL of test compound solution which was prepared by dissolving in 2.5 % DMSO 
was added in triplicate to the top of the microtitre plate. A vancomycin control set 
(triplicate) and a compound negative control set (triplicate) were also set up on each 
plate. The inoculated culture medium was incubated at 37oC for 30 min shaking it at 
130 rpm and using the multichannel pipette and multistepper pipette the adding, 
transferring and mixing of the inoculum were performed on the wells of the plates. The 
plates were incubated at 37oC for 18 h shaking at 100 rpm in an environment with 90% 
relative humidity and the results were recorded as the highest dilution of test compound 
that prevented bacterial growth (MIC). The MIC was also determined for DMSO (2.5%) 
as a control measure. 
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APPENDIX IV 
Antimalarial activity testing147 (performed by 
Kamchonwongpaisan, S., BIOTEC, Thailand) 
 
Materials and Methods 
 Samples were made up in DMSO solution. Using the Microdilution Radioisotope 
Technique, the in vitro antimalarial activity of the alkaloids was tested against P. 
falciparum, TM4 and K1 strains. The first strain is an anti-folate sensitive one while the 
second is an antifolate resistant strain.  
 
Antimalarial assay 
 The sample (25 µl, in the culture medium) was placed in triplicate in a 96-well 
plate. Red blood cells (200 µl) infected with P.  falciparum with a cell suspension 
(1.5%) of parasitemia (0.5-1%) were added to the wells. The range of the final 
concentrations of the samples varied from 1 x 10-5 to 1 x 10-8 g/ml with 0.1% of the 
organic solvent. The plates were cultured under standard conditions for 24 hours and the 
3H-hyphoxanthine (25 µl, 0.5 mCi) was added. The culture was incubated for 18-20 
hours. The parasites’ DNA was then harvested from the culture onto glass fibre filters. 
A radiation counter determined the amount of 3H-hypoxanthine. The inhibitory 
concentration of the sample was determined from its dose-response curves or by 
calculation. 
 The Trager and Jensen method148 was used to culture the P. falciparum K1 strain. 
The parasites were maintained in human red blood cells in a culture medium. RPMI 
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1640 was supplemented with 25 mM HEPES, 0.2% sodium bicarbonate, and 8% human 
serum, at 37oC in a CO2 incubator.  
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APPENDIX V 
Cytotoxicity testing (performed by Vine, K., University of 
Wollongong) 
 
Materials and Methods 
Test compounds 40, 60 and 64 were made up in 10% MeOH in DCM solution.  Using 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H 
tetrazolium, inner salt (MTS) assay, the in vitro cytotoxicity of these compounds was 
tested against human hystiocytic lymphoma cells (cell line U937). 
The U937 cancer cells were supplied by the Garvan Institute of Medical Research, 
Sydney, Australia.  Cells were routinely maintained in vitro (37oC, 5% CO2 in 
humidified atmosphere) in a culture medium of RPMI-1640 media supplemented with 
2mM L-glutamine, 5.6% (2g/L) sodium bicarbonate (Univar Analytical Reagents, Ajax 
Chemicals) and 5% Foetal Calf Serum (FCS) (MultiSerTM Thermo Trace). 
 
Cytotoxicity testing 
Test compounds were tested for cytotoxicity against human hystiocytic lymphoma cells 
(cell line U937).  Test compound dissolved in 10% MeOH in DCM solution was added 
to the wells of a sterile, 96 well microtitre plate from 100µg/mL to 1µg/mL.  The 10% 
MeOH/DCM in the test solution was removed by either N2 or Ar gas until the 
compound was completely dry.  Cells (2x104 cells/well) in RPMI/5% FBS were added 
to the test compounds to give a final volume of 100µL.  Positive control cultures were 
incubated with RPMI/5% FCS only, or in the case of solvent controls, 100µL EtOH 
dried with N2 or Ar gas.  Negative control cultures were incubated with RPMI/5% FCS 
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and 50% EtOH, all in triplicate.  The cells were incubated for 24h at 37oC (5% CO2 
atmosphere), and then MTS (20L) was added in the dark.  The cells were incubated 
for a further 3h to allow colour development. Plates were read in the SpectroMax® 250 
plate reader using Softmax Pro software V. 4.0 (Molecular devices, USA) at 490 nm.  
  
 
 
 
 
 
 
 
